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Abstract
Progressive development of pathology in neuroanatomically connected brain regions is a 
common feature of many neurodegenerative diseases. The spread of disease pathology is 
suggested to be dependent on the transmissibility of disease-associated proteins, particularly 
soluble aggregates of misfolded proteins. Emerging evidence suggests that many disease-
associated proteins such as α-synuclein (aSyn) and tau, in certain misfolded and aggregated 
states convert from physiologically normal proteins into forms that lead to progression of 
disease pathology in a template-dependent manner, which is also known as seeding. The 
propagation and the proteinopathy have been suggested to occur via cell-to-cell transmission. 
The exact mechanisms involved in the seeding and spreading process are incompletely 
understood. In this thesis work, three critical steps of the seeding pathway (a process involves 
multiple steps), the intracellular aggregation, cellular release and uptake of aSyn and tau, were 
carefully studied primarily via a newly developed platform based on protein-fragment
complementation assay. The main findings of this thesis are:
a) Prolyl oligopeptidase (PREP) is a serine peptidase that was previously known to 
accelerate the process of aSyn aggregation and suppress autophagy clearance in cells 
and transgenic aSyn mice.  The results of this thesis show that PREP directly interacts 
with aSyn in neuro2A cells and cell-free environment, and enhances aSyn dimerization, 
which is an early event in aSyn aggregation pathway. In addition, the PREP-mediated 
aSyn dimerization can be antagonized by KYP-2047, a small-molecule PREP inhibitor. 
b) Late-onset Alzheimer’s disease (LOAD) susceptibility genes affect the individual risk 
of developing Alzheimer’s disease, which is one of the common tauopathies. In this 
work, the functional connection between selected LOAD susceptibility genes and cell-
to-cell transmission of tau was studied in vitro. We observed that RNAi knockdown of
CD2AP and FRMD4A reduced tau secretion, and knockdown of APOE reduced tau 
uptake in HEK293T cells. Further mechanistic studies revealed that FRMD4A 
modulates tau secretion via the FRMD4A-cytohesin-Arf6 signalling pathway and the 
Par6/aPKC polarity signalling complex. This data, for the first time, demonstrates a 
functional connection between LOAD risk genes and cell-to-cell propagation of tau. 
c) Following internalization, extracellular, hyperphosphorylated tau was found to be 
recruited to stress granules, transient non-membraneous cytosolic structures composed 
of RNA and self-aggregating RNA-binding proteins. Tau recruitment was dependent on 
TIA-1, an RNA-binding stress granule protein. Importantly, the stress granules induced 
by and containing internalized tau were resistant to normal clearance and associated 
with increased sensitivity of cells to other stresses. This data describe a previously 
unrecognized mechanism and pathological consequence of cell-to-cell propagation of 
tau-mediated by stress granules, which have previously been associated with the 
pathophysiology of various neurodegenerative diseases.
Overall, the work described in this thesis provides several novel findings that improve 
our understanding of cellular mechanisms underlying the development and spreading of aSyn 
and tau-related neurodegenerative pathologies. These pieces of knowledge may be potential 
avenues towards the development of crucial therapeutics against aSyn and tau-related
neurodegenerative diseases.
 1 
1 Introduction  
Dynamic protein-protein interactions (PPIs) that constitute multi-protein complexes and 
networks predominantly determine the cellular functionalities. Impairments in these 
complexes and networks could result in various pathological disorders. For example, protein 
misfolding and subsequent aggregation in certain brain regions is a pathological characteristic 
shared by many neurodegenerative diseases (Lashuel et al., 2013, Lee et al., 2001).  
Cerebral accumulation and aggregation of microtubule-associated protein tau is a 
common feature of diseases associated with tauopathy such as Alzheimer’s disease (AD), 
which is the most common neurodegenerative disease with age-related dementia (Lee et al., 
2001). The accumulation and aggregation of α-Synuclein (aSyn) in various brain regions such 
as substantia nigra is a hallmark of Parkinson’s disease (PD), which is the most common 
neurodegenerative movement disorder (Fahn, 2003, Spillantini et al., 1997). Despite the fact 
that tau and aSyn are distinct proteins, and have been extensively studied in distinct 
pathological contexts, the mechanisms involved in the aggregation process and propagation of 
pathology of these two proteins are proposed to be highly converged and overlapping based on 
existing evidence (Moussaud et al., 2014). For example, both aSyn and tau aggregation 
exhibits an inducible nucleation-elongation mechanism (Wang and Mandelkow, 2016, Lashuel 
et al., 2013). Both aSyn and tau are present in cerebrospinal fluid (CSF) of human patients, 
and are transmissible between cells and animal models (Blennow et al., 1995, Borghi et al., 
2000, Guo and Lee, 2014b). In the theories of Braak staging, Lewy body pathology and 
tauopathies develop sequentially in neuroanatomically connected brain regions in a time-
dependent manner (Braak and Braak, 1991, Bancher et al., 1993, Braak et al., 2003). This thus 
implicates that pathological forms of aSyn and tau could get access to the extracellular space, 
and moreover spread from one region to another during the pathogenesis of neurodegenerative 
diseases.  
Emerging evidence on the spread of various disease-associated proteins in a "prion-like" 
manner in vitro and in vivo have implicated the existence of a common mechanism in the 
spread of pathology of neurodegenerative diseases as reviewed in Guo and Lee (2014a). In the 
“prion-like” paradigm, it was suggested that many amyloidogenic proteins, including aSyn, 
tau and as well as other known pathology-related proteins such as amyloid-β (Aβ), TDP-43, 
superoxidase dismutase 1 and huntingtin, might transmit between cells and spread pathology 
into distinct but connected brain regions with a mechanism similar to prion proteins. In prion 
diseases, such as Creutzfeldt-Jacob disease (CJD), normal prion proteins sporadically convert 
to pathological species that have altered conformations and act as infectious agents that further 
convert normal prion proteins into pathological species in a template-directed manner, and 
thus spread the pathology rapidly (Bolton et al., 1982, Aguzzi, 2009). The amyloidogenic non-
prion proteins mentioned above were also proposed to undergo this feedforward loop by 
seeding aggregation into neighbouring cells (Guo and Lee, 2014b, Brettschneider et al., 2015). 
The exact mechanisms of cell-to-cell transfer and seeding of the disease-associated proteins 
are poorly understood, but the mechanisms are implicated in involving gain of seeding 
property, release from donor cells and uptake by recipient cells. Hence understanding the 
molecular mechanisms, protein pathways and risk factors related to the transcellular 
propagation of disease-associated proteins would grant us not only knowledge of our 
physiological and pathological conditions but also avenues to develop crucial therapeutics.   
The improved well-being and success of modern medicinal therapeutics have expanded 
our life expectancy. However, longer life also results in various age-related diseases that add a 
high cost to our society. Among all, neurodegenerative diseases lay a particular burden. For 
2example, in 2015 there were 47 million patients with neurodegenerative dementia and the 
global economic cost of this was $818 billion (Wimo et al., 2016). Hence, it grows urgent for 
us to put a vast investigation effort into this field. The development of therapeutics and early 
diagnosis of neurodegenerative diseases can be expensive and time-consuming, and thus the 
fundamental research should focus more on the early events in disease pathogenesis such as 
abnormal PPIs. Furthermore, in synucleinopathies and tauopathies, neurodegeneration is 
caused by multiple cascade-events, and thus the study should investigate the mechanisms 
involved in the multiple steps of cell-to-cell propagation of pathological form of aSyn and tau.
In this thesis, aggregation, cellular release and uptake of aSyn and tau, which are the three 
critical steps involved in the cell-to-cell propagation, are thoroughly investigated. 
Understanding how protein interaction partners and genetic risk factors contribute to these 
steps could potentially reveal novel therapeutic targets and grant us knowledge of our 
physiological and pathological conditions.
 3 
2 Review of literature 
 Protein misfolding and aggregation 2.1
Protein misfolding is a cascade of events, starting from the natively unfolded protein and 
culminating in the mature fibril formation that is collectively termed aggregation. Protein 
misfolding associated with cellular dysfunction and cell death is a common molecular event in 
many neurodegenerative diseases. In physiological conditions, protein folds into its native 
state, which is the lowest energy state with hydrophobic residues inside the folded protein 
structure, after translation (Jahn and Radford, 2005). aSyn and tau are primarily translated in 
the cytosol, whereas secretory and membrane proteins are translated into the lumen of 
endoplasmic reticulum (ER). Many factors could impair this process, such as genetic 
mutations, environmental factors, etc. When misfolding occurs in certain proteins, the 
hydrophobic residues may become exposed forming unspecific interactions with other 
proteins, causing clustering and aggregation. In this process, a “healthy” protein may be 
trapped, or sequestered into a largely irreversible complex, known as aggregates, which may 
severely impair cellular functions (Ogen-Shtern et al., 2016).  
To maintain cellular homeostasis during these situations as illustrated in Figure 1, 
molecular chaperones such as heat shock family proteins, can bind to the hydrophobic motifs 
of misfolded proteins in the cytosol, and prevent them from further interactions and 
aggregation (Chaari et al., 2013). The bound misfolded proteins may be conjugated with 
ubiquitin, which diverts them for proteasomal degradation (Balch et al., 2008), or direct to 
autosomal-lysosomal degradation pathway (Rubinsztein, 2006). However, when the formation 
of misfolded or aggregated proteins overruns the capacity of the clearance machinery, as the 
final attempt these proteins could be packed into β-sheet-like structures (also known as 
amyloids), which can further be assembled into amyloid fibrils reducing toxic interactions to 
the minimum (Eisenberg and Jucker, 2012). During pathogenesis process, certain protein 
monomers that may be natively unfolded oligomerize and gradually form large irreversible 
aggregates and fibrils. The solubility has been shown to decrease as the degree of aggregation 
increased in cells or animal models  (Kothawala et al., 2012, Hirata-Fukae et al., 2009). 
However, the exact mechanisms involved are poorly understood as not all the intermediates 
involved in the aggregation pathway have been fully characterized(Kothawala et al., 2012, 
Hirata-Fukae et al., 2009). The misfolded secretory and membrane protein in ER may active 
unfold protein response, and are refolded by ER chaperones such as binding immunoglobulin 
protein and ER-localized J-protein (Schroder and Kaufman, 2005). Some of the misfolded 
proteins could re-translocate through ER membrane into the cytoplasm, and become 
ubiquitinated and are delivered for proteasomal degradation in a process called ER-associated 
degradation (Bernales et al., 2012). (Bernales et al., 2012) It has been suggested that the 
misfolding of cytosolic proteins such as aSyn and tau could enhance ER stress, elevate the rate 
of unfold protein response and disrupt the protein homeostasis in ER (Matus et al., 2011). 
 These insoluble protein deposits can take many forms and are reported in many 
neurodegenerative diseases. For example, in PD and other synucleinopathies, cytoplasmic 
inclusions occur in many regions of central nervous system (CNS) and autonomic system. 
These inclusions are also known as Lewy bodies, which are plaques primarily composed of 
misfolded aSyn and a variety of other components such as ubiquitin, cytochrome C, MAP-
family proteins, tyrosine hydroxylase, superoxide dismutase, lipids, etc. ((Lashuel et al., 2013, 
Dennis Dickson, 2011, Braak and Del Tredici, 2008). In AD, plaques mainly composed of Aβ 
aggregates (also known as amyloid) and plaques primarily composed of hyperphosphorylated 
4tau aggregates (also known as neurofibrillary tangles?NFTs) also occur in multiple regions 
of CNS during pathogenesis (Wang and Mandelkow, 2016, Dennis Dickson, 2011, Bancher et 
al., 1989). One of the common characteristics of neurodegenerative diseases is the progressive 
impairment of cellular function and selective vulnerability and death of neurons in specific
brain regions. The impairment of the proteostasis and death of neurons is thought to be caused 
by the pathological proteins that misfold, aggregate and constitute the protein deposits (Taylor 
et al., 2002).
Figure 1. Schematic presentation of general pathways that aim at restoring cellular homeostasis during protein 
misfolding and aggregation in the cytosol. Misfolded proteins are degraded by ubiquitin-proteasome system (UPS) 
and autophagy-lysosomal pathway (ALP) to maintain cellular homeostasis. Failing to remove misfolded protein 
result in further aggregating to amyloid intermediates and small fibrils. When aggregates massively overwhelm the 
cellular homeostasis machinery, amyloids are formed, and moreover, result in tangles and plaques. The solubility 
and reversibility of misfolded proteins usually decrease during the aggregation process. Upper right image 
modified from Mufson et al. (2012)
5α-synuclein2.2
2.2.1 Structure and biological functions
aSyn has been 
known for its 
pathological role as a
constituent of Lewy
Bodies in various 
neurodegenerative 
diseases. It is encoded 
by the SCNA gene in 
humans with multiple 
splicing isoforms. 
The full-length aSyn 
with 140 amino acids
has important 
physiological 
functions and is 
involved in 
pathological 
conditions (Beyer, 2006). As shown in Figure 2, full-length aSyn is a 14 kDa protein with N-
and C-terminal helices, and a highly dynamic C-terminal tail (Ulmer et al., 2005). In the native 
state, aSyn can bind to membranes via N-terminal helix, leaving its C-terminal helix for 
nuclear localization and PPIs (Eliezer et al., 2001).
The entity of aSyn native state has been extensively debated. Recombinant aSyn protein 
derived from E.coli was reported to be mostly unfolded monomers at native state (Eliezer et 
al., 2001, Weinreb et al., 1996). However, it has been pointed out by a study using 
endogenous aSyn isolated from mammalian cell lines that aSyn exists primarily as a stable 
tetramer at native state, which is resistant to aggregation and fibrillization (Bartels et al., 2011).
This is likely due to different post-translational modifications and folding in various species. 
But on the other hand, N-terminal acetylation that was observed in native aSyn tetramer 
derived from mammalian cells was reported not to result in significant change in protein 
oligomeric state, sub-cellular localization, membrane-binding properties as compared with 
aSyn at native state of unfolding monomers (Weinreb et al., 1996, Fauvet et al., 2012).
Besides, these studies also showed that there is little difference between aSyn derived from
different species including human, mice and E.coli in a native or denaturing gel. However, 
aSyn expressed in E.coli was found to be highly dynamic, suggesting the possible more 
disordered internal structure as compared with aSyn derived from mammalian cell lines
(Wang et al., 2011). Several studies reported that both crosslinked aSyn derived from 
mammalian cells and aSyn purified from E.coli displayed a set of aSyn species from 
monomers to hexamers in native gel, suggesting that aSyn likely adopts multi-forms at native 
state (Wang et al., 2011, Gudmundsson et al., 1993).
aSyn belongs to the synuclein family of proteins that is evolutionarily conserved in 
vertebrate, and display a consistent pattern of localizing at the presynaptic terminals of 
neurons (Kaplan et al., 2003). Early studies demonstrated that at the presynaptic terminals,
aSyn is closely associated with synaptic vesicles, and modulates plasticity (Iwai et al., 1995, 
George et al., 1995). aSyn binds to phospholipid vesicles, and regulates phospholipase D2, a 
Figure 2. α-synuclein structure. 
aSyn has three structural motifs.
The N-terminal amphipathic 
helix contains most genetic 
mutations related to familial PD 
pathology (A30P, E46K, H50Q, 
G51D and A53T). The 
hydrophobic helical region that 
is also named non-amyloid-β 
component mediates aSyn 
oligomerization and 
fibrillization. The acidic 
unstructured region is suggested 
to be protective against 
aggregation. (Left image is 
adapted from Protein Data Bank 
ID: 1XQ8).
6lipase involved in membrane trafficking (Jenco et al., 1998, Jo et al., 2000). Knockdown of 
aSyn decreases the size of presynaptic vesicle pool in hippocampal neuron (Murphy et al., 
2000). Knockdown of synuclein family proteins in mice model triggers age-related 
neurological deficits suggesting that synuclein family proteins share common functions to 
maintain neuronal homeostasis (Burre et al., 2010). Another study showed that aSyn binds to
SNARE proteins synaptobrevin-2, VAMP2, and modulates SNARE complex assembly, which 
plays a central role in vesicle membrane fusion (Burre et al., 2010). As a consequence aSyn 
regulates presynaptic vesicle formation and fusion, and also the release of neurotransmitters as 
illustrated in Figure 3. This could potentially explain previously observed reduction in 
dopamine, catecholamine release, and abnormal presynaptic vesicles with synaptic deficits in
aSyn overexpressing neurons and transgenic mice (Nemani et al., 2010, Larsen et al., 2006, 
Lundblad et al., 2012).
aSyn may also regulate dopamine (DA) transmission via multiple pathways. It has been 
suggested that aSyn interacts with tyrosine hydroxylase (TH), the rate-limiting enzyme in DA 
synthesis that converts L-tyrosine to L-DOPA (Lundblad et al., 2012). It has been indicated 
that aSyn blocks TH phosphorylation via direct PPIs or activates protein phosphatase 2A to
dephosphorylate TH (Perez et al., 2002, Peng et al., 2005). Besides, it has been shown that 
aSyn downregulates Nurr1, a transcription factor involved in the expression of DA transporter, 
VMAT2 and AADC, which are essential proteins in regulating DA level (Jankovic et al., 
2005). AADC activity and phosphorylation were shown to be significantly reduced upon 
aSyn overexpression (Tehranian et al., 2006).
Figure 3. aSyn modulates neurotransmitter release by regulating SNARE family proteins. aSyn modulates the 
activity of v-SNARE and t-SNARE proteins, and thus vesicular trafficking at multiple stages. aSyn in red 
indicates a step that is impaired due to loss of aSyn physiological function e.g. in synucleinopathies; aSyn in 
blue indicates a step where aSyn regulates trafficking and refilling of the presynaptic vesicle. Adapted by 
permission from Macmillan Publishers Ltd: Nature Reviews Neuroscience, Lashuel et al. (2013), copyright ©
2013. Permission was conveyed through Copyright Clearance Center, Inc.
72.2.2 α-synuclein aggregation
Misfolding of a protein is a consequence of failing to achieve or maintain the correct 
structure, which is generally considered as the prerequisite of aggregation. Misfolded aSyn
oligomerizes and aggregates following the general pattern explained in section 2.1(Eliezer et 
al., 2001, Weinreb et al., 1996, Bartels et al., 2011). A few studies including electron
microscopy and immunoblot have demonstrated that aSyn (expressed in E.coli) can take 
different forms that exist in equilibrium with each other (Weinreb et al., 1996, Pountney et al., 
2004, Volles and Lansbury, 2002, Horvath et al., 2012). These primarily include unfolded and
folded membrane-bound monomers, dimers or trimers, ring- or pore-shaped oligomers, and 
beta-sheet intermediates as shown in Figure 4. Various factors promote aSyn to adopt certain 
conformations, e.g. aSyn favour α-helical structure upon binding to phospholipid membrane
(Davidson et al., 1998). However, it has been shown that aSyn derived from mammalian cells 
acquires the helical structure without need to bind to phospholipid membrane, suggesting a 
more stable internal structure as compared with E.coli derived aSyn (Bartels et al., 2011).
Many factors contributing to aSyn aggregation are directly linked with aSyn structure. Some 
genetic mutations, gene duplication or truncation can alter aSyn structure to favour 
aggregation (Lashuel et al., 2013). Some external factors, such as phosphorylation, oxidative 
stress, fatty acid, proteolysis failure, can also modulate aSyn or aSyn-related pathways that 
enhance aSyn aggregation, accumulation or reduce aSyn clearance. Some of these 
morphologies of aSyn were suggested to be linked with its physiological or pathological roles 
that will be reviewed later in the thesis.
Figure 4 A schematic representation of aSyn species and aggregation pathways. aSyn takes forms of unfolded,
folded or membrane-bound monomers, which have the potency to form higher order oligomers. Some membrane-
bound aSyn monomers with α-helical structures could also form β-sheet intermediate oligomers. These oligomers 
including some amorphous ones can also transform into different forms, e.g. ring-shaped or membrane-embedded 
pore-like structures. At high monomer concentrations, they have a slow tendency to form fibril-like structures
irreversibly. During some pathological conditions, small fibrils further aggregate into amyloid fibrils, which gather 
together to form visible protein deposits in cells known as Lewy bodies. Modified from Lashuel et al. (2013).
2.2.2.1 α-synuclein structure and aggregation
As shown in Figure 2, the non-amyloid component fragment (NAC) of aSyn composed 
of 35 amino acid residues (61-95) composes central hydrophobic region, and it plays a major 
role in aSyn oligomerization and aggregation (Hashimoto et al., 2000). As explained in section 
2.1, this hydrophobic motif may get exposed during misfolding, and initiate aggregation. 
8Mutation or deletion of this region significantly reduces aSyn filament assembly (Giasson et 
al., 2001). The C-terminal tail of aSyn was suggested to have a protective function against 
aggregation, and the residues 104, 105, 114 and 115 on the C-terminal tail are needed for this 
function (Murray et al., 2003). Even though the mechanism is not fully understood, the 
truncation of the C-terminal tail leads to increased aSyn aggregation in both experimental and 
pathological conditions (Li et al., 2005).
2.2.2.2 Genetic factors
The mutations that are associated with familial form of PD are mostly reported at the N-
terminal helix of aSyn. A30P, E46K, H50Q, G51D and A53T mutation at the N-terminus have 
been proposed to likely associate with the acceleration of aSyn fibrillization and possibly 
elevate aSyn-mediated toxicity (Choi et al., 2004, Beyer, 2006, Lesage et al., 2013, Rutherford 
et al., 2014). These mutation-mediated effects were suggested to be a result of altered aSyn
secondary structure (A30P, A53T), enhanced aSyn binding to phospholipids (E46K) or aSyn 
fibril formation that are more prone to activate caspase-3 related apoptotic pathways (G51D).
In rare cases, duplication and triplication of SNCA gene lead to the autosomal dominant form 
of PD (Ibanez et al., 2004, Singleton et al., 2003, Chartier-Harlin et al., 2004). The mechanism 
of how multiplication of SNCA gene contributes to PD pathogenesis is poorly understood, but 
this is a strong indication that aSyn plays an important role in the development of the disease.  
2.2.2.3 Post-translational modification
An early in vitro study demonstrated that aSyn S87 and S129 residues are constitutively 
phosphorylated (Okochi et al., 2000). However, it was later discovered that both pS87 
(phosphorylation of S87) and pS129 are significantly increased in Lewy bodies from both 
patient samples and animal models (Paleologou et al., 2010, Fujiwara et al., 2002).
Phosphorylation of S87 was found to increase aSyn conformational flexibility, which leads to 
reduced binding affinity to lipid membranes, and reduced potential to form fibrils (Oueslati et 
al., 2012). The same study also showed that hyperphosphorylation or mutation mimicking 
hyperphosphorylation of S87 (S87E) reduced aSyn aggregation and toxicity in a rodent model. 
aSyn with pS129 is found in a minor population of total aSyn at physiological conditions 
but increase to over 90% of total aSyn in Lewy bodies context (Fujiwara et al., 2002, 
Anderson et al., 2006). Also, aSyn with pS129 hyperphosphorylation is also exclusively 
ubiquitinated in pathological conditions. As certain patterns of poly-ubiquitination of proteins
direct them to proteasomal degradation, pS129 was thought to play a critical role in mediating 
aSyn proteasomal degradation (Anderson et al., 2006). For example, S129A mutation 
blocking S129 phosphorylation was found to reduce the rate of aSyn proteasomal and 
autophagy degradation (Tenreiro et al., 2014).
C-terminal truncation of aSyn is another common post-translational modification, and the 
amount of aSyn with C-terminal truncation was found to be significantly enriched in Lewy 
bodies (Li et al., 2005). The mechanism is poorly understood, but in vitro experiments 
demonstrated that C-terminally truncated aSyn induced significant wild-type aSyn aggregation 
upon co-expression in a template-directed manner, suggesting a prion-like behaviour of 
truncated aSyn species (Liu et al., 2005a). The site-directed expression of C-terminal truncated 
aSyn at nigral dopamine neurons was shown to markedly reduce dopamine levels in a 
transgenic mouse model, suggesting a failure to maintain aSyn regulated DA homeostasis as 
explained in section 2.2.1 (Daher et al., 2009).
Oxidative damage can happen to any protein typically resulting in oxidative modification 
of cysteine, tyrosine and methionine residues. aSyn has four tyrosine and methionine residues, 
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make it susceptible to oxidative stress. Nitration of tyrosine and oxidation of methionine are 
common oxidative modifications of aSyn found in Lewy bodies (Chavarria and Souza, 2013). 
Reactive oxygen species (ROS) and reactive nitrogen species from mitochondrial metabolism 
during cellular stress conditions were suggested to promote aSyn aggregation (Andersen, 
2004). Application of rotenone, a drug that generates ROS by inhibiting mitochondrial 
complex I, induces aSyn aggregation in neurons (Chaves et al., 2010).  
It was previously found that nitrated aSyn species are enriched in PD brain lysate 
(Giasson et al., 2000). The mechanism and significance of this phenomenon are poorly 
understood. Application of a nitrating agent to cell culture was reported to promote aSyn 
aggregation (Paxinou et al., 2001). However, controversial shreds of evidence showed that 
nitration reduced aSyn fibrillization by nitrating aSyn at tyrosine residues, and stabilized aSyn 
oligomers with improved folded secondary structure (Uversky et al., 2005).  
Methionine oxidation of aSyn is thought to be primarily metal-catalysed (Chavarria and 
Souza, 2013). aSyn is most susceptible to copper oxidation because it has two copper binding 
sites at N- and C-termini, which can simultaneously accommodate Cu (I) and (II), and 
facilitate copper reduction (Binolfi et al., 2008, Jiang et al., 2007). The compound of aSyn-Cu 
(I) can further generate oxidative damage, and causing more aSyn to aggregate (Camponeschi 
et al., 2013). Other metal ions like iron were also shown to induce aSyn oxidation and 
aggregation when co-incubated with peroxide in vitro (Hashimoto et al., 1999a).  
Di-tyrosine crosslink is another common oxidative modification found in aSyn structure 
both in vitro and in vivo (Souza et al., 2000, Pennathur et al., 1999). Cytochrome was shown 
to be important in the induction of aSyn di-tyrosine formation in the presence of peroxide (Ruf 
et al., 2008, Bayir et al., 2009). This cytochrome peroxidation system is thought to be a good 
model for studying aSyn aggregation in PD, as cytochrome is also found in Lewy bodies 
(Hashimoto et al., 1999b). 
2.2.2.4 Lipids 
There have been numerous studies showing that lipid binding promotes aSyn 
fibrillization, and aSyn aggregation is significantly enhanced in the presence of lipids both in 
vitro and in vivo (Rivers et al., 2008, Cole et al., 2002, Zhu et al., 2003, Lee et al., 2002, 
Sharon et al., 2003a). Lipid composition and level is associated with synucleinopathy 
progression in mouse brain, suggesting a relationship between aSyn aggregation and lipids 
during pathological conditions (Sharon et al., 2003b). Higher lipid concentrations protect aSyn 
from aggregation in dopaminergic neurons, whereas low lipid concentrations promote aSyn 
aggregation, suggesting that the ratio between aSyn and lipids may be the determinant of the 
aggregation (Zhu and Fink, 2003). It was proposed that lipid membrane may serve as a 2D  
scaffold, binding to membrane increases aSyn local concentration thus promotes aggregation 
(Aisenbrey et al., 2008). This is in agreement with the observation that even at low nanomolar 
range concentration, spontaneous aSyn aggregation can still be induced by the presence of 
lipid (Rabe et al., 2013). A recent study explained this phenomenon by demonstrating that 
local aSyn concentration is boosted by at least 1000-fold upon binding to lipid vesicle 
membrane (Galvagnion et al., 2015).  
Several pathological mutations of aSyn are associated with changing its binding affinity 
to lipids. E46K is close to residue 39-45, which is the section of aSyn that penetrates to 
membranes the most. Hence the E46K mutant shows increased binding affinity to membranes, 
resulting in forming a higher local aSyn concentration that can lead to increased aggregation 
(Stockl et al., 2008). NRM data show that after binding to the phospholipid membrane, A30P 
and G51D mutated aSyn purified from E.coli adapt a membrane-bound conformation with the 
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hydrophobic core exposed instead of burying it in the membrane, causing membrane-induced 
aggregation with a mechanism explained in section 2.2.2.1 (Jensen et al., 1998, Ysselstein et 
al., 2015).
2.2.3 Clearance of aggregation
2.2.3.1 Ubiquitin-Proteasomal degradation
As mentioned in section 2.1, misfolded or aggregated proteins are generally degraded 
through the ubiquitin-proteasome system (UPS) and autophagy-lysosomal pathway (ALP) 
(Figure 1)(Rubinsztein, 2006). In UPS, protein is first conjugated with ubiquitin by a chain of 
reactions via enzyme E1, E2 and E3, then recognized by 26S proteasome, and is degraded by 
subunits 19S and 20S via proteolytic activity (Pickart and VanDemark, 2000, Jariel-Encontre 
et al., 2008). aSyn can be degraded via UPS and ubiquitinated aSyn and components from 
UPS are frequently found in Lewy bodies (Kuzuhara et al., 1988, Zhou et al., 2004, Bennett et 
al., 1999). In addition, the reduction of UPS subunit expression and UPS activity are seen 
throughout the development of synucleinopathies (Bukhatwa et al., 2010). Mutation of two 
subunits of UPS, UCH-L1 and parkin, are associated with the development of familial PD 
(Shimura et al., 2001, Leroy et al., 1998). Inhibition of UPS promotes accumulation aSyn thus 
aggregation in vitro and in vivo, suggesting that malfunction of UPS can be responsible for 
aSyn aggregation (McNaught and Olanow, 2006). Mutated forms of aSyn such as A30P and 
A53T, exhibit a slower turnover rate by UPS, and in some cases reduced UPS activity, 
suggesting that some forms of aSyn may be partially resistant to proteolytic degradation, and 
thus impair the UPS pathway (Bennett et al., 1999, Tanaka et al., 2001, Smith et al., 2005).
Because protein needs to be unfolded by the 19S domain into a peptide chain to translocate 
into the active site of 20S catalytic domain, it is possible that high degree of aggregation could 
prohibit the unfolding of aSyn, thus impair the normal function of 19S domain (Shabek et al., 
2012). It is currently thought that aSyn aggregation and UPS may exhibit a “Chicken or the 
egg” relationship: severe aSyn aggregation blocks and impairs UPS; and dysfunction of UPS 
promotes further aSyn aggregation (Ebrahimi-Fakhari et al., 2012).
2.2.3.2 Autosomal-lysosomal pathway
ALP consists of multiple pathways including macroautophagy, chaperone-mediated 
autophagy (CMA) and microautophagy, all of which mediate proteins for lysosomal 
degradation. In CMA, proteins, including aSyn, with a KFERQ peptide sequence are 
recognized by chaperones like Hsp70 and are directed to a lysosomal receptor, such as LAMP-
2A, which mediate protein translocation across the lysosomal membrane for degradation 
(Cuervo and Wong, 2014). Lack of this motif in aSyn results in reduced cellular turnover rate 
(Vogiatzi et al., 2008). A reduction of ALP activity and expression of ALP-components are 
seen throughout the development of synucleinopathies (Ebrahimi-Fakhari et al., 2012). Mice 
with a deficiency of cathepsin D, a lysosomal enzyme, showed significant accumulation of 
endogenous aSyn but not aSyn mRNA in brain neurons (Qiao et al., 2008). Knockdown of 
LAMP-2A was also reported to induce aSyn deposits in cells (Vogiatzi et al., 2008). These 
pieces of evidence suggest that the impairment of ALP results in a failure of aSyn clearance. 
On the other hand, both dopamine-modified and mutated aSyn such as A30P and A53T, 
display a higher affinity to LAMP-2A. These mutations interrupt LAMP-2A mediated 
translocation of aSyn by blocking the receptor, hence impairing CMA activity and increase 
aSyn accumulation (Cuervo et al., 2004, Xilouri et al., 2009, Martinez-Vicente et al., 2008). In 
these studies, some post-translational modifications in aSyn, such as pS129 and certain 
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nitrated forms, also showed to reduce lysosomal translocation of aSyn, suggesting that certain 
forms of aSyn could impair and block CMA. Hence the "Chicken or the egg" relationship 
described for UPS and aSyn could also apply to the case of ALP: certain aSyn aggregation
may overrun and impair ALP, and dysfunction of ALP promotes further aSyn aggregation.
In addition to CMA, macroautophagy is also involved in aSyn degradation. Unlike CMA 
that is highly selective and constantly active, macroautophagy is only effective under certain 
circumstances like cellular starvation or stress. In conditions like these, cellular components 
are engulfed via autophagosome for bulk degradation (Ebrahimi-Fakhari et al., 2012).
Inhibition of autophagy by bafilomycin A1 mildly increases aSyn aggregation under an 
unstressed condition in cells, whereas induction of autophagy by rapamycin significantly 
boosts aSyn clearance (Webb et al., 2003). The expression of Beclin-1, a protein important for 
autophagy protein sorting, and LH3-II, an autophagosome membrane protein, were found to 
be increased in PD patients and mice with Lewy bodies, whereas mTOR, a negative regulator 
of autophagy, was reduced, showing an altered autophagy activity during synucleinopathies 
(Yu et al., 2009, Crews et al., 2010).
2.2.4 α-synuclein toxic species
aSyn aggregates frequently remain in Lewy bodies after the death of neuron. Hence it is 
commonly deduced that the aSyn aggregates are the toxic species that cause neuronal 
degeneration. It has been reported that S87E aSyn mutant aggregated less and exhibits less 
toxicity on DA neurons, whereas S87A showed the opposite (Oueslati et al., 2012). Direct 
application of aSyn fibrils to cells exhibits significantly higher toxicity than oligomers likely 
due to disruption of membrane permeability, suggesting that aSyn aggregates may exhibit a 
higher level of toxicity than soluble oligomers (Pieri et al., 2012). On the other hand, there is 
also controversial evidence. A wildly recognized view suggests that aSyn aggregation may be 
a protective process responding to the overwhelming pre-fibrillar aSyn oligomer that is toxic 
to the cells (Wan and Chung, 2012). For example, cellular toxicity of aSyn was shown to be 
reduced by directly or indirectly speeding up aSyn aggregation process in pharmacological 
approaches (Bodner et al., 2006, Outeiro et al., 2007). An in vivo study confirmed that aSyn 
species that aggregated faster were less toxic, whereas aSyn species that stayed as soluble 
oligomers caused the most damage to neurons (Winner et al., 2011). To make this more 
puzzling, recent study points to a direction that the toxicity of aSyn is highly dependent on 
various properties of different aSyn strains, which could result in distinct inclusion structure 
and pathological phenotypes (Peelaerts et al., 2015). In this study, a structurally defined aSyn
oligomer, ribbon and fibril assemblies were injected to mouse. aSyn fibrils caused the most 
toxicity, oligomers the least, and ribbons resulted in a phenotype resemble the pathological 
condition of PD the most. Another study on oligomer related toxicity demonstrated that by 
using different oligomerization protocol, different strains of aSyn oligomers were induced, 
likely associated with distinct mechanisms of disrupting cellular homeostasis and aggregation 
in as strain-specific manner (Danzer et al., 2007). It was revealed by an electron microscopy 
(EM) study that even the well-characterised genetic mutations such as A30P and A53T, tend 
to form different protofibrils strains under different conditions (Lashuel et al., 2002b). Like 
other neurodegenerative proteins, such as Tau, prion protein and Aβ, the strain properties 
might play a critical role in modulating the process of aSyn aggregation, intermediate 
structures, final aggregates and the toxicity. Currently little is known about the underlying 
molecular mechanisms. Details of how strains of aSyn play a role in the cell-to-cell 
propagation of synucleinopathy will be reviewed under a different section below. 
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Despite the ongoing debate on aSyn toxic species, the intracellular locations of abnormal 
aSyn species may potentially implicate the mechanisms of aSyn to exhibit toxicity. aSyn 
annular protofibrils were shown to bind to cell membranes, obtained an octameric structure 
that shares homology to bacterial pore-forming toxins, permeabilized membranes causing an 
influx of calcium (Ding et al., 2002, Tsigelny et al., 2012, Kim et al., 2009a). aSyn was also 
reported to bind and permeabilize the outer membrane of mitochondria, and thus triggered the 
release of cytochrome c, which is an apoptotic factor, and promoted oxidative stress and 
apoptosis (Hashimoto et al., 2004, Parihar et al., 2008). The A53T mutant of aSyn was shown 
to interact with ER chaperones, and sensitized cells to ER stress and disrupted ER-Golgi 
transport upon overexpression (Heller et al., 2012, Cooper et al., 2006). Apart from these gain 
of toxic functions, loss of aSyn physiological function could also result in toxicity. As 
reviewed in section 2.2.1, the loss of physiological function of aSyn in pathological conditions 
would result in the impairment of DA homeostasis and pre-synaptic vesicular trafficking. For 
example, the abnormal pre-synaptic vesicles morphology and impaired neurotransmitter 
release, which lead to the synaptic deficit, have been reported in aSyn overexpression 
transgenic mice (Scott et al., 2010).
2.2.5 Prolyl oligopeptidase
Prolyl oligopeptidase (PREP) is one of the evolutionarily conserved serine peptidases, 
which cleaves peptides with less than 30 amino acids at the C-terminal side of proline residues
(Rawlings and Barrett, 1994). PREP consists of a hydrolytic and a β-propeller domain, 
arranged in a “PacMan” shape with the active site located between the two domains (Fulop et 
al., 2000). PREP is widely expressed in the body tissues such as brain, liver, lung and spleen,
and is likely involved in the hydrolysis of substance P, angiotensin, thyrotropin and arginine-
vasopressin (Myohanen et al., 2012b, Garcia-Horsman et al., 2007, Mannisto et al., 2007).  A 
Recent study suggested that PREP also regulates pancreatic insulin and glucagon secretion in 
mice (Kim et al., 2014).
PREP has been implicated in neuronal function(s). For example, PREP has been 
suggested to modulate the function of GABAergic and cholinergic neurotransmitter release, 
and thus is involved in excitatory and inhibitory signalling pathway in the brain (Peltonen et 
al., 2011). PREP inhibition benefits the spatial memory in mice (Jalkanen et al., 2007). PREP 
deficiency impairs synaptic plasticity in mice (Hofling et al., 2016). PREP regulates inositol 
metabolism that serves as an important drug target in bipolar affective disorder (Williams et 
al., 2002). Also, PREP activity in brain changes during normal aging, but also in AD and PD 
(Myohanen et al., 2009). For example, hippocampal PREP activity is increased in the brains of 
aged mice and mice with AD as compared with young or wild-type ones (Rossner et al., 2005).
PREP was found to co-localize with aSyn and tau in AD and PD patient brain samples 
(Hannula et al., 2013). PREP was reported to enhance aSyn aggregation in vitro, which can be 
blocked by PREP inhibitors (Brandt et al., 2008). Some studies demonstrated that PREP 
inhibitor benefited learning and memory by modulating neuropeptide level, whereas some 
other studies showed the opposite (Shishido et al., 1998, Toide et al., 1997, Morain et al., 2002, 
Jalkanen et al., 2007). KYP-2047, which is a small-molecule inhibitor of PREP, was shown to 
reduce aSyn-mediated cytotoxicity in responding to oxidative stress and aSyn oligomerization 
in in vitro and in vivo studies (Dokleja et al., 2014, Myohanen et al., 2012a). KYP-2047 
treatment in transgenic mice and cells of PD model was also shown to increase cell and 
neuron viability with reduced high-molecular-weight oligomeric aSyn (Savolainen et al.,
2014). In the same study, it was also shown that KYP-2047-mediated inhibition of PREP also 
13
significantly increased autophagy activity, and thus suggesting that PREP inhibition could 
elevate autophagy activity and enhance protein clearance. It is currently not known if PREP 
has a direct effect on aSyn even though they have been reported to co-localize in PD-related
inclusions (Brandt et al., 2008). In the same study, aSyn seemed not to be a substrate of PREP 
enzyme activity as co-incubation of aSyn and PREP in vitro did not result in truncation of full-
length aSyn, which contains five Proline residues that may serve as potential hydrolytic sites 
for PREP.
Tau2.3
2.3.1 Structure and biological functions
Tau was first discovered and known for its physiological role in regulating microtubule 
assembly and stability (Weingarten et al., 1975). It belongs to microtubule-binding protein 
(MAP) family and is encoded by 16 exons of MAPT gene on chromosome locus 17q21 (Neve
et al., 1986). As shown in Figure 5, the full-length human tau protein has 441 amino acids.
Tau protein is structurally divided into the acidic region, the proline-rich region, the
microtubule-binding repeat region and C-terminal region (Mandelkow et al., 1996). The four 
regions constitute two functional domains: the N-terminal projection domain (N-domain) and 
the microtubule-binding domain (R-domain). Depending on the presence or absence of 1N, 
2N or 2R regions, there are six tau isoforms found in man: 0N3R (1R, 3R and 4R only), 1N3R 
(1N, 1R, 3R, 4R), 2N3R, 0N4R, 1N4R (1N, 1R-4R) and 2N4R (Gendron and Petrucelli, 2009).
N-terminal projection domain is mostly acidic, hence negatively charged, bends and projects 
from the surface of microtubule as shown in Figure 7 (Hirokawa et al., 1988). This domain 
interacts with many known proteins, and was suggested to modulate cellular signalling by 
interacting with several Src-family kinases, phospholipase C-γ, growth factor receptor-bound 
protein 2, phosphatidylinositol bisphosphate, Pin1. (Reynolds et al., 2008, Surridge and Burns, 
1994, Flanagan et al., 1997, Morris et al., 2011, Lu and Kosik, 2001). The microtubule-
binding domain functions primarily through the four highly conserved repetitive motives (R1-
R4) that regulate microtubule polymerization (Simic et al., 2016). The adult tau isoforms with 
R1-R4 repeats show significantly higher efficacy in promoting microtubule assembly than 
fetal tau isoform 0N3R, which lacks R2 region, highlighting the importance of R2 region in
regulating microtubule polymerization (Simic et al., 2003). In vitro study further demonstrated 
4R tau has a significantly higher binding affinity to microtubules than 3R tau (Lu and Kosik, 
2001).
Tau is widely expressed such as in submandibular gland, sigmoid colon, liver, scalp, and 
abdominal skin(Dugger et al., 2016), and is most abundant in brain, especially in neuron axons
and somatodendritic compartment (Gu et al., 1996, Dugger et al., 2016). The primary function 
of tau, regulating microtubule assembly and stability, is highly compensated by other MAP 
family proteins. Silencing tau in neuronal culture does not trigger neurodegeneration or 
prevent axon growth (Qiang et al., 2006). It is suggested that MAP1B rather than tau is more 
crucial in regulating microtubule stability (Takei et al., 2000). In neurons, tau was shown to 
interact with many proteins including Fyn kinase, post-synaptic density 95 and NMDA 
receptor, which are highly expressed in synaptic terminals (Klein et al., 2002, Lee et al., 1998, 
Mondragon-Rodriguez et al., 2012). Silencing tau in mice impairs long-term potentiation 
suggesting a role of tau in NMDA receptor-dependent memory (Ahmed et al., 2014).
Overexpression of tau in cells induces tau secretion in vesicles-bound form suggesting certain 
homeostatic cell mechanisms regulate the intracellular level of tau (Simon et al., 2012a). The 
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localization of tau in the nucleus suggests that tau may be involved in DNA modification or 
post-translational modification (Brady et al., 1995). In response to acute oxidative stress and 
heat stress, dephosphorylated tau was shown to accumulates in nuclei, and bound and 
protected DNA from oxidative damage, and possibly also enhanced DNA repair (Sultan et al., 
2011). Tau also binds and inhibits tubulin deacetylase, histone deacetylase 6, which is 
involved in protein sorting and transport in the autophagy pathway and is suggested to 
modulate both UPS and ALP (Perez et al., 2009, Leyk et al., 2015).
Figure 5. The domain 
structure of full-length tau. 
Full-length tau has 441 
amino acids, and has four 
structural domains: acidic 
region, proline-rich region, 
repeat region and C-terminal 
region, which are 
functionally divided into N-
terminal projection domain 
that projects away from 
microtubules and
microtubule-binding domain 
that binds microtubules and 
mediates tau aggregation 
(Gendron and Petrucelli, 
2009). The presence or 
absence of two regions at the
N-terminus (N1, N2) and four 
regions in the repeat region 
(R1-R4) makes six isoforms of tau as explained in the text. Two hexapeptides VQIVYK and VQIINK in the R2 and 
R3 regions are essential for tau-tau interaction and aggregation (von Bergen et al., 2000). Disease-associated
mutations in tau are clustered in the repeat region and primarily contribute to familial tauopathies (Wang and 
Mandelkow, 2016).
2.3.2 Phosphorylation
Tau is a phosphoprotein, and its biological activity is heavily regulated by 
phosphorylation (Kopke et al., 1993a, Kanemaru et al., 1992). For example, 0N3R tau in fetal 
brain is significantly more phosphorylated as compared to tau in the adult brain suggesting 
that tau phosphorylation occurs already at the fetal developmental stage (Goedert et al., 1993).
Neuronal development and neurite formation controlled by microtubule dynamics are highly 
regulated by tau phosphorylation because tau binding affinity to microtubules is heavily 
dependent on phosphorylation at specific sites (Garcia de Ancos et al., 1993). Also, tau 
activity is also altered by phosphorylation during mitotic cell division suggesting that 
phosphorylation is essential for both developmental and functional regulation of tau (Delobel 
et al., 2002, Wang and Liu, 2008).
As introduced in section 1, tau is a major pathological protein involved in AD. In
pathological conditions, tau has often been hyperphosphorylated that yield up to eight 
phosphates per tau molecule as compared to one phosphate per tau molecule in physiological 
condition (Kopke et al., 1993b). As shown in Figure 6, almost 85 potential phosphorylation 
sites have been identified on full-length tau so far, and 80 of them are Serine (Ser, S) or 
Threonine (Thr, T) residues, and only a few are Tyrosine (Tyr, Y) (Hanger et al., 2009). Over 
30 of phosphorylation sites found in AD brain have been reported to cluster in the proline-rich 
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and C-terminal regions (Wang and Liu, 2008). Among them, 17 Thr or Ser sites prior to 
Proline (Pro) are found abnormally hyperphosphorylated in AD brain and are considered most 
attractive regarding pathology (Wang and Mandelkow, 2016). A few widely used antibodies 
such as AT8, AT100, AT180, 12E8 and PHF-1 have been developed to specifically recognize 
them (the identified epitopes are as shown in Figure 6).
2.3.3 Kinases and phosphatases
Tau phosphorylation homeostasis is regulated by multiple protein kinases and 
phosphatases (Liu et al., 2007). Depending on motif-specificity, kinases are divided into
proline-directed (phosphorylate Thr or Ser sites prior to Pro) and non-proline-directed protein 
kinases (Meraz-Rios et al., 2010). The major proline-directed protein kinases related to tau 
include glycogen synthase kinase-3 (GSK-3), cyclin-dependent kinase 5 (CDK5), dual-
specificity tyrosine-phosphorylation-related kinase 1A (DYRK1A) and mitogen-activated 
protein kinase family (MAPKs) (Wang and Liu, 2008, Martin et al., 2013). All of them, 
especially GSK-3β (one of the two GSK-3 proteins), are strongly associated with tau 
phosphorylation in both physiological and pathological conditions(Wang and Liu, 2008, 
Martin et al., 2013).
GSK-3, in general, regulates multiple cellular signalling, metabolic and structural 
proteins functions (Grimes and Jope, 2001). GSK-3, especially the β form, is one of the most 
important tau kinases that phosphorylate tau at over 30 sites known to regulate tau 
physiological functions (Cho and Johnson, 2003, Ishiguro et al., 1993, Grimes and Jope, 2001).
In addition, GSK-3β also impairs tau binding affinity to microtubule by hyperphosphorylating 
tau in pathological conditions. CDK5 is involved in maintaining cellular function and 
development of CNS (Lew et al., 1994). Prolonged activity of CDK5 under stress conditions 
Figure 6. Tau phosphorylation sites. Tau phosphorylation sites showed in the figure are derived from experiments, 
theories and hypothesis.  Tau phosphorylation sites in physiological and pathological conditions are indicated by 
different colours. The commonly used antibodies recognize pathologically relevant phosphoepitopes are shown in 
purple. Adopted from Simic et al. (2016) with permission under Creative Commons Attribution License, copyright 
(2017).
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lead to tau hyperphosphorylation, cytoskeletal abnormality and neuron degeneration (Patrick 
et al., 1999). DYRK1A was suggested to play a major role in neuronal growth and 
development (Duchon and Herault, 2016). In addition, DYRK1A encoding gene is known to 
localize on chromosome 21, trisomy of which causes Down syndrome (DS) (Wiseman et al., 
2009). As it was reported that most DS patient developed AD-like dementia by the age of 40, 
the fact the DYRK1A regulates tau phosphorylation become interesting in term of connected 
pathologies (Park et al., 2009). MAPKs are a family of kinases including MAPK, MAPK2/3, 
extracellular signal–regulated kinases (ERK), Jun NH2-terminal kinase (JNK), p38 etc, and 
are primarily involved in signalling transduction and several cellular functions such as cell 
growth, apoptosis and proliferation (Schaeffer and Weber, 1999, Munoz and Ammit, 2010).
MAPKs-mediated pathways have been suggested to be involved in several types of cancers, 
and also AD, PD and amyotrophic lateral sclerosis (ALS) (Kim and Choi, 2010). Several 
members of MAPKs such as JNK, ERK1/2 and p38 were reported to be related to abnormal 
tau phosphorylation in pathological conditions (Churcher, 2006).
Non-proline-directed protein kinases that phosphorylate tau include casein kinase 1(CK1),
protein kinase C (PKC), calmodulin-dependent protein kinase II (CaMKII), Fyn, and cyclic 
AMP-dependent protein kinase (PKA), all of which apart from Fyn phosphorylate tau at 
Ser/Thr sites (Meraz-Rios et al., 2010, Wang and Liu, 2008).  All of these kinases have been
shown to be related to abnormal phosphorylation of tau in pathological conditions (Kuret et al., 
1997, Yamamoto et al., 2002, Liu et al., 2003, Zhang et al., 2006, Lee et al., 2004). PKA is
primarily involved in cAMP-mediated cellular signalling pathways and was also shown to
phosphorylate GSK-3 and CDK5 in addition to tau (Wang et al., 2007a). Fyn is one of the 
very few kinases phosphorylate tau at Tyr residues, and is involved in cell signalling and 
several neuronal functions (Resh, 1998). In addition, Fyn has been reported to 
hyperphosphorylate tau in an Aβ-dependent manner (Williamson et al., 2002).
In mammalian cells, the protein phosphatase (PP) 1, PP5, PP2A, PP2B and PP2C are the 
major phosphatases that dephosphorylate tau at specific Ser/Thr residues (Liu et al., 2005b). It 
has been reported that PP2A activity is decreased in AD brains while the endogenous inhibitor 
of PP2A, I1PP2A and I2PP2A level are increased (Tanimukai et al., 2005). In addition, PP2A, 
I1PP2A and I2PP2A colocalize with tau aggregates in pathological inclusions, suggesting that 
PP2A is closely linked with abnormal tau phosphorylation in pathological conditions, and thus
may serve as a drug target for AD (Liu et al., 2005b, Tian and Wang, 2002).
2.3.4 Other post-translational modifications
Apart from phosphorylation, other important tau post-translational modifications include
truncation, glycosylation, acetylation, nitration, methylation and ubiquitinations (Gong et al., 
2005). In glycosylation, proteins are covalently linked with oligosaccharides in N- or O-
glycosidic bond. Paired helical filaments (PHF) has been reported to consist of tau with N-
glycosylation modification, which was suggested to affect tau phosphorylation via kinases-
and phosphatases-mediated pathways (Liu et al., 2002). O-glycosylation of tau was reported to 
take place at Ser or Thr residues that are important residues for tau phosphorylation during 
pathogenesis of AD as mentioned above, and thus was suggested to be protective in
pathological conditions, possibly by competing Thr/Ser sites with proline-directed kinases 
against hyperphosphorylation (Morris et al., 2015, Liu et al., 2004). Tau poly-ubiquitination is 
linked with tau clearance and is discussed in a different section below. Hyper-acetylation of 
tau has been reported to inhibit ubiquitin-mediated tau degradation, thus enhances 
accumulation of hyperphosphorylated tau, and moreover induces toxicity in pathological 
conditions (Min et al., 2010). Nitrations of tau were reported to occur on tyrosine residues 18, 
17
29, 197 and 394 in NFTs, and thus were suggested to have a link to tau fibrillization
(Reynolds et al., 2005). Methylation of tau has been observed on lysine residues, but the exact 
functional relevance is yet not fully understood (Thomas et al., 2012). Tau truncations, 
especially C-terminal truncations, were suggested to contribute to tau aggregation pathways, 
and are discussed below. 
2.3.5 Tau aggregation
It is widely recognized that hyperphosphorylation is a significant contributor and 
regulator to tau aggregation pathway. In physiological condition, tau binds and stabilizes 
microtubules, and its phosphorylation homeostasis is maintained by transient reversible 
phosphorylation via kinases and phosphatases as shown in Figure 7. However, abnormal 
phosphorylation of tau occurs when the phosphorylation/dephosphorylation cycle is disturbed 
resulting in accumulation of hyperphosphorylate tau in cells. Certain patterns of 
hyperphosphorylation lead to reduced tau binding affinity to microtubules and destabilize 
microtubules. Free tau molecules could further oligomerize, forming fibrils known as paired 
helical filaments (PHF). Additional aggregation of PHFs forms NTFs that are commonly 
observed after the death of neurons in tauopathies.
Tau aggregation follows a similar pattern of nucleation-elongation mechanism as aSyn. 
Several factors contributing to the aggregation process are shared between aSyn and tau, such 
as structural characteristics favouring aggregation, truncations, post-translational 
modifications and genetic mutations (Wang and Mandelkow, 2016).
2.3.5.1 β-sheet intermediate
Despite the fact that natively unfolded tau monomers are structurally highly dynamic, tau 
aggregates are generally packed into well-ordered β-sheet-like structures (Simic et al., 2016).
Two hexapeptides VQIINK and VQIVYK on R2 and R3 motives of tau (Figure 5) are 
Figure 7. A schematic representation of tau aggregation pathway. In physiological conditions, tau promotes 
microtubule assembly and stabilization by binding to microtubules via the microtubule-binding domain. 
Homeostasis of tau phosphorylation is maintained by kinases and phosphatases. In pathological conditions, tau 
can be hyperphosphorylated due to increased kinase activity or decreased phosphatase activity, and detaches from 
microtubules. This causes microtubules to disassemble and loss physiological functions. Free soluble tau with 
hyperphosphorylation and other post-translational modifications such as truncations tend to aggregate to paired-
helical filaments (PHF), which further aggregate into insoluble neurofibrillary tangles (NFT) that are commonly 
observed in the clinical situations of tauopathies. Right top image is modified from Clavaguera et al. (2009).
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essential for the formation of “zipper-like” interdigitated β-sheet structures, and thus play a 
major role in mediating tau oligomerization and aggregation (von Bergen et al., 2000). Certain 
mutations, e.g. mutations at K280 and P301, which disrupt the structure of paired β-sheet, tend 
to have a significant impact on tau aggregation. For example addition of proline after K280 
significantly reduces the tendency of tau aggregation, whereas certain mutations like deletion
of K280 or P301L strongly promote tau aggregation in vitro (Khlistunova et al., 2006). Most 
of these mutations were originally identified in patients who have familial dementia (Rizzu et 
al., 1999, Iijima et al., 1999, Hutton et al., 1998).  It was suggested that the aggregation in the 
manner of “steric zipper” is a characteristic shared between over 30 different fibril-forming-
prone proteins including amyloid-β and aSyn, suggesting that amyloid diseases share common 
mechanistic features at the molecular level during aggregation (Sawaya et al., 2007).
2.3.5.2 Truncation
Truncation is one of the post-translational modifications that are closely linked with the 
aggregation property of tau. There are multiple potential cleavage sites on full-length tau as 
shown in Figure 8. Truncations of tau lead to many fragments containing the microtubule-
binding region that are highly prone to aggregation (Wang and Mandelkow, 2016).
Inoculation of tau151-391 that was isolated from PHFs via pronase was shown to induce 
wildtype tau aggregation and neurofibrillary pathology in a transgenic mouse model (Wischik
et al., 1988b, Zilka et al., 2006).  Inoculation of tau1-421 that is cleaved by caspase 3 was also 
shown to form NTFs in a transgenic mouse model (de Calignon et al., 2010). Lysosomal 
asparagine endopeptidases cleave tau at Asn255 or Asn368, and the resulting tau1-368 is not 
only prone to aggregation but also has compromised ability to bind and to stabilize 
microtubules (Zhang et al., 2014). In the cellular model of tauopathy, deletion of P280 triggers 
a stepwise proteolysis of tau: starting from N-terminal cleavage by thrombin-like protease 
preceding to C-terminal cleavage by cathepsin I, resulting in fragments F1 (Tau257-441), F2 
(Tau257-363), F3 (Tau257-360) (Wang et al., 2007b). The F3 fragment was found to aggregate 
rapidly and can form the core of AD-related PHFs (Wang et al., 2009b, Simic et al., 2016).
2.3.5.3 The role of phosphorylation in tau aggregation
In 1990 M. Goedert and colleagues found all isoforms of tau are hyperphosphorylated 
within PHFs, and after that, it has been widely accepted that PHFs consist of mostly 
hyperphosphorylated tau species (Goedert and Jakes, 1990). In addition, since tau 
hyperphosphorylation has long been observed in tau aggregates from patients or animal 
models, it has been reasoned that phosphorylation is responsible for driving tau aggregation 
(Braak et al., 1994b). There is evidence support this theory. For example, 
hyperphosphorylated tau isolated from AD patients’ brain self-assembles into PHFs (Alonso 
et al., 2001), but it is not known if other co-factors or modifications are involved. On the other 
hand, AD-like tau hyperphosphorylation without aggregation is observed in hibernating 
animals or anaesthesia-induced hypothermia indicating that hyperphosphorylation may not be 
sufficient to trigger tau aggregation alone (Arendt et al., 2003, Planel et al., 2007). Some 
phosphorylation events, e.g. Ser214/262 even show protection against aggregation (Schneider 
et al., 1999). No evidence has yet proved that phosphorylation alone accounts for tau 
aggregation.  Many contradictory conclusions are derived probably due to the complexity and 
a significant number of tau phosphorylation sites (Simic et al., 2016). But indeed tau 
hyperphosphorylation is linked to aggregation, for example, it has been proposed that 
hyperphosphorylation of tau could induce tau detachment from microtubules that may 
potentially accelerate and feedforward the aggregation process (Wang and Mandelkow, 2016).
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2.3.5.4 Template-directed aggregation
The widely accepted view stating that PHFs mostly consists of hyperphosphorylated tau 
has been challenged by the studies from Wischik, C. M. and colleagues since 1995. They 
demonstrated that phosphorylated tau species makes up a fuzzy coat accounting for only 15% 
of total tau in PHFs, whereas truncated tau of 12 kD fragments that only contain repeat 
domains (in a pattern of 1R2R3R or 2R3R4R or 1R3R4R, Figure 5) make up the proteolysis-
stable core of PHFs (Lai et al., 1995, Wischik et al., 1995, Wischik et al., 1988a, Jakes et al., 
1991). The identified truncations that consisted of three repeats region of tau microtubule-
binding domain was suggested to enhance or even lock tau oligomers upon interaction into a
complex that is resistant to proteolysis degradation (Jakes et al., 1991, Simic et al., 2016).
While full-length tau was incubated with this type of 3-repeat tau fragments during repeated
protease digestions in vitro, full-length tau was digested into similar 3-repeat tau fragments
but not in the absence of co-incubation with the 3-repeat tau fragments before digestion 
(Wischik et al., 1996). A Recent study also demonstrated that co-expression of repeat domain 
fragments with full-length tau in cells triggered similar template-directed truncations, which 
represent AD-like PHFs core units, and the resulted fragments also have compromised ability 
of microtubule binding (Harrington et al., 2015). Taken together, pathological tau species may 
bind to physiologically normal tau, and convert normal tau into similar pathological species in 
a template-directed manner, thus suggesting a prion characteristic of tau-tau interaction with 
disease-related post-translational modification of truncations (Simic et al., 2016). As the entire 
process does not require phosphorylation, it was suggested that certain interactions of tau 
repeat domains in pathological conditions may be the driver of the redistribution of tau into 
disease-associated species that further aggregate into PHFs, whereas abnormal 
phosphorylation of tau may accelerate this process by reducing microtubule binding of tau 
(Simic et al., 2016).  
2.3.5.5 Disease-associated mutation of tau
There have been more than 80 mutations found on human MAPT gene, some of which 
promote tau aggregation and induce familial tauopathies (Wang and Mandelkow, 2016). Both 
Figure 8. The potential 
cleavage sites on tau. 
Tau is cleaved 
sequentially at multiple 
sites as indicated in the 
picture, forming
truncated fragments
from repeat domain
regions that are highly 
prone to aggregation.
Cleavages are suggested 
to take place while tau is 
unbound from 
microtubule, and/or 
associated with other tau 
molecules or proteins 
other than tubulin. The 
picture is modified from
Simic et al. (2016) .
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missense and splicing mutations have been reported previously. As shown in Figure 5, most of 
the missense mutations are clustered in or near the repeat domains and have a tendency to 
reduce tau binding affinity to microtubules and to increase tau aggregation (Barghorn et al., 
2000, Hong et al., 1998).  There are also mutations far from the repeat domain regions exhibit 
a similar effect on tau. For example, it was reported that progressive supranuclear palsy (PSP)-
related mutation A152T located far from the repeat domains reduced tau binding to 
microtubule and tau-mediated microtubule assembly (Coppola et al., 2012). R5H and R5L 
mutations, which disrupt tau binding to p150 that is a dynactin subunit acts as a cofactor of 
microtubule motor dynein, reduced microtubule-mediated axonal transport (Magnani et al., 
2007). Splicing mutations are mostly clustered in or near intron 10 (N279K, L284L, ∆N296,
N296N, N296H, S305N, S305S, etc.), and result in increased inclusion of exon 10, which 
encodes for the R2 region, thus alter the 1:1 physiological ratio of R4:R3 tau isoforms (Wang 
and Mandelkow, 2016, Ballatore et al., 2007). 0N4R tau was shown to have significantly 
higher efficacy in promoting microtubule assembly than 0N3R tau that lacks R2 region
(seeFigure 5), highlighting the importance of R2 region in regulating tau-mediate microtubule 
assembly and stability (Simic et al., 2003). In addition, R2 region of tau contains the VQIINK
hexapeptide (Figure 5) that is essential for tau oligomerization and aggregation (von Bergen et 
al., 2000). Taken together, this evidence could potentially offer an explanation of the increased 
R4: R3 ratio as a characteristic of tauopathies in frontotemporal dementias (Hong et al., 1998).
2.3.6 Genetic risk factors of Alzheimer’s disease
AD is one of age-related dementia characterized by progressive neurodegeneration in 
certain connected brain regions, which correlates with the gradual decline of cognitive 
function (Dennis Dickson, 2011). Study of AD brain at autopsy revealed numerous senile 
plaques and deposits in blood vessels, which primarily consist of Aβ and NFTs (Braak and 
Braak, 1991). The etiology of AD is currently incompletely understood, but many studies have 
made the consensus that the disease progression and onset are closely linked with genetic 
factors. The misfolding and aggregation of tau play essential roles in the pathogenic pathway 
of AD. There are many genetic risk factors are potentially associated with the increased 
chance of developing AD. Currently, there lacks direct connection between some of these 
genetic risk factors and tauopathies observed in AD. Part of this thesis work demonstrates a 
previously unrecognized mechanism of a protein that is encoded by a late-onset Alzheimer’s 
disease (LOAD) susceptibility gene FRMD4A, modulating the cellular propagation of tau.
Occasionally before the age of 65, patients with rare mutations in APP and PSEN1/2
genes (also known as early-onset AD risk genes) develop familial AD (Cacace et al., 2016).
However, over 95% AD cases are the late-onset (LOAD) type. A large number (>700) of risk 
genes have been identified for LOAD using genome-wide association studies (GWAS) and 
candidate gene approaches, which correlate the frequency of the risk variants of certain alleles 
with diseases in defined groups (Bertram et al., 2010, Chouraki and Seshadri, 2014). GWAS
covers entire genome with known polymorphisms, and screens potential association of SNPs 
to phenotypes in a manner of hypothesis-free. Thus GWAS is statistically powerful and 
generates massive data. In GWAS discovery stage, a p-value threshold of 5 x 10-8 is usually 
set to avoid false-positive (McCarthy et al., 2008). In addition, during replication stage, 
selected variants are often re-studied by de novo genotyping multiple independent populations 
to further filter out false-positives (Chouraki and Seshadri, 2014). Since 2007 when APOE
was the first LOAD risk gene reported by GWAS, multiple genes with SNPs or variants 
associated with AD had been identified: ABCA7, BIN1, CASS4, CD33, CD2AP, CELF1, CLU,
CR1, DSG2, EPHA1, FERMT2, HLA-DRB5/DRB1, INPP5D, MS4A, MEF2C, NME8,
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PICALM, PTK2B, SLC24H-RIN3, SORL1 and ZCWPW1 (Medway and Morgan, 2014, Calero 
et al., 2015, Karch and Goate, 2015). Using other similar approaches such as genome-wide 
haplotype association study or alternative methods such as exome sequencing, FRMD4A,
TRIP4, TREM2 and PLD3 were also reported as novel loci related to AD susceptibility 
(Lambert et al., 2013a, Ruiz et al., 2014, Jonsson et al., 2013, Cruchaga et al., 2014, Guerreiro 
et al., 2013a)
Among all the LOAD susceptibility genes, APOE, especially APOE ε4 allele, is by far 
the most important and frequently reported genetic risk factor related to the pathogenesis of 
non-familial, sporadic late-onset AD (Strittmatter et al., 1993, Corder et al., 1993).  APOE
gene locates on chromosome 19q13.2, and encodes for apolipoprotein E (APOE) that 
physiologically functions as lipoprotein ligand, which regulates lipoprotein internalization, 
cholesterol and other lipids transport and metabolisms in brain and periphery (Pericak-Vance 
et al., 1991, Siest et al., 1995, Mahley, 1988, Kim et al., 2009b). APOE has three isoforms 
depending on two variations in amino acid sequence. APOE4 (R112, R158) corresponds to 
APOE ε4, APOE2 (C112, C158) corresponds to APOE ε2, and APOE3 (C112, R158) 
corresponds to APOE ε3 (Zannis et al., 1982, Weisgraber et al., 1981). As schematically 
illustrated in Figure 9, APOE ε4 could elevate the AD risk from 3-15 folds depending on 
whether the allele is in homozygosis or heterozygosis (Kim et al., 2009b). But unlike PSEN1/2
and APP mutations, APOE ε4 alone is not sufficient to induce AD (Bertram et al., 2007, 
Farrer et al., 1997). Many LOAD risk genes including APOE may not significantly contribute 
to AD by itself, but the presence of multiple LOAD risk gene with disease-associated SNPs or 
variants at the same time would remarkably increase the risk of developing AD (Bertram et al., 
2007). Over half of AD patients were not APOE ε4 carriers, but the presence of APOE ε4 was 
suggested to affect the age of onset of familial AD (Corder et al., 1993). By far the exact role 
and molecular mechanisms of APOE in AD pathogenesis are not fully understood (Chouraki 
and Seshadri, 2014). Evidence suggested that APOE could modulate Aβ aggregation and 
metabolism through direct or indirect routes such as binding or regulating low-density 
lipoprotein receptor-related protein 1 (LRP1)(Verghese et al., 2013, Castellano et al., 2011). In 
addition, APOE was also shown to bind to tau, but the functional relevance of this binding is 
yet unknown (Strittmatter et al., 1994). Fortunately, APOE ε3 is the most common genotype, 
and together with APOE ε2 show protective role against the development of AD (Weisgraber 
et al., 1981, Corder et al., 1994).
Table 1 and Figure 9 summarize some of the top susceptibility risk genes with associated 
cellular functions. These genes are functionally grouped into vesicular trafficking [bridging 
integrator 1(BIN1), CD2-associated protein (CD2AP), FERM containing domain 4A 
(FRMD4A), Phosphatidylinoaitol binding clathrin assembly protein (PICALM) and sortilin-
related receptor LDLR class A repeats containing (SOR1)], cholesterol metabolism [ATP-
binding cassette transporte A7 (ABCA7), ADAM10, apolipoprotein E (APOE4), clusterin 
(CLU) and SOR1] and immune response [ABCA7, CLU, complement receptor 1 (CR1),
CD33, triggering receptor expressed on myeloid cells 2 (TREM2) and membrane-spanning 4-
domains subfamily A (MS4A)] (Karch and Goate, 2015, Jones et al., 2010, Medway and 
Morgan, 2014). It is not fully understood that how these LOAD risk genes are connected to 
AD or tau, but BIN1, CD2AP, and APOE were previously reported to influence CSF tau level 
and tau-mediated neurotoxicity (Chapuis et al., 2013b, Cruchaga et al., 2013b, Shulman et al., 
2011). The exact function(s) of other newly identified LOAD risk genes are yet to be 
elucidated. Functional studies to explore the connections between LOAD risk genes and tau 
propagation pathway are particularly interesting in term of pathology and may identify new
drug targets.
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Table 1 Some of the top LOAD risk genes apart from APOE. The pathological relevance of the LOAD genes is from 
several GWAS studies (Naj et al., 2014, Harold et al., 2009, Lambert et al., 2009, Seshadri et al., 2010, 
Hollingworth et al., 2011).
Gene Biological functions Pathological relevance
CLU Multiple cellular functions such as 
apoptosis, lipid transport (Jones and 
Jomary, 2002, May et al., 1990, Choi-
Miura et al., 1992).
Multiple SNPs associated with AD 
risk and some showed protective roles 
during AD pathogenesis 
ABCA7 Regulate phospholipid, cholesterol 
trafficking and APP processing (Ikeda et 
al., 2003, Wang et al., 2003, Quazi and 
Molday, 2013, Chan et al., 2008).
Several ABCA7 variants were 
identified, but the functional relevance 
is unknown 
BIN1 Multiple cellular functions such as 
endocytosis, calcium homeostasis, 
intracellular vesicle trafficking and 
apoptosis (Tan et al., 2013).
BIN1 has been shown to interact with 
tau (Chapuis et al., 2013a). BIN1 has 
multiple SNPs identified by GWAS to 
be associated with increased AD risk.
CD2AP Cytoskeleton organization (Dustin et al., 
1998, Lehtonen et al., 2002)
Multiple SNPs associated with 
increased risk of AD 
CD33 Cell-to-cell signalling and binding 
(Crocker et al., 2007, Jandus et al., 
2011)
Several SNPs associated with reduced 
AD risk 
CR1 Mediating immune response (Weis et 
al., 1987, Klickstein et al., 1988).
Several SNPs associated with 
increased AD risk 
EPH Cell-to-cell signalling, axonal guidance 
and plasticity (Lai and Ip, 2009, 
Yamazaki et al., 2009)
A few SNPs near locus that are 
associated with reduced AD risk 
FRMD4A Belongs to FERM superfamily, and the 
exact function(s) is yet incompletely 
understood (Tepass, 2009)
Multiple SNPs associated with 
increased AD risk.
MS4A A gene cluster involved in immune 
response (Liang et al., 2001, Ishibashi et 
al., 2001, Liang and Tedder, 2001).
Several SNPs near MS4A4E and 
MS4A6A genes associate with 
decreased AD risk.
PICALM Clathrin-mediated endocytosis (Miller et 
al., 2011)
Multiple AD risk-associated SNPs 
were found at or near PICALM locus, 
and some of which were shown to be 
protective during AD development.
SORL1 Multiple cellular functions, vesicular 
trafficking, cargo sorting, and also in 
APP processing and trafficking, and Aβ 
production (Yin et al., 2015, Offe et al., 
2006, Spoelgen et al., 2006)
Rs11218343 was recently shown to be 
a SORL1 SNPs related to AD risk.
TREM2 Inflammation response (Rohn, 2013) One SNP, rs75932628, on TREM2 
was identified by advanced 
sequencing studies to cause a mutation 
(R47H) that is related to the increased
AD risk and the onset of pathology. 
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2.3.7 Tau ubiquitination and clearance
Tau isolated from AD brains was shown to carry ubiquitin-modifications at multiple sites,
such as Lys254/257/311/317/353, which are clustered in or near the repeat domains and 
influence microtubule binding affinity of tau (Mori et al., 1987, Morishima-Kawashima et al., 
1993, Cripps et al., 2006, Matenia and Mandelkow, 2009). Some of these poly-ubiquitin-
modifications are chained through Lys48/63, which are previously described signalling 
pathways for proteasomal degradation (Pickart, 2001). The C-terminus of heat-shock cognate 
70-interacting protein (CHIP) and tumour-necrosis-factor-receptor-associated factor 6
(TRAF6) are the two known ubiquitin E3 subunits that ubiquitinate tau and colocalize with tau 
in NFTs (Shimura et al., 2004, Hatakeyama et al., 2004, Babu et al., 2005). Specific proline-
directed Ser/Thr phosphorylation of tau is needed for CHIP recognition, whereas KXGS
phosphorylation motif in the repeat domain reduces tau ubiquitination (Dickey et al., 2007, 
Shimura et al., 2004). Overexpression of CHIP or promoting formation polyubiquitin chained
at Lys48/63 can trigger tau aggregation suggesting ubiquitination plays an important role 
regulating tau aggregation (Petrucelli et al., 2004, Tan et al., 2008).
Despite the fact that tau is polyubiquitinated, it is currently debated if tau is
predominantly degraded by UPS (Wang and Mandelkow, 2012). Tau appears to be the 
substrate of UPS in some studies but is hardly influenced by UPS in other studies (Shimura et 
al., 2004, Dickey et al., 2007, David et al., 2002, Wang et al., 2009b, Brown et al., 2005, 
Feuillette et al., 2005). Cell lines, tau species, microenvironments, etc. differences between 
studies are considered as the cause of the contradictory results suggesting tau may be degraded 
by distinct mechanisms under different circumstances (Wang and Mandelkow, 2012). In
cancer cell lines such as SH-SY5Y, tau is degraded by UPS, whereas in primary neurons, tau 
is actively degraded by ALP (David et al., 2002, Kruger et al., 2012). While using the same 
immortalized mouse cortical neuron CN1.4, full-length tau is degraded by UPS whereas 
Asp421 truncated tau that represents an AD pathological species is predominantly degraded 
via the ALP (Dolan and Johnson, 2010). In rat primary neurons, after inhibition of heat-shock 
protein Hsp90, Tau P301L, an aggregation-prone mutant, is actively degraded via UPS while
WT tau is not (Luo et al., 2007). Natively unfolded tau can be degraded via 20S proteasome in 
Figure 9. Genetic 
landscape of the top
susceptibility genes related 
to late-onset Alzheimer’s
disease.  Genome-wide 
association and related 
studies on LOAD genes 
generated an enormous 
amount of data that 
provides a statistic view on 
the chance of a gene variant 
to trigger diseases, and the 
distribution in the 
population. Compared with 
autosomal dominant 
disease causative genes 
such as APP, PSEN1/2, the LOAD risk genes have much lower chance to trigger disease alone. APOE4 homo-
and heterozygote have different contribution to disease. The primary cellular functions of the proteins encoded 
by these genes are indicated as colour in the boxes, and the additional functions are indicated as the edge lines. 
Modified from Karch et al. (2015).
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vitro, and this can be inhibited by GSK3-? phosphorylation of tau (Poppek et al., 2006, David 
et al., 2002). Additionally, like aSyn (reviewed in section 2.2.3.1), higher order oligomers and 
aggregates of tau are precluded from UPS as the narrow channel of UPS only allow unfolded 
and linearized peptide chain to pass through (Rubinsztein, 2006). In many cases, these tau 
fibrils impair UPS activity (Keck et al., 2003).
Just like aSyn, tau also has the KFERQ motif that is recognized by Hsp70 and is used to 
direct tau for ALP degradation (Wang et al., 2009b). Activation of autophagy by rapamycin 
reduces tau level in cell and Drosophila models, whereas inhibition of autophagy promotes tau
aggregation (Hamano et al., 2008, Berger et al., 2006). ALP degrades most forms of tau, 
including both soluble and insoluble tau, including tau with KXGS motif phosphorylated that 
is not degraded by UPS (Wang et al., 2009b). Like aSyn, certain tau aggregates or mutants
such as P301L, G272V, R406W, can impair ALP-mediated degradation (Shemesh and Spira, 
2010, Lin et al., 2003, Lim et al., 2001).
2.3.8 Toxic species of tau
The pathogenesis of neurodegenerative diseases with tauopathies is not fully understood 
(Wang and Mandelkow, 2016). It is currently debated if NFTs is associated with the cognitive 
decline seen in AD patients due to limited data from human brains and lack of understanding 
of disease mechanisms (DeFelipe, 2016). Several studies carried out in transgenic mice 
indicated that NFTs may not strongly relate to cognitive impairment (Gomez-Isla et al., 1997, 
Andorfer et al., 2005, Spires-Jones et al., 2008). However, tau aggregation is a common 
characteristic of several neurodegenerative diseases and is also observed in aged brains from 
cognitively normal subjects (Crary et al., 2014). Like aSyn, the tau aggregates such as NFTs 
were at first considered to be toxic due to the correlation with diseases progression (Wang and 
Mandelkow, 2016). But later a lot of evidence has suggested that insoluble tau aggregates may
not be the most toxic species. For example, switching off tau P301L expression (an 
aggregation-prone mutant) improved memory dysfunction in transgenic mouse regardless of 
the presence of NFTs suggesting that synapse loss or cognitive deficit is not dependent on the 
presence of tau aggregates (Santacruz et al., 2005). In several other animal models, neuronal
death is not correlated with NFTs, and neurons can live surrounded by NFTs for years 
(Andorfer et al., 2005, Spires-Jones et al., 2008). This agrees with the observations in human. 
In superior temporal sulcus region of 37 AD patients’ brains, the ratio between the neuronal 
loss to NFT population can be 7:1, suggesting a lot more neurons dead in the absence of NFTs
(Gomez-Isla et al., 1997). With computer modelling, neurons in man were shown to survive
over 20 years with NFTs (Morsch et al., 1999).
There have been views suggesting that the filamental assembly of pathological tau 
species might be neuron-protective, possibly by “packaging up” pathological tau species into 
PHFs and NFTs to prevent further cellular damage (Alonso Adel et al., 2006). As mentioned 
previously, certain misfolded tau species have their hydrophobic residues exposed and could 
recruit normal proteins with low complexity including tau itself upon interaction, and form a 
further aggregation. Hence by packaging into fibrils, the hydrophobic residues could be buried 
inside, and thus prevents pathological interaction that could cause other normal proteins and 
tau to gain toxic function or to lose their physiological functions.
There are also views suggesting that the most toxic tau species are certain oligomeric
intermediates (Lasagna-Reeves et al., 2012c, Maeda et al., 2007). However, due to the 
heterogeneity of tau oligomers, there has not been a clearly defined toxic property assigned to 
different oligomers species of tau (Wang and Mandelkow, 2016). For example, exposing 
primary neuron to hyperphosphorylated full-length tau oligomers trigger degeneration of 
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dendritic spines (Tepper et al., 2014). Treating SH-SY5Y cells with tau monomers, oligomers
or fibrils demonstrated that tau oligomers are the most toxic species, which caused significant 
neuronal death possibly by disrupting membrane integrity (Flach et al., 2012). Incubating 
human neuroblastoma cells with tau monomers, dimers and trimers showed that trimer was the 
most toxic species even at a low nanomolar concentration (Tian et al., 2013). Some studies 
have tested both pro-aggregant and anti-aggregant tau mutants in mouse models, showing that 
only pro-aggregant tau induced the development of AD-like pathology in mice suggesting that 
tau aggregation potential may be needed for toxicity and brain pathology (Eckermann et al., 
2007, Mocanu et al., 2008). Previous studies suggested that tau strains/species, especially 
preformed fibrils (Pffs), affect the rate of cell-to-cell transmission, possibly also the 
propagation of pathology (Sanders et al., 2014a). The contribution of tau and aSyn to the 
spread of pathology will be discussed in a different section below. 
Apart from tau oligomer related-toxicity, hyperphosphorylation could also induce tau
gain of toxic functions. For example, hyperphosphorylation promotes tau interaction with JIP1, 
and impair kinesin complex while normal tau does not (Bhaskar et al., 2005). In a Drosophila
model, hyperphosphorylation of tau impairs the actin network and causes neurodegeneration
(Fulga et al., 2007). It was suggested that this gain of toxic function could be a result of tau re-
localization to postsynaptic spines after hyperphosphorylation or caused by mutations and 
impairs synaptic functions (Tai et al., 2014, Hoover et al., 2010, Thies and Mandelkow, 2007).
It has been reported that missorted dendritic tau mediates A? toxicity by recruiting tyrosine 
ligase-like enzyme 6 into dendrites and triggering Spastin to sever microtubules, causing 
dendritic spine degeneration (Zempel et al., 2013).
Neurotoxicity could also be due to loss of tau’s physiological functions. Loss of tau 
function is generally considered as a loss of microtubule binding that results in microtubule 
disassembly (Wang and Mandelkow, 2016). As reviewed in section 2.3.1, the function of tau 
can be compensated by other proteins like MAP1, but acute silencing of tau in 12-month old 
mice showed impaired cognitive behaviour suggesting that tau is also needed for normal 
neuronal functions (Lei et al., 2014). Considering that tau is also involved in DNA protection, 
neurogenesis, etc. (reviewed in section 2.3.1), loss of these functions may also contribute to 
neurodegeneration (Wang and Mandelkow, 2016).
2.3.9 Interconnection between aSyn and tau
It has been widely recognized that tauopathies are not restricted to AD, nor 
synucleinopathies restricted to PD (Galpern and Lang, 2006). Many familial cases with 
mutations in MAPT or SNCA genes can have both Parkinsonism and dementia at the same 
time (Polymeropoulos et al., 1997, Zarranz et al., 2004, Fujioka et al., 2014, Spillantini et al., 
1998, Dumanchin et al., 1998). As schematically illustrated in Figure 10, aSyn and tau 
inclusion could co-occur in multiple diseases such as Lewy body variant of AD (LBVAD), 
Parkinson’s disease with dementia (PDD), dementia with Lewy bodies (DLB), Guam-
Parkinson-ALS dementia complex, and even Down’s syndrome (Lippa et al., 1998, Lippa et 
al., 1999, Forman et al., 2002, Moussaud et al., 2014). PD patients have increased risk of 
developing dementia, and frequently developed NFTs at autopsy, while many AD patients 
developed Lewy bodies at autopsy, suggesting remarkable crosstalk between 
synucleinopathies and tauopathies (Aarsland et al., 2005, Leverenz et al., 2009, Leverenz et al., 
2008, Hamilton, 2000, Galpern and Lang, 2006, Bancher et al., 1993).
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Despite the fact that aSyn and tau are 
distinct proteins that primarily contribute to 
different disease-specific pathologies, 
much evidence forged a link between aSyn 
and tau in aggregation pathways
(Moussaud et al., 2014). A direct 
interaction between aSyn and tau has 
already been demonstrated in 1999 while 
pulling down aSyn from brain lysates by 
affinity chromatography (Jensen et al., 
1999). Interestingly, the co-incubation of 
aSyn could induce all six isoforms of tau to 
aggregate, while neither β-synuclein nor
Aβ peptide could do the same (Giasson et 
al., 2003). Conversely, in the same study, 
the presence of tau also accelerated aSyn 
fibrillization. In addition, A53T mutation 
of aSyn was reported to enhance aSyn-
induced tau fibrillization (Kotzbauer et al., 
2004). Tau overexpression was reported to 
change aSyn aggregation pattern, reducing 
number but increasing in size and toxicity 
of aSyn aggregates (Badiola et al., 2011).
In the presence of ionic inducer such as 
Al3+ and Fe3+ or DMSO at a certain 
concentration, aSyn and tau were reported to co-oligomerize and co-aggregate even at a low 
nanomolar concentration (Nubling et al., 2012a). These pieces of evidence suggest that aSyn 
and tau could already interact with each other at monomeric or soluble oligomeric state, thus 
could cooperate and contribute together to aggregation at the early stage of pathogenesis 
(Moussaud et al., 2014).
Apart from the convergence of aSyn and tau in the aggregation pathway, there are also a 
few disease-associated risk factors shared between aSyn and tau. LRRK2 that is a kinase 
genetically associated with PD pathogenesis was shown to phosphorylate tau (Reinhardt et al., 
2013). Moreover, disease-associated mutation of LRRK2 (G2019S) reduced both tau and aSyn 
expression in human-derived stem cells. 14-3-3 protein, which shares some physical and 
functional homology with aSyn, could bind and phosphorylate tau, and moreover reduce tau-
mediated microtubule stability (Ostrerova et al., 1999, Hashiguchi et al., 2000). Both tau and 
aSyn can bind to tubulin, where tau stabilizes microtubule, and aSyn enhance tubulin 
polymerization (Alim et al., 2002, Zhou et al., 2004, Alim et al., 2004). Thus losing 
microtubule assembly and stability could potentially be related to loss-of-function of both 
aSyn and tau. For example, while disease-associated hyperphosphorylation of tau reduces tau-
mediated microtubule assembly, disease-associated mutations of aSyn, A30P, A53T, E46k 
were also shown to reduce microtubule stability (Qureshi and Paudel, 2011, Prots et al., 2013).
These pieces of evidence taken together suggest convergent overlapping pathways in the 
pathogenesis of clinically divergent diseases, e.g. AD and PD.
Much evidence showed that pathological aSyn species are closely associated with the 
phosphorylation of tau that is known to regulate both tau physiological functions and 
pathological aggregation. The interaction of aSyn and tau induces tau phosphorylation at S262
Figure 10 Overlap of proteinopathies. Inclusions 
composed of aSyn (yellow), tau (blue) and Aβ (red) have 
been found in many different neurodegenerative diseases,
which are histopathologically classified based on the 
development, location and nature of the inclusions in the 
brain. However, pathology is not an isolated category, 
and the co-existence of synucleinopathy and tauopathies 
have been observed many diseases such as  Lewy body 
variant of AD (LBVAD), Parkinson’s disease with 
dementia (PDD) and dementia with Lewy bodies (DLB). 
Synucleinopathy and tauopathy often appear as 
secondary symptoms in AD and PD respectively. 
Modified from Moussaud et al. (2014)
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in vitro, which is a phosphorylation associated with loss of tau-mediated microtubule stability 
(Qureshi and Paudel, 2011). In the same study, disease-associated aSyn mutations, A30P, 
A53T and E46K were shown to enhance aSyn interaction with tau, and thus enhance loss-of-
function of tau.  Multiple evidence suggested that aSyn forms a complex with tau and GSK-3β 
via NAC and acidic region, and simulate GSK-3β-mediated phosphorylation of tau at AT270 
(T181, an established biomarker for AD) and PHF-1/AD2 (S396 and S404, AD-associated 
phosphoepitope) (Duka et al., 2006, Duka et al., 2009). The activity of ERK and JNK, which 
are two kinases of tau, and tau phosphorylation at PHF-1/AD2 were increased in transgenic 
mice overexpressing aSyn or aSyn mutant A30P or A53T (Kaul et al., 2011, Oaks et al., 2013, 
Frasier et al., 2005). The interaction of tau with aSyn and phosphorylation at AT270 and PHF-
1/AD2 can be suppressed by Hsp70 overexpression or be enhanced by aSyn A53T mutation 
(Ciaccioli et al., 2013, Kawakami et al., 2011). In cell model of PD, GSK-3β inhibition 
reduced tau phosphorylation but increased aSyn accumulation suggesting a role of tau in aSyn 
aggregation (Duka et al., 2009). It was reported that exogenous aSyn of certain strains such as 
pre-formed fibrils could induce tau hyperphosphorylation and aggregation followed by 
internalization into neurons overexpressing tau (Guo et al., 2013, Waxman and Giasson, 2011). 
These observations could potentially provide mechanisms of how the co-existence of 
synucleinopathies and tauopathies could worsen the clinical outcome during diseases such as 
Lewy body variant of AD (LBVAD) and dementia with Lewy bodies (DLB). 
Taken together, aSyn and tau are interconnected and may feed-forward each other during 
the development and progression of neurodegenerative diseases. Understanding the 
connection between aSyn and tau pathogenic pathway could provide novel insights into the 
pathogenesis mechanism(s) and new drug targets (Moussaud et al., 2014). 
2.3.10 Therapeutic strategies against tauopathies and synucleinopathies  
Although the roles and species of tau and aSyn causing neurotoxicity in tauopathies and 
synucleinopathies remain debatable, it is widely accepted that these disease-associated 
proteins are likely building blocks of these diseases (Wang and Mandelkow, 2016). In general, 
tau and aSyn-directed strategies against tauopathies and synucleinopathies focus on reducing 
the neurotoxic gain of functions of tau and aSyn. This may be achieved by reducing tau and 
aSyn accumulation, aggregation and transmission as shown in Figure 11. MicroRNA (miRNA) 
or small interfering RNA (siRNA) may be used to silence MAPT and SNCA gene or to 
suppress the correspondent promoters, and thus reduce the synthesis and intracellular 
accumulation of tau and aSyn. Some preclinical studies in mice have shown some benefit of 
knockdown these genes, but target delivery and genetic manipulation in human have always 
been obstacles (DeVos et al., 2013, Cooper et al., 2014). An alternative way could involve 
promoting the clearance of tau and aSyn. Activation of ALS and UPS pathways would elevate 
the overall rate of proteins and macromolecules degradation. The proteolytic degradation of 
tau and aSyn may also be enhanced by activating various related-proteases such as cathepsin 
D, neurosin, and metalloproteinases 9 (MMP9), etc. (Nubling et al., 2012b, Iwata et al., 2003, 
Malik et al., 2011). Apart from modulating tau and aSyn accumulation, reducing the 
aggregation of tau and aSyn was another traditional approach to alleviate the correspondent 
neurotoxicity. Many post-translational modifications are associated with the aggregation 
property of tau and aSyn, such as phosphorylation, C-terminal cleavage, oxidation and 
nitration, etc. as mentioned previously. Reduction of these aggregation-prone factors was 
thought to alleviate related-pathology. For example, tideglusib, an inhibitor of GSK-3β that 
heavily phosphorylates tau, has entered Phase II trial in individual with mild AD (Lovestone et 
al., 2015). On the other hand, dithiocarbamates, a small molecule activator of GSK-3β that is 
 28 
upstream of nuclear factor erythroid 2-related factor 2-mediated neuroprotective pathway, was 
also suggested to exert therapeutic potentials, revealing the fact that the choice of therapeutic 
targets can be complicated even contradictory in these diseases (Kanninen et al., 2011). Direct 
intervention of the aggregation processes was also interesting in term of therapeutics. For 
example, entacapone and tolcapone that inhibit the aggregation of aSyn and Aβ by stabilizing 
high-molecular-weight oligomers, are protective against extracellular neurotoxicity from aSyn 
and Aβ aggregation (Di Giovanni et al., 2010). Methylene blue treatment, which inhibits tau 
aggregation, was shown to preserve cognition in AD mice model, and one of its derivatives 
further showed benefit in Phase II trial in individual with mild AD (Wischik et al., 2015, 
Hochgrafe et al., 2015). Anti-oxidants, such as Omega-3, have been interesting to public not 
only because of its role in reducing protein oxidation including tau and aSyn, but also its effect 
in neuroprotection (Green et al., 2007). Other non-tau and aSyn-directed approaches against 
tauopathies and synucleinopathies involve growth factors such as GDNF, and anti-
inflammatories, which are mainly for neuroprotection during tauopathies and 
synucleinopathies (Lashuel et al., 2013). Immunotherapy has emerged to be an important 
therapeutic strategy against tauopathies and synucleinopathies.  Specific antibodies were 
thought to bind to tau and aSyn, and reduce the cell-to-cell transmission (Wang and 
Mandelkow, 2016, Lashuel et al., 2013). For example, one of the aSyn antibodies could bind 
to preformed fibrils of aSyn (Pffs), and inhibit its uptake of by cells (Tran et al., 2014). One of 
the tau antibody blocks cell-to-cell transmission of tau, and improved cognition of AD mice 
(Yanamandra et al., 2013). The antibodies were also reported enter cells via Fcγ-receptors, and 
inhibited intracellular aggregation of tau and aSyn (Sahin et al., 2016). For example, an 
antibody of cis-tau reduces tau aggregation in Fcγ-receptor-mediated manner, and decrease the 
development and spread of tauopathies in mice with traumatic brain injury (Kondo et al., 
2015). 
Figure 11 Possible therapeutic 
strategies against tauopathies and 
synucleinopathies. Possible 
strategies focus on reducing tau 
and aSyn accumulation, 
aggregation and transmission.   
siRNA and miRNA may be used to 
reduced tau and aSyn synthesis. 
Activation of mechanisms or 
protein involved in clearance 
would reduce aberrant protein 
accumulation. Approaches that 
involve anti-aggregating, 
antioxidant or post-translational 
modification could be used to 
reduce the aggregation of tau and aSyn. Immunotherapy may be used to reduce tau and aSyn transmission. 
Modified from Lashuel (2013). 
 Misfolded protein propagation in pathological conditions 2.4
Intraneuronal accumulation of protein aggregates is a common pathological feature 
shared by many neurodegenerative diseases. Increasing evidence indicates that transcellular 
transmission of these aggregates may be a common mechanism of the propagation of 
pathologies. Many disease-associated proteins that were previously not known to transfer 
between cells have been shown to seed aggregation during cell-to-cell transmission in a 
“prion-like” manner.  
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2.4.1 Prion-like seeding
The term and theory of “prion-like” come from the molecular mechanisms of the 
propagation of prion diseases, which are also known as spongiform encephalopathies. In prion 
diseases, normal prion proteins such as PrPC, sporadically convert to misfolded pathological 
species, e.g. PrPSc, which have altered conformations and act as infectious agents that spread 
the pathology rapidly by interacting and converting normal prion proteins into pathological 
species in a template-directed manner, and thus is also called “seeding” (Bolton et al., 1982, 
Aguzzi and Rajendran, 2009). The molecular mechanism of “prion-like” seeding was 
originally proposed as seeded polymerization of amyloid-proteins that may be involved in AD 
and scrapie (Jarrett and Lansbury, 1993). Many neurodegenerative disease-associated proteins 
that were originally thought to lack seeding properties, such as aSyn and tau, also exhibit 
characteristics of “prion-like” self-propagation (Guo and Lee, 2014b). As summarized in
Table 2, various species of A? and tau, aSyn, superoxide dismutase 1 (SOD1) and TDP-43
(TAR DNA-binding protein 43, related to Amyotrophic Lateral Sclerosis, ALS), 
Polyglutamine repeat proteins, such as mutant Huntingtin (mtHH, related to Huntington’s
Disease) have been experimentally shown to seed aggregation in different model systems
(Guo and Lee, 2014b).  Most of these studies have confirmed that the transfer of lysates from 
human or mouse brain containing disease-associated protein aggregates to healthy cells or 
animal branch can seed the corresponding pathology suggesting that these disease-associated 
proteins can transmit pathology in a “prion-like” manner, and this characteristic can be
pathologically specific to each disease.
Studies of tau propagation revealed that Pffs of tau proteins are highly efficient in 
sequestering soluble tau into aggregates, causing tau loss-of-function toxicity in a time-
dependent manner (Guo and Lee, 2011a, Iba et al., 2013a).  From the same study, the
observation that tau Pffs can be spontaneously uptaken by cells suggests that the uptake of tau 
could involve pinocytosis. Tau seeding was reported to occur more predominantly in cells 
overexpressing 4R tau but less in 3R tau overexpressing cells, and also when using synthetic 
fibrils derived from 4R tau as compared to 3R tau or fibrils composed of other proteins such as 
aSyn, suggesting that tau isoforms, especially ones with R2 domain, could play a dictate
seeding (Iba et al., 2013a, Nonaka et al., 2010b). Besides, tau monomer was reported not be 
able to seed aggregation suggesting that the oligomeric state of tau is required for seeding 
(Frost et al., 2009). These shreds of evidence indicate that tau propagation is highly dependent 
on different physiochemical and oligomeric properties of various strains and species (Sanders 
et al., 2014a).
A few aSyn studies have demonstrated that both synthetic aSyn fibrils and lysates from 
PD mice brains induce synucleinopathies sufficiently with endogenous aSyn, unlike tau that 
requires overexpression of tau in recipient cells or tissue (Volpicelli-Daley et al., 2011, Luk et 
al., 2012a). This suggests that aSyn may be more aggregation prone under physiological 
conditions than tau. In cells overexpressing aSyn, recombinant aSyn fibrils were reported to 
recruit soluble aSyn, and converting them into hyperphosphorylated (S129) and ubiquitinated 
aggregates (Luk et al., 2009). Similar post-translational modification of aSyn aggregates was 
also induced by introducing recombinant nucleation seeds via transfection in SH-SY5Y cells 
(Nonaka et al., 2010b). Interestingly, in the same study, applying a series of chemicals such as
exifone and gossypetin, which block amyloid filament formation, significantly reduced the 
toxicity of aSyn inclusions in recipient cells, suggesting a potential therapeutic approach by 
preventing protein aggregation at the step of cell-to-cell transmission. Inoculation of aSyn 
synthetic fibrils induces Lewy bodies-like pathology in mice, whereas soluble aSyn does not,
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suggesting that aSyn propagation may be dependent on oligomeric state and exhibit similar 
strain-specificity as tau (Masuda-Suzukake et al., 2013a).
Among studies of pathological protein propagation, bioluminescence imaging has been 
used to monitor A? propagation and demonstrated that AD mice brain extracts and fibrils 
derived from recombinant A? can seed cerebral ?-amyloidosis in transgenic mice (Stohr et al., 
2012). Interestingly, this seeding property is abolished if seeding A? is pre-denatured or 
immunodepleted (Meyer-Luehmann et al., 2006).  TDP-43 aggregates extracted from ALS or 
frontotemporal lobar degeneration patients’ brains could induce TDP-43 aggregation in a self-
templated manner in SH-SY5Y cells (Nonaka et al., 2013). Synthetic fibrils of ALS-associated 
SOD1 mutant was reported to be uptaken by cells via macropinocytosis and could recruit and 
induce cytosolic soluble SOD1 mutant to form aggregates (Munch et al., 2011). It is worth 
mentioning that in the same study, after the initial seeding, the cell-to-cell transmission of 
SOD1 aggregates was remarkably efficient without requiring direct cell-cell contact. The 
introduction of fibrillar polyglutamine peptide aggregates into mammalian cells was reported 
to recruit soluble cytosolic proteins that share homologous amyloidogenic sequences, e.g. 
glutamine-rich polypeptides, and also UPS components and chaperones to form aggresomes 
(Ren et al., 2009).
Table 2 Summary of the major studies of the transmissibility of neurodegenerative disease-associated non-prion 
proteins. Adopted from Guo and Lee (2014b)
Protein Type of seed Model system used for seeding
A? Synthetic fibrils, 
mouse or human brain 
lysates
Mice (Stohr et al., 2012, Meyer-Luehmann et al., 
2006, Eisele et al., 2010)
Tau Synthetic fibrils, Neuronal, non-neuronal cells, mice (Guo and Lee, 
2011b, Iba et al., 2013b, Guo and Lee, 2013, Frost 
et al., 2009, Nonaka et al., 2010b)
Mouse or human brain 
lysates
Mice (Clavaguera et al., 2009, Lasagna-Reeves et 
al., 2012b, Clavaguera et al., 2013)
aSyn Synthetic fibrils Neuronal, non-neuronal cells, mice (Volpicelli-
Daley et al., 2011, Luk et al., 2012c, Luk et al., 
2012d, Masuda-Suzukake et al., 2013b, Luk et al., 
2009, Nonaka et al., 2010a)
Mouse or human brain 
lysates
Mice (Luk et al., 2012b, Masuda-Suzukake et al., 
2013a)
TDP-43 Synthetic fibrils Non-neuronal cells (Chen et al., 2010)
Human brain lysates Neuronal cells (Nonaka et al., 2013)
SOD1 Synthetic fibrils Neuronal cells (Munch et al., 2011)
Polyglutamine
e.g. mtHH
Synthetic fibrils Non-neuronal cells (Ren et al., 2009)
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2.4.1.1 Potential mechanisms of seed formation
The molecular mechanism(s) of the initial conversion of the normal proteins into 
misfolded seeds is poorly understood, and this step is suggested to be the rate-limiting step of 
pathological propagation of the proteins (Jucker and Walker, 2013, Knowles and Buehler, 
2011). Protein misfolding has demonstrated conformational plasticity meaning more than one 
stable tertiary structure could be adopted at equilibrium (as schematically presented Figure 4
and Figure 7)(Meredith, 2005). Different strains or intermediates of a misfolded protein could 
form different fibril types differ at the atomic level, thus exhibit transmissibility to a different 
degree. For example, Marc I. Diamond and colleagues isolate tau from 29 patients with five
different tauopathies [AD, argyrophilic grain disease (AGD), corticobasal degeneration (CBD), 
Pick’s disease (PiD) and progressive supranuclear palsy (PSP)], and showed that different
strains of tau exhibit different toxicity level and localization in recipient cells following 
internalization (Figure 12)(Sanders et al., 2014b). Ronald Melki and colleagues have 
demonstrated that WT aSyn can be induced to two distinct strains just by pre-incubating in
slightly different conditions (Bousset et al., 2013, Melki, 2015). Electron microscopy (EM)
and nuclear magnetic resonance (NMR) revealed that these strains were distinct in oligomer 
packing pattern. Functional studies in cells demonstrated that they permeabilize cells to 
different extents, recruited intracellular soluble aSyn with different efficacy and elongated at 
different rates, and thus exhibited different toxicity and propagation propensities.
Despite the fact that how each strain of aSyn and tau is involved in pathogenic progress is
poorly understood, a converged 
mechanism of amyloid seed propagation 
has been proposed as shown in Figure
13A. The formation of amyloid seed may 
undergo a slow nucleation phase until the 
initial amyloid spine is formed, and a
series of intermediate species of the 
protein may be involved (Jarrett and 
Lansbury, 1993, Lee et al., 2011).
Followed by the appearance of the initial 
amyloid seed, soluble monomers and 
oligomers can be conformationally
converted, attached to the end of the seed, 
and grow in length into fibrils. Depending
on the conformation and stability, fibrils 
can break spontaneously or by cellular 
activities, forming new amyloid seeds 
(Jucker and Walker, 2013). In this case, 
the accumulation of aggregates can be 
regarded as a function of the rate of 
protein misfolding, nucleation, fibril 
growth and fragmentation (Knowles and 
Buehler, 2011). As described in Figure 
13B and C, an introduction of pre-formed seed can remarkably accelerate the aggregation 
process, which explains the advanced onset of pathologies by introducing seeds into cell 
cultures or animal models compared to spontaneous aggregation (Jucker and Walker, 2013).
Figure 12 Distinct localization of internalized tau. Tau 
strains were isolated from 29 patients with tauopathies and 
induced the distinct pattern of cellular distribution and 
toxicity the following internalization into recipient cells. .
The image was reprinted from Figure 8B in Sanders et al. 
(2014b), with permission from Elsevier. Copyright © 2014,
Elsevier Inc. Permission was conveyed through Copyright 
Clearance Center, Inc.
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Figure 13 Putative mechanisms of prion-like seeding. A: amyloid formation from monomer to fibrils includes a 
slow nucleation phase and relatively faster growth phase with multiple intermediate states of the proteins in 
between (Jarrett and Lansbury, 1993, Lee et al., 2011). Native protein monomers or oligomers can bind to seeding 
aggregates, and get conformationally converted to pathological species. During the nucleation and extension
phases, fibrils may break up to form further seeds. B: Compared to spontaneous aggregation, the addition of 
amyloid seed skips the slow nucleation phase, thus accelerating the accumulation of aggregates. C:  Inoculation of 
amyloid seed (redline) in specific brain regions of animal model would advance the onset of protein aggregation 
and pathology. Modified from. Adapted by permission from Macmillan Publishers Ltd: Nature, Jucker and Walker 
(2013), copyright © 2013. Permission was conveyed through Copyright Clearance Center, Inc.
2.4.2 Cell-to-cell transmission of α-synuclein and tau
The release of the seeds from the donor cells and uptake of the seeds by the recipient 
cells are likely two essential steps involved in the cell-to-cell propagation of amyloid seed. 
The exact mechanisms of intercellular transport of disease-associated proteins, and related 
intracellular vesicular transport events are not fully understood, but the processes have been 
hypothesized to involve direct penetration of the membranes, vesicle-mediated transport 
events, receptor-mediated endocytosis, macropinocytosis and direct cell-cell contact as 
illustrated in Figure 14 (Guo and Lee, 2014a). It has been suggested that due to the size and 
nature of aSyn and tau aggregates, the uptake of these fibrils are not likely through receptor-
mediated endocytosis, which requires specific interaction between proteins and receptors at 
the cell surfaces (Guo and Lee, 2014a).
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Figure 14 Putative pathways 
of cell-to-cell transmission of 
aggregated proteins at the 
synaptic cleft. Protein or 
protein aggregates can be 
released into extracellular 
space as (a) free monomers or 
oligomers or protofibrils, and 
enter plasma membrane of
recipient cells by 1) direct 
penetration, 2) fluid-phase
endocytosis or 
macropinocytosis, 3) receptor-
mediated endocytosis. The 
protein may also be released 
in (b) membrane-bound 
vesicles like exosomes or
ectosomes, and uptake by recipient cells by 4) membrane fusion. In some cases, direct cell-cell contact or 5) 
nanotubes connecting two cells provide direct routes for protein transfer. Modified from Guo and Lee (2014a).
2.4.2.1 Vesicular release of α-synuclein
It has been proposed that the release of vesicle-bound aSyn and tau may be through the 
unconventional secretory pathway, in another word not via classical ER-Golgi pathway (Chai 
et al., 2012b, Malm et al., 2016). The release of vesicles through unconventional secretary 
pathway primarily included secretory lysosome and endoplasmic vesicles release, and 
microvesicles shedding (Nickel and Rabouille, 2009). Exosomes can be released with the last 
two ways, whereas ectosomes are generally released by membrane budding. The released 
proteins are surrounded by vesicles, which can be recognized and purified based on their size, 
e.g. exosome (50-200 nm) and ectosome (0.1–1 μm). The largely unexplored secretary 
pathway(s) is also called misfolding-associated protein secretion (MAPS), which is not likely 
specific to synapses and could be studied in non-neuronal cells with certain limitations. 
aSyn has been identified in the CSF and plasma of patients with synucleinopathy,
suggesting that aSyn is secreted into the extracellular space in human (Borghi et al., 2000) (El-
Agnaf et al., 2003). Despite the fact that the mechanisms of aSyn release are incompletely 
understood, aSyn has been identified in the exosome-bound and free form in conditioned 
media from SH-SY5Y cells (Emmanouilidou et al., 2010). Many groups have reported that 
free aSyn is the predominantly secreted species by neuron and non-neuronal cells with 
exosomal fraction representing a smaller population (Pan-Montojo et al., 2012, Vella et al., 
2016, Paillusson et al., 2013). A study using protein-fragment complementation assay has 
demonstrated that exosomal aSyn is internalized much more efficiently than free aSyn 
suggesting that vesicle might offer a more efficient route for aSyn to get access into cells
(Danzer et al., 2012). In vivo studies have demonstrated that exosomal aSyn level in plasma
and CSF of PD patients is associated with severity of the pathology (Shi et al., 2014).
Accumulating evidence suggest that exosomal release of aSyn may be modulated by the 
ALP (Vella et al., 2016). It is not fully understood if this is specific to the aSyn release, 
because ALP induction and stimulation have been shown to modulate the amount of exosome 
released, and ALP impairment causes intracellular accumulation of misfolded aSyn (Fader et 
al., 2008, Baixauli et al., 2014). As reviewed in section 2.2.3.2, ALP dysfunction plays an
important role in PD pathology, hence the exosomal release of aSyn may be altered in PD. 
Indeed, inhibition of fusion of autophagosome to lysosome via bafilomycin has been shown to 
increase the exosomal release of aSyn (Poehler et al., 2014, Alvarez-Erviti et al., 2011, Danzer 
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et al., 2012). Impairment of mitochondrial, lysosomal and autophagic function via treatment of 
rotenone also enhanced neuronal release of aSyn in exosomes (Pan-Montojo et al., 2012).
Also, a few PD-related genes, such as LRRK2, VPS35 and PARK9 are linked to autophagic 
and endocytic pathways, and were also shown to influence exosome release (Fraser et al., 
2013, Follett et al., 2014, Kong et al., 2014).
2.4.2.2 Vesicular release of tau
Tau can be detected in CSF of both healthy individuals and AD patients, but the amount 
is increased in pathological conditions (Blennow et al., 1995, Vigo-Pelfrey et al., 1995). The 
mechanisms of tau secretion have not been extensively studied like aSyn and Aβ, because tau 
release was originally thought to be consequences of neuronal death or exocytic process (Frost 
et al., 2009). However, increasing evidence reveal that tau can be released both passively and 
by exosomes, and free tau represents the major species (Saman et al., 2012b, Chai et al., 
2012b, Simon et al., 2012b). Recent evidence shows that vesicular tau is predominantly 
released in ectosomes, which are similar but larger vesicles compared with exosomes (up to
1000nm), and are formed directly from plasma membrane budding (Dujardin et al., 2014a, 
Fevrier and Raposo, 2004). It has been proposed that vesicular release of tau could be induced 
by overexpressing tau in cell models and is likely to be one route for cells to eliminate excess 
proteins to reduce toxicity (Simon et al., 2012b). Microvesicles-associated tau has been 
reported in human CSF sample and was shown to be phosphorylated at T181, which is also 
known as AT270, an established biomarker for AD (Saman et al., 2012b). This suggests that 
vesicle-bound tau species could be pathologically relevant. 
Some studies indicated that the presence of N-terminus, C-terminal truncation, tau 
isoforms, synaptic activities, several MAPT mutations (P301L/S, R406W) might have a link 
to tau secretion, but the mechanisms are poorly understood (Pooler et al., 2013, Yamada et al., 
2014, Karch et al., 2012, Kanmert et al., 2015). For example, activation of AMPA receptor 
contributes to tau release in cortical neurons in a calcium-dependent manner that can be 
reduced by tetanus toxin or tetrodotoxin, which block pre-synaptic vesicle release or neuronal 
activity (Pooler et al., 2013). Another in vivo study also showed similar observation that 
extracellular tau level is rapidly increased when neuronal activity is enhanced (Yamada et al., 
2014). In the same study, tau was released within a few hours, but the extracellular tau had a
half-life of more than 11 days, suggesting a much less sufficient clearance of tau outside cells.
Karch CM. and colleagues have explored the effect of various factors on tau release (Karch et 
al., 2012). Apart from confirming the previous findings that both phosphorylated and 
unphosphorylated tau can be secreted via unconventional pathways in a calcium-dependent 
manner, they showed that there was little difference between the level of secreted 0N3R or 
0N4R tau (Figure 5). However, extracellular 2N3R level was significantly higher than 2N4R, 
suggesting that various isoforms of tau may have different propagation propensities (how 
prone they are to propagate). They also showed that several disease-associated mutations 
(P301L, P301S and R406W) reduced tau secretion, suggesting a role of mutations in tau 
secretion pathway. In the studies conducted by Kanmert D. and colleagues, C-terminal 
truncated tau was shown to be the predominantly secreted species from three neuronal models, 
while intracellular tau was mostly full-length (Kanmert et al., 2015). Among these C-terminal 
truncated tau species in the extracellular space, a minor population had microtubule-binding 
domains that are required for tau aggregation as mentioned previously. Interestingly, the 
microtubule-binding domains containing tau fragments were primarily released passively 
during cell death rather than active secretion, suggesting that the factors inducing cell death 
may be needed to seed tau aggregation. 
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2.4.2.3 Annular protofibrils-mediated membrane permeabilization
Free aSyn and tau have been proposed as the major extracellular species, but the exact 
mechanisms of how they are secreted by cells are poorly understood (Vella et al., 2016, 
Dujardin et al., 2014a). Both aSyn and tau have been reported to form intermediate annular 
protofibrils (APFs) that adopt ring/pore-like structures share homology with some bacterial 
toxins (Lasagna-Reeves et al., 2014, Ding et al., 2002). It was previously shown that many 
bacterial toxins such as α-hemolysin assemble into pore-like oligomers and permeabilize cell 
membrane, implicating that aSyn and tau APFs might also form pore in plasma membrane and 
induce release of free aSyn and tau, and thus provide an explanation for the observed 
membrane permeabilization induced by aSyn and tau in several in vitro and in vivo studies 
(Flach et al., 2012, Jones et al., 2012, Stefanovic et al., 2014, Parker and Feil, 2005, Montoya 
and Gouaux, 2003).
APFs of several disease-associated proteins including aSyn, tau and Aβ have been 
identified from human brain of pathological conditions (Lasagna-Reeves et al., 2011, 
Pountney et al., 2004, Lasagna-Reeves et al., 2014). Disease-associated mutations have been 
reported to accelerate the formation of aSyn and Aβ APFs (Lashuel et al., 2002a). Besides, 
both phosphorylation and disease-associated mutation (P301L) have been implicated to affect 
tau APFs formation (Lasagna-Reeves et al., 2014). A Recent study showed that aSyn amyloid 
fibrils could permeabilize membranes, and the treatment of flavonoid epigallocatechin gallate 
(EGCG), which is small molecule previously described to remodel aSyn aggregation pattern 
and reduced tau mutant aggregation, could inhibit this process (Wobst et al., 2015, Lorenzen 
et al., 2014). In this study, aSyn fibrils did not only permeabilize cell membrane but also 
vesicle membranes, suggesting that vesicle post-secretion release may also contribute to the 
excess of extracellular free aSyn and tau. 
2.4.2.4 Macropinocytosis
Macropinocytosis is a subtype of bulk endocytosis and is defined by its function to 
uptake large volumes of extracellular liquid and dissolved molecules (Bloomfield and Kay, 
2016). Macropinocytosis is highly conserved in eukaryotic cells and has different functions in 
various cell types, e.g. ingestion of extracellular material in leukocytes, bulk endocytosis in 
neuron during synaptic activity (Amyere and A. and Courtoy, 2001, Clayton and Cousin, 
2009). However, it is worth mentioning that macropinocytosis involves extensive membrane 
turnover, and thus is not highly active in mature neurons. Macropinocytosis has been proposed
as an important route for cells to uptake large aggregates during cell-to-cell transmission of 
protein aggregates (Zeineddine and Yerbury, 2015). Extracellular SOD1, TDP-43 and aSyn 
aggregates were recently reported to bind to the cell surface, followed by internalization via
Rac1-mediated membrane ruffling and macropinocytosis (Zeineddine et al., 2015).  The same 
study also demonstrated that these disease-associated proteins enter the cytosol by rupturing 
macropinosomes membrane. Low molecular weight recombinant tau aggregates and short 
fibrils were shown to be uptake by macropinocytosis at synaptic terminals, and transported
along axons (Wu et al., 2013). It has also been reported that tau and aSyn fibrils bind to 
heparan sulphate proteoglycans, and stimulate macropinocytotic uptake of fluid and
aggregates (Holmes et al., 2013). Amyloid Precursor Protein (APP) can also be internalized 
from cell surface via macropinocytosis that bypasses early and late endosome, and thus directs
APP to lysosomes in an Arf6-dependent manner (Tang et al., 2015). APP is degraded to A? in 
lysosomes, suggesting a role of macropinocytosis in A? accumulation that could contribute to 
AD pathogenesis (Tang et al., 2015).
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2.4.2.5 Other routes for internalization of aSyn and tau 
Some studies have proposed that aSyn may bind to dynamin, and enter cells via receptor-
mediated endocytosis (Hansen et al., 2011, Desplats et al., 2009). Some other studies
suggested that there might a link between the uptake of aSyn and tau and adsorptive 
endocytosis, which exhibit the characteristic of both receptor-mediated endocytosis and non-
specific bulk endocytosis (Volpicelli-Daley et al., 2011, Guo and Lee, 2011b). In these studies, 
the induction of cytoplasmic aggregates via seeding did not give rise to vesicle-bound species 
of aSyn or tau inside cells, suggesting that either receptor-mediated endocytosis is not the 
major route for aSyn and tau internalization or these proteins escape rapidly from vesicles into 
the cytosol.
Tunnelling nanotubes (TNTs) that serve a role in cell-to-cell communication have been 
proposed to participate in mediating prion proteins propagation (Gousset et al., 2009). A 
Recent study has demonstrated that TNTs also mediate cell-to-cell transmission of aSyn by 
providing a shortcut between two cells for transferring lysosomal vesicles that contain aSyn 
aggregates (Abounit et al., 2016). It is recently reported that impairment of UPS lead to the 
accumulation of misfolded proteins in the cytoplasm, and the excess misfolded proteins are 
deubiquitylated and packaged by ER-resident deubiquitylase USP19 into late endosomes, 
which then fuse with plasma membrane and release the misfolded proteins into extracellular 
space (Lee et al., 2016, Volkmar et al., 2016). Interestingly, apart from the donor cells and the 
recipient cells, a "third party," microglial cells were also suggested to participate in mediating 
cell-to-cell transmission of misfolded proteins. Microglial cells may collect and package 
misfolded proteins that are secreted by neurons with pathology from extracellular space into 
vesicles via phagocytic endocytosis, and deliver them back to neurons via vesicle-mediated 
transport events, e.g. exosomes (Asai et al., 2015a). It was previously noted that microglial 
cells internalize microvesicles, which contain Aβ and tau, from other neurons and neuroglia 
(Fruhbeis et al., 2013, Yuyama et al., 2012, Asai et al., 2015a). This may have a connection to 
the fact that the activation of microglia in in vivo AD models benefits amyloid pathology 
possibly by promoting A? clearance while worsening tau pathology (Lee et al., 2013, Malm 
et al., 2016). Hence the participation of microglia to the propagation of pathology may be 
specific to tau, but further studies are needed to clarify these findings.
2.4.2.6 Stress granules
Stress granules (SGs) are transiently formed non-membrane-bound RNA granules 
nucleated by various RNA-binding proteins (RBPs) under stress conditions to reduce 
translation (Anderson and Kedersha, 2008, Gilks et al., 2004). Many of these RBPs, such as 
TDP-43, fused in sarcoma proteins and heterogeneous nuclear ribonucleoproteins, have been 
shown to be related to neurodegenerative diseases (Kim et al., 2013, Liu-Yesucevitz et al., 
2010, Sreedharan et al., 2008, Vance et al., 2009). Increasing evidence support the hypothesis 
that stress granules (SGs) may provide a location for misfolded and normal proteins to interact, 
and possibly converting normal protein to pathological species upon interaction, hence 
seeding aggregation (Wolozin and Apicco, 2015). Mutation in valosin-containing protein gene 
that mediates autophagosomal clearance of SGs was reported to cause ALS (Johnson et al., 
2010). SG makers have also been reported in several disease-associated inclusions (Bentmann 
et al., 2013). One SGs maker, TIA-1 has been reported to co-localize with NFTs in AD, and 
increase in the amount proportionally with increased diseases severity (Vanderweyde et al., 
2012). It is yet unclear the relation between tau and SGs. Part of this thesis work partially 
provides a mechanistic explanation of how tauopathies propagate in an SGs mediated-manner.
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2.4.3 Spread of pathology
The progressive accumulation of protein aggregation in specific brain regions and the 
spread of pathology in stereotypical patterns are features of many common neurodegenerative
diseases, such as AD and PD (Brettschneider et al., 2015).  Some examples are shown in
Figure 15. Based on post-mortem brains samples collected from random individuals, tau
aggregates (NFTs) appears in the locus coeruleus first, then sequentially develops in the 
transentorhinal and entorhinal regions, and at last in the hippocampal formation and neocortex
(Braak and Del Tredici, 2011, Braak et al., 2006). Aβ aggregates appear in the neocortex first,
and then subsequently develop in allocortical, diencephalic and basal ganglia, and brainstem, 
and sometimes in the cerebellum (Thal et al., 2002). aSyn aggregates  (Lewy bodies) can
appear in olfactory bulb and dorsal motor nucleus of the vagus nerve first,  then subsequently 
develop from the brainstem to the telencephalon including the pons and midbrain in between,
and finally in the basal forebrain and neocortex (Braak et al., 2003, Goedert et al., 2013).
TDP43 from ALS can appear in the motor cortex, brainstem motor nuclei and α-motor 
neurons in the spinal cord at an early stage, subsequently in the prefrontal neocortex, 
brainstem reticular formation, and at the late stage in anteromedial temporal lobe and
hippocampus (Brettschneider et al., 2013).
Figure 15 Sequential development of pathologies in AD, PD and ALS. The pathology related to tau (a,b) and Aβ
(c,d) from AD, aSyn (e,f) from PD, and TDP43 from ALS sequentially develop in the brain regions indicated in 
darker colored areas till lighter ones as indicated by arrows. AC: allocortex; AGN: agranular motor cortex; BFB:
basal forebrain; BN: brainstem nuclei; BSM: brainstem somatomotor nuclei; CB: cerebellum; DMX: dorsal motor 
nucleus of the vagus nerve; ENT: entorhinal cortex; LC: locus coeruleus; MTC: mesiotemporal cortex; NC:
neocortex; OB: olfactory bulb; PFN: prefrontal neocortex; SC9: spinal cord grey-matter lamina IX; SN: substantia 
nigra; TH: thalamus. Adopted from. Adapted by permission from Macmillan Publishers Ltd: Nature Reviews 
Neuroscience, Brettschneider et al. (2015), copyright © 2015. Permission was conveyed through Copyright 
Clearance Center, Inc.
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2.4.4 The spread of pathology- what is missing from the story?
The sequential appearances of the accumulation of NFTs in AD and Lewy bodies in PD 
in different brain regions characterized by Braak and colleagues have been widely cited to 
support the hypothesis of the spread of pathologies that are via certain neuronal networks and 
pathways (Brettschneider et al., 2015). However these elegant studies were based on post-
mortem brains from uncontrolled subjects at various age and various causes, and thus were
argued not to fully explain the progression of the pathology (Walsh and Selkoe, 2016). Also, it 
has been argued that the clinical severity of diseases is not always associated with 
amyloidogenesis, e.g. synucleinopathy often occurs without neurological sign in aged-human 
autopsy brain and animal models (Burke et al., 2008).  Alternatively to the hypothesis of the
spread of pathology, the sequential appearance of the pathologies in different brain regions
was proposed to be a result of selective neuronal vulnerability (Walsh and Selkoe, 2016). The 
concept of selective neuronal vulnerability suggests that certain neurons are intrinsically more 
vulnerable than others during pathogenic processes (Jackson, 2014). What determines 
“intrinsic vulnerability” is poorly understood, and it may refer to gene expression profiles that 
make some neuron more and earlier dysfunctional and structurally abnormal than others.
Apart from neurons, microglial cells also exhibit changes in number, density and gene 
expression during AD pathology, e.g. several genes including TREM2, CD33 mainly 
expressed in microglia are associated with AD risk, and thus suggesting that the intrinsic 
vulnerability of neurons may be influenced by neighboring microglial cells (Grubman et al., 
2016, Wes et al., 2016, Bachstetter et al., 2015). Interestingly, in autopsy-based studies, early 
aSyn aggregates can be detected in the neurons of gut, submandibular gland and olfactory bulb,
and this corresponds to the fact that some patients with early PD developed symptoms such as 
dysphagia and constipation, thus suggesting that the free transfer of disease-associated protein 
is not only restricted in CNS but also in peripheral nervous system (Del Tredici et al., 2010, 
Edwards et al., 1992, Hawkes et al., 1999, Holmqvist et al., 2014, Wakabayashi et al., 1990).
Currently, the exact mechanisms of cell-to-cell transmission of disease-associated
proteins are poorly understood. Thus there lacks a bridge connecting the emerging evidence of 
seeded propagation of pathology from in vitro studies and the observed stereotypical patterns 
of pathology in vivo. In animal experiments, certain groups of neurons are sequentially 
affected depending on the location of the initial injection of pre-formed fibrils (Pffs). For 
example, injection of tau Pffs into the striatum of transgenic mice induced tau aggregation in a 
time-dependent manner in substantia nigra and thalamus, which are both connected to striatum, 
whereas injection of tau Pffs into the hippocampus induced sequential aggregation of tau in 
entorhinal cortex and contralateral hippocampus (Iba et al., 2013a). Injection of brain lysates 
from the PD-mice model or aSyn Pffs into the neocortex and striatum of aSyn transgenic mice 
induced Lewy body-like inclusions in the interconnected area such as frontal cortex, thalamus, 
hypothalamus, brainstem nuclei, and major white-matter tracts (Luk et al., 2012d). Intrastriatal 
inoculation of aSyn Pffs in wild-type mice induced Lewy body-like inclusions in the ventral 
striatum, thalamus, and occipital cortex in a time-dependent manner from 30-180 days post 
injection (Luk et al., 2012c). Different groups of neurons are affected depending on the 
location of Pffs inoculated but not neuron types, suggesting that gene profile of an individual 
group of neurons may not be the key determinant of the propagation of pathology. On the 
other hand, the human brain is so complex, based on countless neuronal connectivity it is not 
fully understood why the propagation of observed lesions only follow certain neuroanatomical 
pathways (Walsh and Selkoe, 2016). Thus neither selective neuronal vulnerability nor spread 
of pathology via a certain neuronal network would be a perfect model to explain the 
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pathogenic pathways of AD and PD (Brettschneider et al., 2015). Alternatively, selective 
vulnerability of certain neuronal network may also be an explanation. Lastly, it is worth 
questioning that to what extend mouse model represent human, e.g. some transgenic mouse 
with NFT showed no disruption in neuronal functions (Santacruz et al., 2005, Berger et al., 
2007).
In conclusion, despite the missing knowledge in the field, such as the initiation of aSyn 
and tau proteins misfolding, what are the species of aSyn and tau that are transmissible, and
how misfolded aSyn and tau transfer between cells, it has been suggested that therapeutics 
should focus on preventing the cellular release and uptake of the misfolded proteins
(Brettschneider et al., 2015, Walsh and Selkoe, 2016). Understanding the pathway(s) of cell-
to-cell transmission of misfolded aSyn and tau could provide novel insights into the etiology
of pathogenesis and new drug targets.
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3 Aims of the study
The principal aim of this thesis was to develop a novel live-cell platform method based
on the principle of protein-fragment complementation assay, to investigate the hence 
oligomerization and cell-to-cell transmission of aSyn and tau, and further explore cellular
processes regulating secretion and uptake of aSyn and tau. 
The specific aims of the thesis were to: 
1. Set up and functionally validate an assay platform to study the effect of prolyl 
oligopeptidase on intracellular dimerization, cellular secretion and uptake of aSyn.
2. Set up and functionally validate an assay platform to study the effect of late-onset 
Alzheimer’s disease susceptibility gene silencing on intracellular dimerization, cellular 
secretion and uptake of tau.
3. Conduct mechanistic studies to further understand the fate of tau after internalization from 
the extracellular space, and to explore potential mechanisms involved in tau uptake-induced 
cellular stress.
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4 Materials and methods
The methodology is briefly described here, for more detailed pleases refer to materials 
and methods/ experimental procedures sections of adjoining original publications (I-III).
Plasmid constructs and recombinant proteins4.1
The split Gaussia princeps luciferase (GLuc) plasmids were originally provided by prof. 
Stephen Michnick (Université de Montréal, Montreal, Canada), and are expressed as 
previously described (Michnick, 2001). Human aSyn cDNA was obtained from ORFeome 
library (accession number BC013293, Version 3.1, Genome Biology Unit, Institute of 
Biotechnology, University of Helsinki), and was used to clone aSyn(Δ118–140) and 
aSyn(Δ98–140) (with amino acid 118-140 or 980-140 removed respectively), and were PCR-
cloned into GLuc vector with HA-tag at KpnI-XhoI restriction sites (Publication I/Figure 
2A and 4A).  The human PREP and PREP(S554A) plasmids were as previously described,
and were cloned into PREP-GLuc2 and PREP(S554A)-GLuc2 (publication I/Figure
3A)(Savolainen et al., 2014). The human tau cDNAs was purchased from Thermo (isoform 
0N4R, BC114948), and was cloned to GLuc as previously described (Nykanen et al., 2012).
Human CD2AP cDNAs were purchased from Thermo (BC019744). The FRMD4A–GFP 
plasmid was kindly provided by Junichi Ikenouchi (Kyushu University, Fukuoka, Japan).
pcDNA3/HA-Arf6 (Addgene plasmid # 10834) was kindly provided by Thomas Roberts 
(Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA). pCMV5B-Flag-Par6 
wt (Addgene plasmid # 11748) and pMEP5-Flag Par6 S345A (Addgene plasmid # 24648) 
were kindly provided by Jeff Wrana (Department of Molecular Genetics, University of 
Toronto, Toronto, Canada). aPKCζ cDNA was from ORFeome library (University of Helsinki)
and was used to clone C20ζ (amino acids 405–592) into the pcDNA6-V5/His expression 
plasmid (Invitrogen). TIA-1 cDNA was purchased from Thermo (BC046812.1). TauE14
plasmid was kindly provided by Mel B. Feany (Harvard Medical School, Boston, MA, USA). 
Tau(P301L) plasmid (Addgene plasmid #46908) was kindly provided by Karen Ashe 
(University of Minnesota, Minneapolis, MN, USA). Split GFP plasmids (1–214 and 215–230
amino acid) were obtained from Sandia Biotech Inc., USA. Human TIA-1, TREM2 and CD33
shRNA, and mouse FRMD4A shRNA (in pLKO.1 vector backbone) were obtained from the 
TRC1.0 library (Functional Genomics Unit Biomedicum Helsinki). siRNAs for silencing 
LOAD risk genes follow-up from Invitrogen (Ambion Silencer Select Predesigned siRNA). 
Real-time quantitative polymerase chain reaction (qPCR) was used to determine the 
knockdown efficacy of the siRNAs with primers as previously described (Martiskainen et al., 
2015a). Primers for qPCR of TIA-1 were: (forward) 5′-ACAGCAGAACAAAGGAACCC-3′, 
(reversed) 5′-TGTCTGTTTCCTTGCTGGTT-3′. PREP(S554A) protein was kindly provided 
by Anne-Marie Lambeir (University of Antwerp, Belgium). All plasmids were sequenced to 
confirm their identity. Recombinant porcine PREP was purified as previously described 
(Venalainen et al., 2006).
Chemicals4.2
Dimethyl sulfoxide (DMSO), sodium arsenite, rotenone, salubrinal, DBeQ, GW4869 and 
recombinant human aSyn protein were purchased from Sigma-Aldrich. aSyn protein was 
expressed in E. coli, and thus may not be correctly folded. SecinH3 was purchased from R&D 
Systems. TAT-TAMRA peptide was purchased from Anaspec. KYP-2047 was synthesized by 
42
the School of Pharmacy, University of Eastern Finland, as previously described (Jarho et al., 
2004). Hoechst 33342 was purchased from Invitrogen.
Antibodies4.3
The following primary antibodies were used: anti-HA (Sigma), Tau-5 (Invitrogen), AT8 
(Thermo), anti-PREP (R&D Systems), anti-PREP serum (collected from a rabbit immunized 
against DPDSEQTKAFVEAQNK peptide, and validated by ELISA from Thermo), anti-
Flotillin-1 (BD Transduction Labs) and anti-GAPDH (Millipore). The following secondary 
antibodies were used: Alexa-Fluor-568-conjugated anti-mouse-IgG secondary antibody 
(Invitrogen) and horseradish peroxidase-conjugated secondary antibodies (Thermo). The 
dilutions of antibodies were as recommended by manufacturers and providers, e.g. 1:500-
1:1000 for Western blotting and IF. 
Cell culture and transfections4.4
Mouse Neuro-2A (N2A) neuroblastoma cells, human embryonic kidney 293T cells 
(HEK293T) and human microglial CHME-5 cells (kindly provided by Dr. Mikko Airavarra, 
University of Helsinki) were cultured in full Dulbecco’s Modified Eagle Medium [DMEM 
with 1% (v/v) L-Glutamine-Penicillin-Streptomycin solution (Lonza), 10% (v/v) FBS (Gibco, 
Invitrogen)]. Mouse primary cortical neurons were prepared as previously described (Nykanen 
et al., 2012). Primary neurons were cultured in neurobasal medium with 2% B27 supplement, 
1% penicillin/streptomycin, and 1% glutamine. 50% of the medium Ultracentrifuge every 
three days. All cells were cultured at 37°C, 5% CO2 and water saturated air. 
JetPei and Jetprime (Polyplus) were used to transfect N2A, HEK293T and CHME5-cells
with plasmid DNA and/or siRNA-DNA according to manufacturer’s instructions. Neurons 
were transduced at 21 DIV with the lentiviral vector that was prepared and operated as 
previously described (Kysenius et al., 2012). Media was conditioned for three days post-
transduction. Real-time quantitative (qPCR, SYBR Green Maxima kit, Thermo, and RT-PCR 
cycler, Bio-Rad CFX95) was used to study the knockdown efficacy of siNRAs and shRNAs. 
Quantitation of qPCR data used comparative Ct method and was normalized to GAPDH.
Protein-fragment complementation assay4.5
Protein-fragment complementation assay (PCA) is a live-cell method to study protein-
protein interactions. In PCA, proteins of interest are tagged with fragments of the reporter 
protein. The reporter protein fragment reconstitutes enzymatic activity if they are brought to 
proximity less than 10Å during the interaction of the protein of interest, and generate 
bioluminescence when the substrate is present (Figure 17A)(Michnick et al., 2007).
Humanized Gaussia princeps luciferase was used as a reporter (GLuc, 19.9 kDa, 185 aa), and 
native coelenterazine (nCol, NanoLight Technology) as substrate. 
Cells were transiently transfected with proteins tagged or untagged to reporters and/or 
cotransfected with siRNA (100 ng of DNA and 5 nM of siRNA per well) 24 h post-plating on 
96-well plates (9,000-10,000 cells per well, poly-L-lysine-coated) as previously described 
(Martiskainen et al., 2015b). PCA signal is measured from cells 48 h post-transfection. 30min 
before signal measurement, media was changed to phenol red-free DMEM (Gibco, Invitrogen) 
without serum (PRF-DMEM) after gently washing cells with PBS. Victor3 1420 Multilabel 
Counter (PerkinElmer) or Varioskan Flash multiplate reader (Thermo) are used to titrate nCol 
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(final concentration of 20 ?M) and monitor signal from 4 replicates wells of each condition. 
Chemicals were pre-diluted into PRF-DMEM media and applied to cells. 
4.5.1 Tau and aSyn secretion assay
Cells were plated and transfected as described above. 16 h before signal measurement,
cells were gently washed once with warm PBS and changed to PRF-DMEM (140 μl per well). 
30 minutes before signal measurement, cells were spin down at 200-300 ? g for 3-5 minutes. 
Conditioned cell-free PRF-DMEM was replaced with fresh PRF-DMEM, and transferred to 
different 96-well plates. PCA signal from 75 μl of this conditioned media and cells were read 
separately. 50 μl of the conditioned media was analyzed with lactate dehydrogenase (LDH) 
release assay according to manufacturer’s instructions (Promega CytoTox 96® Non-
Radioactive Cytotoxicity Assay, G1781).
4.5.2 Assessment of tau and aSyn uptake
4.5.2.1 Conditioned media production
HEK293T or N2A cells were plated into poly-L-lysine-coated 10-cm plates at a density 
of 2-3 million cells per plate and transiently transfected with 9 mg of tau-GLuc1/2 or aSyn1/2 
plasmids 24 h post-plating. Cells were washed once with PBS to remove remaining
transfection reagent 24 h post-transfection. Then media was changed to PRF-DMEM. Media 
was conditioned for 24 hours. Next, media was collected, and centrifuged at 3,000 ? g for 30 
min to remove cell debris. The level of tau-GLuc1/2 and aSyn-GLuc1/2 dimers/oligomers in 
the media was determined by PCA. Total human Tau ELISA kit was used to determine tau 
level in the conditioned media according to manufacturer’s instructions (#KHB0041, 
Novex/Life Technologies). Media (full neurobasal media) was conditioned from mouse 
primary cortical neurons for 3 d post-transduction, and tau in the conditioned media was 
determined by mouse-specific tau ELISA kit (KMB7011, Novex, ThermoFisher).
4.5.2.2 Tau uptake assay
Naïve N2A cells or HEK293T cells were plated and transfected as described above on 
96-well plates. 24 h post-transfection, cells were washed once with PBS and changed to
conditioned media that contained reporter proteins and were produced as described above.
Cells were exposed to conditioned media for 4 h, and washed with PBS, then incubated with 
20 μg/ml heparin (Sigma) diluted in PRF-DMEM for 5 min [remove cell surface-bound
proteins (Holmes et al., 2013)]. Next, cells were washed with PBS and changed to 75 μl PRF-
DMEM, and intracellular PCA signal was read as described above. All wash processes were 
done gently to prevent disturbing cells. 
Electrophoretic techniques4.6
4.6.1 Western blotting
Western blotting (WB) were done as previously described (Nykanen et al., 2012). Cells 
were plated and transfected as mentioned above. 48 h post-transfection, cells were washed 
twice with ice-cold PBS, and extracted with extracting buffer [10 mM Tris-HCl, pH 6.8, 150
mM NaCl, 1 μM NaF, 1% Triton X-100, 0.25% Nonidet P-40, 1 mM EDTA, Protease and 
Phosphatase Inhibitor cocktail tablets (Roche)], and incubated on ice for 30 min. Extracts were 
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centrifuged at 16,000 ? g for 10 min to remove debris, and BCA protein assay kit (Thermo)
was used to determine protein concentration according to manufacturer’s instruction. Equal 
amounts of total proteins from cell lysates were loaded per well, and ran on 4–12% gradient 
Bis-Tris gels according to manufacturer’s instruction (Novex, Invitrogen). Proteins were then 
transferred from the gel to PVDF membranes (GE Healthcare) via semidry blotting (Bio-Rad). 
Blots are stained with primary antibodies as mentioned in the chemical section. Horseradish-
conjugated secondary antibodies and ECL Western blotting detection reagent (Thermo) were 
used to generate chemiluminescence. QuantityOne software (Bio-Rad) was used to analyse the 
blots semi-quantitatively.
4.6.2 Native polyacrylamide gel electrophoresis
Native Polyacrylamide Gel Electrophoresis (PAGE) in publication I was prepared and 
performed as previously described (Szeltner et al., 2013). 6 μg of recombinant porcine PREP 
or PREP(S554A) proteins were pre-incubated with KYP-2047 or DMSO for 30 min at room 
temperature. An equal amount of sample per lane was run on 10% native gel containing a 
stacking gel. The gel was fixed using destaining buffer (45% methanol, 10% acetic acid). 30 
min post-fixation, the gel was stained in 0.1% Coomassie Brilliant Blue R-250 for 2 h with 
additional washes.
In publication II, conditioned media was prepared as described above, and concentrated 
using Amicon Ultra-15 Centrifugal Filters (Merck Millipore, UFC903008). Native-PAGE 
Novex™ Tris-Glycine Native Sample Buffer (LC2673), Novex™ Tris-Glycine Native 
Running Buffer (LC2672) and NuPAGE™ Novex™ 3-8% Tris-Acetate Protein Gels 
(EA0375BOX; Novex, ThermoFisher Scientific) were used to prepare and ran samples 
according to manufacturer's instruction. An equal volume of sample was loaded per well. Gels 
of Native-PAGE from both publication I and II was then blotted and analysed as described in 
Western blotting.
Fractionation techniques4.7
4.7.1 Protein fractionation
Protein solubility was studied by protein fractionation. Protein samples were extracted 
from cells as described above. After incubation on ice, an equal volume of samples was loaded 
into polycarbonate centrifugation tubes (Beckman Coulter), and centrifuged at 100,000 x g for 
30 min using TLA-100 rotor and a tabletop ultracentrifuge (OptimaTM ultracentrifuge, 
Beckman Coulter). After centrifugation, soluble fraction was collected into a different tube. 
Insoluble pellets were washed once with milliQ-water and resolved in 50 μl of Laemmli buffer 
(75 mm Tris-HCl with pH 6.8, 3% SDS, 15% glycerol, 3.75 mm EDTA, pH 7.4) with the aid 
of a rod sonicator (Labsonic® M.B. Braun Biotech International). Both samples from soluble 
fractions and insoluble fractions were then analysed by Western blotting as described above.
4.7.2 Media fractionation
Conditioned media was produced as described above, and was fractionated into vesicle-
free, larger microvesicles or ectosomes and exosomes fractions with a previously described 
method (Théry et al., 2006). Briefly, media was centrifuged in a sequence of 3000 x g for 30
min (to clear debris), 20,000 x g for 60 min (to pellet the ectosomal fraction), and 100,000 g
for 70 min (to pellet the exosomal fraction) using ultra-centrifuges (SW41 Ti rotor, Sorvall 
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WX Floor Ultra centrifuge). The supernatants from each centrifuge step were gently collected 
without disturbing the pellets. The pellets were resolved in PBS first, and re-centrifuged to 
pellet again, and were resuspended either in PRF DMEM for PCA measurement, or 1.5x 
Laemmli buffer for Western blotting analysis. Flotillin-1 (BD Transduction Labs #F65020, 
1:500) was used as a marker for ectosomal vesicles. 
 Protein crosslinking 4.8
Proteins in cell lysates and conditioned media were crosslinked to study their oligomeric 
state. Samples from cell lysates and conditioned media were prepared as described above. 
Conditioned media was concentrated by Amicon Ultra-15 Centrifugal Filters (Merck 
Millipore, UFC903008). All samples were crosslinked by BS3 (final concentration of 5 mM; 
Pierce, Thermo) according to the manufacturer's instructions. Tris-HCl (final concentration of 
50 mM, pH 7.5) was used to quench the crosslink reaction buffer. Samples of equal volume 
were analysed by Western blotting. 
 Microscale Thermophoresis 4.9
Microscale Thermophoresis (MST) is a novel cell-free method studies interaction 
between molecules such as proteins and chemicals (NanoTemper Technologies). Recombinant 
porcine PREP and PREP(S554A) proteins (activity was validated as previously described) 
were fluorescently labelled with the Monolith NT.115 protein labelling kit (NT-647 N-
hydroxysuccinimide, NanoTemper Technologies) according to the manufacturer's instructions 
(Savolainen et al., 2014). Labelled PREP and PREP(S554A) were eluted in PBS with 0.05% 
Tween-20. Monolith NT.115 Microscale Thermophoresis device and standard treated 
capillaries (NanoTemper Technologies) were used to study the interaction between aSyn, 
PREP/PREP(S54A) and KYP-2047 (final concentration of 0.05% Tween-20, 0.5 mg/ml BSA, 
and 2.5 mm DTT in PBS). Equal amounts of labelled PREP or PREP(S554A) proteins were 
titrated by recombinant human aSyn (starting from 35 μM; Sigma, #S7820) or KYP-2047 
(starting from 10μM) in series dilution. Curve-fitting was done by NTanalysis software 
(NanoTemper Technologies). GraphPad Prism software was used to calculate the Kd values 
using non-linear regression and one site-specific binding with Hill slope.  
 Immunofluorescence microscopy 4.10
Immunofluorescence microscopy (IF) was performed as previously described (Kysenius 
et al., 2012). Antibodies used are listed in the Antibodies section. Zeiss AxioImager M1 
epifluorescence microscope was used to take images. Adobe Photoshop was used compile raw 
images. Stress granule-positive cells per total number of cells were manually quantified in 
randomly selected fields. Each of selected field contained at least 50 cells.  
TAT-TAMRA peptide (Anaspec) requires live cell activity. In live cell 
immunofluorescence imaging, naïve HEK293T cells were exposed to tau-BiFC conditioned 
media for 4 h, and 10 μM of TAT-TAMRA peptide was added to media in the last hour. Then 
media was changed to PRF DEME with 15 mM Hepes buffer (Life Technologies) before 
taking the image. The image was taken with Zeiss LSM 710 upright confocal and analysed 
with ImageJ software. 
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Cell viability4.11
Two cell viability assays were run side-by-side to monitor cell viability and membrane 
integrity according to manufacturers' instructions. In resazurin assay, cells were exposed to 
PRF DEME with resazurin sodium salt (final concentration of 100 μM; Sigma) at +37 °C with 
5% CO2 for 2 hours. Fluorescence was measured at 530 nm excitation and 590 nm emission 
filters by Victor as previously described (Asai et al., 2015b).
Cellular release of LDH was measured by CitoTox 96 Non-Radio Cytotoxicity Assay 
(Promega). LDH level from cell and media was determined by measuring absorbance at 
490 nm with Victor plate reader 30 min after applying reagent. Relative LDH release is 
calculated as a ratio of LDH (media): LDH (total). Three independent experiments with 4-8
replicate wells per condition were analysed.
Statistical analyses4.12
A minimum of three independent replications were used for each experiment, and four 
independent wells per condition were calculated in average as one datapoint in PCA (I, II, III).
Microsoft Excel software and GraphPad Prism were used to make statistical analyses and 
graphs. Statistical significance was evaluated with Student's t-test (two groups) or one-way
ANOVA with Bonferroni's post-tests (three or more groups), with the significance threshold 
set at p < 0.05 (*), and ** = p < 0.01 and *** = p < 0.001 (I, II, III).
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5 Results
Clarifying molecular mechanisms of prolyl oligopeptidase modulating α-Synuclein 5.1
intracellular dimerization (I)
Dimerization of aSyn is the first event towards aSyn oligomerization and aggregation. To 
study the molecular mechanisms of aSyn dimerization, a live-cell platform method based on
protein-fragment complementation assay (PCA) using split humanized Gaussia princeps 
luciferase (GLuc) was adopted to monitor aSyn dimerization in an in vitro model 
quantitatively. PCA detects direct protein-protein interaction by the reconstitution of 
complementary reporter protein fragments tagged to proteins of interest as described in Figure 
17A (Remy and Michnick, 2006a). Compared with other PCA methods such as split GFP, 
reconstitution of complementary GLuc-reporter protein fragments is reversible. Thus GLuc-
based PCA in live-cell platform also monitors the dynamics of the protein-protein interactions 
in their native cellular environment (Chun et al., 2007a).
5.1.1 Prolyl oligopeptidase promotes α-Synuclein dimerization
Prolyl oligopeptidase (PREP) was previously shown to modulate aSyn aggregation in 
vitro and in vivo as reviewed in section 2.2.5. We chose to co-express PREP and aSyn-GLuc 
(aSyn tagged with GLuc-reporters) in N2A neuroblastoma cells, which express a low level of
endogenous aSyn and PREP (I/Figure 1). PREP(S554A) is an enzymatically inactive PREP
mutant and was used as a control. Interestingly, both PREP and PREP(S554A) overexpression 
mildly increased aSyn level (I/Figure 1). A previously developed and functionally validated 
PCA assay for monitoring aSyn dimerization was used to study if aSyn dimerization was 
increased by PREP (Yan, 2013). We overexpressed aSyn-GLuc1 and aSyn-GLuc2 (hereafter 
aSyn-GLuc1/2, with constructs indicated in I/Figure 2A) at a constant level while co-
expressing PREP and PREP(S554A) at increasing level. As shown in I/Figure 2B, aSyn 
dimerization was increased in a dose-dependent manner with increasing PREP and 
PREP(S554A) overexpression, suggesting that overexpression of PREP promotes aSyn 
dimerization, and this is independent of its enzyme activity. 
Inhibition of PREP was shown to reduce the amount of aggregated aSyn in cells and 
transgenic mice overexpressing aSyn (Brandt et al., 2008, Myohanen et al., 2012a). We treated 
cells co-expressing PREP or PREP(S554A) and aSyn-GLuc1/2 with KYP-2047, a small-
molecule inhibitor of PREP enzyme activity, and observed a reduction in PREP-induced aSyn 
dimerization in cell overexpressing wild-type PREP but not PREP(S554A) mutant (I/Figure 
2C). This effect was specific to PREP as the KYP-2047 treatment had no effect on control
cells overexpressing aSyn only (I/Figure 2D). Besides, overexpression of PREP or treatment
of KYP had no effect on aSyn solubility (I/Figure 2E) suggesting that we are studying an early 
event of aSyn aggregation pathway, where aSyn stayed mostly as soluble dimer or oligomers. 
5.1.2 Direct protein-protein interaction between prolyl oligopeptidase and α-Synuclein
PREP was reported to co-localize with aSyn in Lewy bodies in PD patients brain 
(Hannula et al., 2013). Hence to explore possible mechanisms of PREP-induced aSyn 
dimerization, we decided to address the potential interaction between aSyn and PREP by 
generating PREP-GLuc2 and PREP(S554A)-GLuc2 constructs (I/Figure 3A). We validated 
the expression level and activity of PREP-GLuc2 and confirmed that PREP-GLuc2 and 
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PREP(S554A)-GLuc2 are expressed in N2A cells but at a lower level than untagged PREP 
(I/Figure 3B), and that PREP-GLuc2 maintained hydrolytic activity (I/Figure 3C). 
In PCA study, we observed a significant amount of PCA signal from co-expression of 
aSyn-GLuc1 with both PREP-GLuc2 or PREP(S554A)-GLuc2 (I/Figure 3D), where aSyn-
PREP(S554A) PCA signal was slightly higher than aSyn-PREP. This suggests that there is an 
interaction between aSyn and PREP and PREP(S554A), and the aSyn-PREP interaction could 
be independent of PREP enzyme activity. We further tested the interaction of aSyn-PREP and 
aSyn-PREP(S554A) combination using Microscale Thermophoresis (MST), a cell-free system 
that quantitatively monitors direct protein-protein interactions in solution (Wienken et al., 
2010). In the MST study, recombinant aSyn and PREP interacted with an affinity of Kd=2.96
μM, whereas recombinant aSyn and PREP(S554A) interaction had a Kd of 1.41 μM (I/Figure 
5A, B). Surface plasmon resonance was used to confirm the direct interaction and showed a
Kd of 3.61 μM of aSyn-PREP interaction (I/Figure 5C). These results are in line with PCA 
data suggesting that aSyn-PREP(S554A) interaction had a slightly higher affinity than aSyn-
PREP, and thus confirmed the direct interaction between aSyn and PREP. 
PREP was previously reported to cleave at proline residues at the C-termini of its 
substrates, and aSyn contains five proline residues at its C-terminus (Walter et al., 1971). To 
confirm that aSyn-PREP interaction is independent of PREP enzyme activity, we generated 
two aSyn mutants, aSyn(Δ118–140)-GLuc1 (lacking three proline residues) and aSyn(Δ98–
140)-GLuc1 (lacking all proline residues) as illustrated in I/Figure 4A. Both aSyn mutants are 
expressed in N2A cells as confirmed by WB (I/Figure 4B). Expression of all three pairs of 
aSyn (mutants)-GLuc1 with PREP-GLuc2 showed a comparable level of PCA signal (I/Figure 
4C), suggesting that the C-terminal proline residues of aSyn were not needed for PREP 
binding. This is in line with a previous study, which showed that aSyn is not cleaved by PREP 
hydrolytic activity (Brandt et al., 2008). The signal from aSyn(Δ98–140)-GLuc1 and PREP-
GLuc2 was about 30% lower as compared to the other two pairs, but this may be explained by 
the slightly lower expression level of aSyn(Δ98–140)-GLuc1 (I/Figure 4B).
5.1.3 KYP-2047 alters the conformation of PREP
As a previous study indicated that inhibition of PREP by KYP-2047 reduced PREP-
dependent aSyn dimerization, we studied the effect of KYP-2047 on aSyn-PREP interaction 
using PCA. We treated N2A cells with KYP-2047 and observed roughly a doubled PCA 
signal with aSyn-PREP interaction but an insignificant change in aSyn-PREP(S554A), 
suggesting that KYP-2047 binding enhances PREP interaction with aSyn (I/Figure 3E). KYP-
2047 was previously shown to bind and modify the conformation of PREP (Szeltner et al., 
2013). We confirmed KYP-2047 binding to both recombinant porcine PREP and 
PREP(S554A) by using MST as described in Figure 16, where the Kd values are within 
physiological range.  We preincubated recombinant porcine PREP and PREP(S554A) protein 
with KYP-2047, and resolved on naive PAGE gel. With Western blotting analysis, we
observed three bands of PREP and PREP(S554A) on the native gel (I/Figure 6). This could 
indicate the three different conformations of PREP, monomeric compact, oligomeric and 
monomeric open form, as previously described (Szeltner et al., 2013). However, after pre-
incubation with KYP-2047, PREP adopted only one faster-migrating band (I/Figure 6), which 
represents the monomeric compact form of PREP. This KYP-2047-induced conformational 
change of PREP was not observed with PREP(S554A), although KYP-2047 also binds to 
PREP(S554A). This could provide an explanation about the insensitivity of PREP(S554A) to 
KYP-2047 treatment observed in PCA assays. 
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Figure 16 KYP-2047 binding to PREP (A) and PREP (S554) (B) was studied by MST. An equal 
amount of fluorescence labeled, purified recombinant PREP or PREP(S554A) was titrated by KYP-
2047 at various concentrations. KYP-2047 binds to PREP and PREP(S554A) at Kd of ~5.8 nM and 
~2.7 nM, respectively. The curve and Kd were calculated by averaging Kd curves assimilated using 
NTanalysis software from independent experiments (mean ± SEM; N=3 independent experiments).
Assay development for studying secretion and uptake of α-Synuclein and tau (I, II)5.2
We utilized highly sensitive PCA-based platform as a basis (Figure 17A), and further 
developed the platform to monitor cellular release and uptake of tau and aSyn dimers. As 
shown in II/Figure 1, the concept of monitoring release of protein dimers via PCA is to 
measure both PCA signal from cells and corresponding media at the end of the experiment, 
hence quantitatively analysing the amount of dimers that have been released into media from 
the cells. In uptake assay, recipient cells that are not expressing GLuc-tagged proteins are 
incubated with the conditioned media that contain reporter protein dimers. By measuring the 
PCA signal in recipient cells at the end of the experiment after thorough washing, we can 
quantitatively analyse the amount of dimers that have been internalized.
5.2.1 Development of an assay for studying α-Synuclein release and uptake
PREP has been previously suggested to bind to the microtubule, and serve a role in 
intracellular transport and protein secretion by regulating axonal transport in neuroblastoma 
cells (Morawski et al., 2011). miRNA silencing and chemically inhibition of PREP were also 
reported to increase the overall protein secretion in glioma cells (Schulz et al., 2005). As a
follow-up study of the aSyn-PREP project, we wanted to investigate if PREP modulates aSyn 
dimer release and uptake. We first co-expressed aSyn–GLuc1/2 constructs in increasing 
amount (Figure 17B). The PCA signal in washed cell monolayers and media increased in a 
dose-dependent manner, suggesting both intracellular and secreted aSyn levels correlated with 
the level of aSyn–GLuc1/2 reporter gene dose. To confirm the observed signal in the medium 
is specific to extracellular aSyn dimer and is not due to passive release related to cell death, 
we expressed aSyn–GLuc1 and aSyn–GLuc2 separately. Expression of aSyn reporters alone 
did not generate luminescence signal in either cells or media (Figure 17C). aSyn dimer PCA
signal from the medium was independent of changes in lactate dehydrogenase (LDH) release, 
suggesting that the release of aSyn dimers into the media was not a result of passive release or 
membrane leakage. During an 18-h observation period, aSyn–GLuc1/2 reporters accumulated 
in serum-free culture medium with nearly linear kinetics for up to 12 hours, as shown by an 
LDH-normalized aSyn secretion PCA (Pearson r2=0. 0.9337)(Figure 17D). Using the aSyn 
secretion assay, we co-expressed aSyn with PREP or PREP(S554A). Both PCA signals from 
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cells and media were increased but in the same proportion (Figure 18), suggesting that the 
increase of PCA signal in the media is highly likely a result of increasing PCA signal inside 
the cells rather than altered release of aSyn. As PREP is unlikely altering aSyn release in 
neuro2A cells, KYP was not further tested. 
Apart from the release assay, we also tried to develop an uptake PCA assay for aSyn, but 
by incubating naïve recipient cells with conditioned media containing aSyn-GLuc1/2 or tau-
GLuc1/2, PCA signal generated from aSyn-GLuc1/2 in washed recipient cells was below the 
limit of reliable detection that was set at 500 RLU (Figure 17E). The more sensitive method 
would be needed to study the uptake aSyn dimer further as compared to tau.
Figure 17 Assay development 
data of aSyn release and 
uptake. (A) The concept of 
PCA is to detect protein-
protein interactions in live 
cells based on the 
reconstitution of reporter 
protein fragments fused to 
proteins of interest.
Luminescence signal is 
generated by reporter protein 
in the presence of substrate, if 
reporter proteins are brought 
close enough (<10Å) by the 
interacting proteins of interest.
(B) The aSyn PCA signal 
intensity in cells and medium is 
dependent on the reporter gene 
dosage (reporter plasmids at 
20ng, 40ng, 60 ng, 80 ng and 
100 ng per well of a 96-well
plate, with 10,000 cells plated 
per well). (C) The aSyn–GLuc1 
and aSyn–GLuc2 PCA signal 
in washed cell monolayers 
(left) and in conditioned 
medium (middle) is shown. 
Relative LDH release (right) 
was used as a release control.
(D) aSyn release kinetics 
during an 18-h incubation. The 
aSyn dimer level in the medium 
was determined by PCA, and 
the PCA signal was normalized 
to the LDH release. (E) After 4 
h incubation of naïve recipient 
cells in the mock- (left) or
aSyn–GLuc1/2- (middle) or 
tau–GLuc1/2- (right) 
conditioned medium, cells were 
washed, and measured with 
PCA. RLU, relative light units. 
Results are mean±sd. *P<0.05, 
***P<0.001 (ANOVA).
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Figure 18 Preliminary aSyn secretion assay. aSyn–GLuc1/2 with co-expression of PREP or S55A 
generate PCA signal in washed cell monolayers (left) and in conditioned medium (middle). PREP 
or PREP(S554A) overexpression does not alter the signal ratio between media and cell (right) as
compared with control. Results are mean±s.e.m. N=3.
5.2.2 Tau secretion and uptake assay development
5.2.2.1 Development and functional validation of tau release assay
The tau release assay is also a PCA-based live-cell assay system quantitatively analyses
the cellular release of tau dimers in vitro. The PCA method has been previously used to study 
the cellular regulation of tau (Martiskainen et al., 2015b, Nykanen et al., 2012). Here, tau-
GLuc1 and tau-GLuc2 are expressed in HEK293T cells, which have a negligible level of 
endogenous tau expression (II/Figure 2A). Compared to the pair of tau-GLuc1N and tau-
GLuc2N, tau-GLuc1C and tau-GLuc2C combination (hereafter tau-GLuc1/2) generated 
highest PCA signal with little unspecific signal from individual reporter fragment, thus are 
used in the rest of the experiments (II/Figure 2B C). Tau-GLuc1/2 reported are co-expressed, 
and generated high PCA signal from both washed cell monolayers and conditioned media
(II/Figure 2D). One reporter alone did not generate luminescence signal in either cells or
media. PCA signal from the media was not correlated with change in lactate dehydrogenase 
(LDH) release, suggesting that the presence of tau dimers in the media was not a result of 
passive release or membrane leakage but rather via active secretion process. Both cellular and 
media PCA signal increased in a dose-dependent manner relative to increased level of tau-
GLuc1/2 overexpression (II/Figure 2E), suggesting that both intracellular and secreted tau
levels correlated with the level of tau–GLuc1/2 reporter gene dose. Tau-GLuc1/2 secretion 
accumulation kinetics with LDH-normalization in serum-free media were followed for 24 h, 
and observed accumulation of PCA signal with nearly linear kinetics up to 20 h (Pearson
r2=0.9715, II/Figure 2F).
We explored tau oligomer species in the medium by concentrating media and then 
analysed media samples on native PAGE gel or after chemical crosslinking (BS3) followed by 
analysis with SDS-PAGE. Both methods showed decent level of tau monomer in the media 
(II/Figure 2 G H). In the SDS-PAGE gel, a high molecular mass smear that is tau 
immunoreactive was observed, while the cell lysates indicated that intracellular tau oligomers 
could be mostly dimers or trimers (II/Figure 2 G). The native PAGE showed an equal level of 
dimers as monomers but some tau trapped in the stacking gel suggesting that there was some 
aggregated tau-GLuc present in the media (II/Figure 2H). Taken together, these data suggested
that the majority of tau-GLuc is secreted as monomers and dimers in HEK293T cells, and 
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could also include soluble pre-aggregates or fibrils, indicating that GLuc-tag did not interfere 
with known tau oligomerization and aggregation properties.
It was previously reported that tau dimerizes irreversibly in the split GFP system that is 
another form of PCA (Chun et al., 2007b). Hence we tested the reversibility of tau-GLuc1/2 
dimers by titrating conditioned medium with several detergents. Titration of the media
samples with SDS abolished luminescence signals generated from full-length GLuc or tau-
GLuc1/2, because reporter proteins are denatured (II/Figure 2I).  Triton X-100, a mild non-
ionic detergent, and Saponin, another mild detergent derived from glucoside, were capable of 
dissociating the protein complexes without denaturing them at relatively low concentration.
Titration of the media samples with either one of the detergents reduced luminescence 
generated by tau-GLuc1/2 complex but not full-length GLuc enzyme (II/Figure 2I), suggesting 
that most tau-GLuc1/2 dimers are reversibly associated. This further indicates that tau-GLuc 
PCA is reversible, and HEK293T cells secreted tau species are not predominantly in pre-
aggregation or fibril forms, in which case PCA signal will be diminished. 
To show that tau secretion is specific to tau dimer, we demonstrated that the complex of 
tau-GLuc2 and Pin1-GLuc1, a peptidyl-prolyl cis-trans-isomerase that was previously shown 
to interact with tau by PCA, was not secreted as efficiently as tau-GLuc1/2 (II/Figure 
2J)(Nykanen et al., 2012). Treatment of cells with GW4869, a neutral sphingomyelinase 
(nSMase) inhibitor, reduced tau-GLuc1/2 secretion by 32% (II/Figure 2K). nSMase generates 
ceramide that regulates exocytosis and exosomal secretion (Rohrbough et al., 2004, Trajkovic 
et al., 2008). Hence this result suggests that tau could be secreted in small vesicles as has been 
previously reported (Saman et al., 2012a, Dujardin et al., 2014a).
Total tau level in cell and media samples were analysed by ELISA, and the data was 
normalized to total protein content. As shown in II/Figure 3A, there is 16,700±1300 pg of tau 
per μg of protein in average in cell lysates, and 77.6±7.3 pg of tau per μg of total protein on
average in media, suggesting that less than 0.5% of cellular tau has been released to medium 
by HEK293T cells in our system. This is in line with a previous observation where only 0.1-
0.3% of cellular tau was released from transfected HEK293 T-Rex cells and human neurons 
induced from pluripotent stem cells (Chai et al., 2012a). To explore the 0.5% secreted tau that 
is associated with vesicles, a previously described method for characterising vesicle-bound
aSyn was adopted (Danzer et al., 2012). Conditioned media was treated with 0.005% (v/v) 
trypsin, and noticed that 99.8% of luminescence signals was depleted (II/Figure 3B), while
treatment of the media sample with trypsin plus 0.005% (v/v) saponin, which permeabilizes
vesicles without rupturing the vesicles, removed 99.9% signal. These results suggest that tau is 
primarily secreted as vesicle-free dimers, and that only roughly 0.1% of all secreted tau was
inside vesicles. We further fractionated conditioned media into ectosomal, exosomal and 
vesicle-free fractions with a previously described method (II/Figure 3C), and analysed via 
Western blotting, where flotillin-1 was used as a maker for specifying ectosomes as previously 
described (II/Figure 3D) (Dujardin et al., 2014a, Kowal et al., 2016). Semi-quantitative 
analysis of the Western blots confirmed that 99.7% of tau was secreted in vesicle-free form by 
HEK293T cells, while 0.22% of tau in ectosomes and 0.05% in exosomes (II/Figure 3E). This 
was also confirmed by PCA analysis of the media fractions, showed that majority of tau 
dimers were in the vesicle-free fraction (II/Figure 3F).
5.2.2.2 Development and functional validation of tau uptake assay
In the tau uptake assay, media was conditioned for 24 h with HEK293T cells 
overexpressing tau-GLuc1/2. Naïve recipient cells were incubated with the tau-GLuc1/2 
conditioned medium for 4 h, and then washed with PBS and immunostained for tau. We 
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observed intracellular tau-immunoreactive puncta evenly distributed throughout cytosol
(II/Figure 4A right) whereas incubation of recipient cells with conditioned media generated 
with mock-transfected HEK293T cells had no such pattern (II/Figure 4B). This suggests that
tau-GLuc1/2 was likely internalized by HEK293T cells.
It has been previously reported that heparan sulfate proteoglycans (HSPGs) on the cell
surface mediate tau uptake via macropinocytotic uptake, and can be blocked by heparin 
treatment (Holmes et al., 2013). Hence an additional washing step with 20 μg/ml heparin was 
added in PBS. As shown in II/Figure 4B, PBS wash removed over 99% of luminescence
signal that is generated from reporter proteins outside cells, and addition of the heparin wash 
step even further reduced this luminescence signal. Trypsin was added to remove the
extracellular signal completely, and trypsin plus Saponin was also added to remove the
intracellular signal. The comparison of the two trypsin-treated conditions confirmed that the 
majority of tau signal had been removed by washing (II/Figure 4B), suggesting that the signal 
observed after the multi-step washing procedures represent internalized tau. Thus, the three 
steps wash of PBS, heparin, and then PBS was used in the future uptake experiments.
Next, the uptake kinetics of tau was followed for 24 h, and the uptake slowed down after 
4h (II/Figure 4C), suggesting a saturable mechanism. In addition, the recipient cells were
treated with GW4869 that was shown to reduce tau secretion (II/Figure 2K), and tau uptake 
was increased by the treatment (II/Figure 4D). This suggested that internalized tau may be re-
secreted via a ceramide-regulated mechanism. 
Functional association of LOAD susceptibility genes with tau secretion and uptake 5.3
mechanisms (II)
5.3.1 RNAi screen of LOAD risk genes using the tau secretion and uptake assays
Several top late-onset 
Alzheimer’s disease (LOAD) 
risk genes, such as ApoE, 
BIN1, CLU, and PICALM,
were suggested to modulate 
tau propagation via direct or 
indirect interactions (Avila 
et al., 2015). BIN1 and 
PICALM are functionally 
connected to endocytic 
pathways and tauopathies 
pathogenesis, and thus
knockdown of these two 
genes were also proposed to
affect tau secretion and uptake (Chapuis et al., 2013a, Xiao et al., 2012). Based on the meta-
analysis and recent genetic risk studies of LOAD susceptibility genes, APOE, BIN1, CLU, 
ABCA7, CR1, PICALM, CD33, CD2AP, FRMD4A and TREM2 genes were chosen to 
knockdown via siRNAs (Bertram et al., 2008, Guerreiro et al., 2013b, Jonsson and Stefansson, 
2013, Lambert et al., 2013b). The genes were silenced individually by co-transfecting siRNAs 
with the tau-GLuc reporters. The knockdown efficiencies of siNRAs were validated by qPCR 
in HEK293T cells replicating the previously published study (Figure 19) (Martiskainen et al., 
2015a). The knockdown of the selected LOAD genes did not significantly alter intracellular 
tau level or dimerization (II/Figure 5A). Knockdown of CD33, CD2AP, FRMD4A and
Figure 19 Silencing 
efficacy of siRNAs. 
The target genes 
were silenced by a 
combination of two 
selected siRNAs. 
qPCR data used 
comparative Ct 
method and was 
normalized to 
GAPDH. Results 
are mean±s.e.m.
Originally published 
in (Martiskainen et 
al., 2015a).
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TREM2 decreased tau secretion (CD33 by -27%, CD2AP by -23%, FRMD4A by -19% and 
TREM2 by -55%) as shown by LDH-normalized PCA signal (II/Figure 5B). In the tau uptake 
assay, only the knockdown of ApoE in recipient cells increased tau uptake (by +29%,
II/Figure 5C). 
As the endogenous level of TREM2 and CD33 are very low in HEK293T cells, the 
findings in HEK293T cells were validated in CHME-5 cell line, a human fetal microglia-
derived cell line that expresses relatively higher levels of endogenous TREM2 and CD33 as 
verified by qPCR (data not shown). However, knockdown of TREM2 and CD33 in CHME-5
cells did not alter tau secretion in any way (II/Figure 5D) suggesting that the effect of TREM2 
and CD33 on tau secretion in HEK293T cells might be a false-positive. Therefore, CD2AP 
and FRMD4A were explored in further tau secretion studies.
5.3.2 CD2AP overexpression does not alter tau secretion
CD2-associated protein (CD2AP) is 
encoded by gene CD2AP on chromosome 
6p12, which has two SNPs, rs9296559 and 
rs934907 associated with increased AD risk 
(Hollingworth et al., 2011). CD2AP is 
known as a scaffolding protein involved in
actin cytoskeleton organization and polarity 
(Dustin et al., 1998, Lehtonen et al., 2002).
CD2AP was also reported to regulate 
synapse formation, cell-to-cell interaction 
and endocytosis (Wolf and Stahl, 2003, 
Cormont et al., 2003). Knockdown of 
CD2AP in Drosophila model of AD was shown to increase tau-mediated toxicity (Shulman et 
al., 2014). Here, CD2AP was overexpressed in HEK293T cells, and only very subtle changes
in tau PCA signal was observed in cells and media (Figure 20), suggesting that endogenous
CD2AP may be sufficient to modulate tau secretion, thus unlike knockdown, the 
overexpression of CD2AP would not alter tau secretion. The tau toxicity-modulating effect of 
CD2AP may thus be related to other mechanisms other than tau secretion.  
5.3.3 FRMD4A-cytohesin signaling pathway regulates tau secretion
FRMD4A belongs to the FERM superfamily and is encoded by FRMD4A gene on human 
chromosome 10p13 (Tepass, 2009). The FRMD4A gene has multiple SNPs associated with 
increased AD risk (Lambert et al., 2013a). The exact function(s) of FRMD4A are poorly 
understood. A recent study showed reduced expression of FRMD4A in AD patients’ brains, 
and knockdown FRMD4A in vitro showed increased tau phosphorylation and AD-related NFT 
pathology (Martiskainen et al., 2015a). Here, the intracellular localization of FRMD4A was 
first verified by immunofluorescent study. Both HA-tagged and GFP-tagged FRMD4A 
showed similar punctate intracellular distribution (II/Figure 6A). This punctate distribution of 
FRMD4A did not fully colocalize with tau that is overexpressed, but some FRMD4A-positive 
vesicles at or near the plasma membrane were closely associated with tau (II/Figure 6B). We 
also used FRMD4A-HA to confirm sufficient knockdown efficacy of siRNA, and analysis 
with Western blotting showed a reduction of FRMD4A level by 39% (II/Figure 6C). Next,
FRMD4A was overexpressed in increasing amount in HEK293T cells, and a significant 
increase in tau PCA signal was observed in the media in an FRMD4A gene dose-dependent 
Figure 20 The tau
PCA signal 
intensity in cells 
and media is not
altered by CD2AP
gene dosage 
(CD2AP plasmids 
at 0ng, 10 ng, 30
ng, 50 ng per well). 
Results are 
mean±s.e.m, N=3
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manner (up to +146% increase of secreted tau) while no change in cell-derived tau PCA signal 
was observed (II/Figure 6D). This suggested that FRMD4A regulates tau secretion. 
FRMD4A has been reported to serve as a scaffold protein that mediates the binding of 
cytohesins to the polarity signalling complex Par3/Par6/aPKCζ (Partitioning defective 3/6, 
atypical Protein Kinase C ζ), resulting in ADP ribosylation factor 6 (Arf6) activation 
(Ikenouchi and Umeda, 2010). Arf6 is a small GTPase localized in intracellular membranes,
and plays a key role in regulating actin cytoskeleton dynamics and membrane trafficking 
(D'Souza-Schorey and Chavrier, 2006). Like other small GTPases, Arf6 activity can be
regulated by many guanine nucleotide exchange factors (GEF), GTPase activating proteins 
(GAPs) and guanosine nucleotide dissociation inhibitors (GDIs) (Hongu and Kanaho, 2014).
Cytohesins (also known as Sec7 in yeast) are GEFs of Arf6 (Ashery et al., 1999). Here, cells
were first treated with SecinH3, a small-molecule inhibitor of cytohesin GEF activity, and 
observed a reduction in FRMD4A-induced tau secretion, and increased intracellular tau dimer 
content (II/Figure 6E), suggesting an accumulation of intracellular tau. Similar but milder 
effect was also observed when cells expressing endogenous FRMD4A were treated with 
secinH3 (II/Figure 6F). Next, Arf6 was overexpressed, and a strong increase in tau secretion 
was observed (II/Figure 6G). Overexpression of constitutively active Arf6(Q67L) mutant
significantly enhanced this effect (II/Figure 6H), whereas siRNA knockdown of Arf6 or 
alternatively expressing Arf6 dominant-negative mutant Arf6(T27N) significantly suppressed 
this effect (II/Figure 6G, H). 
Polarity signalling complex Par3/Par6/aPKCζ is connected to the FRMD4A-cytohesin 
pathway as mentioned above. The primary function of this complex is to regulate cellular
polarization, which is a key event involved in cell proliferation, migration, differentiation, etc.
(Suzuki and Ohno, 2006, Goldstein and Macara, 2007). Here, aPKCζ, a ceramide-binding 
protein previously reported to be involved in several membrane trafficking events and 
exocytosis, and C20ζ, the C-terminal ceramide-binding region of aPKCζ (amino acid 405–
592) were chosen to be overexpressed (Horikoshi et al., 2009, Joberty et al., 2000, Wang et al., 
2009a). Overexpression of aPKCζ significantly increased tau secretion whereas 
overexpression of C20ζ had no effect (II/Figure 7A). Co-expression of aPKCζ with C20ζ
suppressed aPKCζ-induced tau secretion, suggesting that both may compete to bind to 
ceramide that appears to be involved in tau secretion. In the polarity complex that regulates 
Arf6 activation in an FRMD4A-dependent manner, Par6 was shown to be an important 
adaptor connects Par3 and aPKCζ in order to carry out normal function at tight junction during 
epithelial cell polarization (Ikenouchi and Umeda, 2010, Joberty et al., 2000). While Par6 was
overexpressed, tau secretion was significantly increased (II/Figure 7C), which was likely
dependent on the Park6 kinase activity as expression of Par6 inactive mutant, Par6(S345A)
did not have this effect.  The addition of SecinH3 did not alter aPKCζ- or Par6- induced tau 
secretion (II/Figure 7B, D), suggesting that the polarity complex induced tau secretion does 
not require cytohesin GEF activity. Taken together, the data suggest that FRMD4A–
cytohesin–Arf6 pathway and the polarity complex with Par6/aPKCζ are involved in the 
regulation of tau secretion. 
Arf6 regulates synaptic vesicle endocytosis and recycling, and also cytohesins have been 
implicated in presynaptic vesicle transport (Ashery et al., 1999, Krauss et al., 2003, Tagliatti et 
al., 2016). Hence neuronal culture expressing endogenous tau was used to validate the 
findings further. Mouse cortical neuron cultures (21 DIV) were transduced with FRMD4A 
shRNA using lentiviral vectors, which was shown to result in 99% knockdown of endogenous 
FRMD4A mRNA (II/Figure 8A). Media was conditioned with transduced neurons for 3 d, and 
analysed by mouse-specific tau ELISA. Compared to control and GFP-transduced conditions, 
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silencing of FRDM4A expression significantly increased tau secretion (+390%, II/Figure 8B). 
Cortical neurons were treated with SecinH3 in increasing doses, and an increase in tau 
secretion was also observed (up to +204% at 20 μM of SecinH3) as analysed by ELISA 
(II/Figure 8C). Taken together, these results confirm that the FRMD4A-cytohesin signalling 
pathway modulates endogenous tau secretion.
The impact of transcellular propagation of tau on cellular stress (III)5.4
5.4.1 Hyperphosphorylated tau is recruited to stress granules after internalization
During tau uptake assay development, the punctate distribution of tau in naïve cells 
exposed to tau conditioned media was particularly interesting, and possibly indicated 
intracellular localization of internalized tau in endosomal or lysosomal compartments. Hence
intracellular localization of tau was followed after uptake using immunofluorescence 
microscopy and compartmental markers. Interestingly, tau was not localized to early 
endosomes (as stained by Rab5, III/Figure D, left), late endosomes (as stained by Rab7,
III/Figure 2D, middle) or lysosomes (as stained by Lamp2, III/Figure 2D, right) in recipient 
cells. Instead, some tau localized to macropinosomes (as stained by fluorescently labelled
TAT-TAMRA peptide in live cell imaging, III/Figure 2E), which is in line with a previous 
study (Holmes et al., 2013). Since (1) there was no co-localization with endo/lysosomal 
markers, (2) only some punctate tau-positive structures co-stained with TAT-TAMRA, and (3) 
some of the structures varied significantly in size and morphology, we hypothesized that these 
tau-containing structures could be non-vesicular cytosolic bodies. The number, size and shape 
of the tau-positive structures indicated stress granules as the most likely candidate. Indeed, co-
staining with a stress granule marker TIA-1 showed significant co-localization of internalized 
tau-GLuc with TIA-1 (III/Figure 2G). Interestingly, TIA-1 had just been reported to co-
localize with tau in brains of AD mouse models, including JNPL3 and rTg4510, as well as 
postmortem human AD patient brain tissue (Vanderweyde et al., 2012).
Stress granules (SGs) are transiently formed non-membrane bound RNA granules 
nucleated by various RNA-binding proteins (RBPs) under stress conditions in order to 
suppress translation (Anderson and Kedersha, 2008, Gilks et al., 2004). SG markers have been 
found in several disease-associated inclusions (Bentmann et al., 2013). Both untagged tau 
(III/Figure 2F) and tau with GLuc-tag (III/Figure 2G) were recruited to SGs by co-stain tau 
with several SG markers, TIA1 and eIF3η (III/Figure 2F, 2G top and middle panels), but TTP 
did not colocalize with tau (III/Figure 2G bottom). On the other hand, exposing cells to
conditioned media containing tau or tau-GLuc significantly increased the amount of SG-
positive cells (+80%, III/Figure 2I), suggesting that tau uptake enhanced SGs formation.
TIA-1 knockdown was shown to reduce tau misfolding and toxicity in hippocampal 
neuronal culture (Vanderweyde et al., 2016). Knockdown of TIA-1 significantly reduced 
colocalization of internalized tau with both SGs markers, TIA-1 and eIF3η (III/Figure 5B with 
quantitative analysis in 5C), suggesting that TIA-1 is required for recruitment of tau to SGs 
after being uptake. Interestingly, knockdown of TIA-1 also significantly reduced tau-induced 
toxicity after internalization (III/Figure 5D). This is in line with a recent study where TIA1 
knockdown reduced tau misfolding and toxicity in hippocampal neuronal culture 
(Vanderweyde et al., 2016).
It was recently proposed that tau hyperphosphorylation promotes tau internalization 
(Wauters et al., 2016). Tau, tau-GLuc and tauE14-GLuc, which is a
pseudohyperphosphorylated tau mutant carrying 14 phosphomimetic mutations, were 
overexpressed and cells co-stained with Tau-5 and TIA-1 antibodies (Khurana et al., 2006).
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Interestingly, compared to tau or tau-GLuc that did not co-localize with TIA-1 (III/Figure 1B 
top), tauE14-GLuc overexpression promoted the formation of SGs, into which tauE14-GLuc 
was recruited (III/Figure 1B bottom left, C), suggesting that hyperphosphorylation of tau is
involved in tau recruitment into SGs. 
TIA-1 was previously reported to interact with tau (Vanderweyde et al., 2012). We 
generated a TIA-1-GLuc1 construct and observed PCA signal from TIA-1-GLuc1 and tau-
GLuc2 (III/Figure 1F), and 6-fold higher PCA signal from TIA-1-GLuc1 and tauE14-GLuc2, 
further suggesting hyperphosphorylation could promote tau binding to TIA-1 or possibly to 
SGs. To further study if tau localization to SGs is a consequence of cell-to-cell transmission, 
cells were first transfected individually with one of the four reporter proteins, TIA-1-GLuc1,
tau-GLuc2, tauE14-GLuc2 and GSK3β-GLuc2 and then co-plated into same plates. 24 h post 
co-plating, strong PCA signal was observed from both combinations of TIA-1-GLuc1/tau-
GLuc2 and TIA-1-GLuc1/tauE14-GLuc2 (III/Figure 1G), confirming the cell-to-cell 
transmission of tau. Notably, wild-type tau-GLuc2 showed a comparable level of interaction 
with TIA-1-GLuc1 in the neighboring cells to tauE14-GLuc2, suggesting that during the 
secretion/uptake process wild-type tau-GLuc2 had acquired a property that enhances its TIA-1
interaction and SG recruitment in the recipient cells. 
Several lines of evidence indicated that hyperphosphorylation might play an important 
role in tau uptake. We analysed conditioned media and corresponding cell lysates by Western 
blotting. Despite the fact that tau is mostly located intracellularly (III/Figure J bottom), AT8,
an AD-associated phosphoepitope of tau, staining showed a remarkable enrichment in tau 
oligomers in the media while in cells phosphorylated tau was mostly monomeric (III/Figure J 
top). Immunofluorescence microscopy also confirmed that the internalized and SGs-associated 
tau was also phosphorylated at the AT8 epitope (III/Figure I). 
Altogether, this data, for the first time, indicates that SGs are a critical cellular structure 
in the cell-to-cell transmission process that underlies the spread of tau pathology in the brain. 
This suggests that TIA-1 and possibly also other SG proteins, which have an intrinsic self-
aggregating property needed for formation of SGs, play a key role in the seeding and 
transmission of pathological, misfolded and hyperphosphorylated tau to healthy cells.
5.4.2 Tau uptake sensitizes cells to stress
RNA-binding proteins and SGs have been implicated to be involved in the pathogenesis 
of neurodegenerative diseases (Maniecka and Polymenidou, 2015, Wolozin and Apicco, 2015).
For example, in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD),
mutations in Tar DNA-binding protein 43 (TDP-43), fused in sarcoma protein (FUS), and 
heterogeneous nuclear ribonucleoproteins (hnRNPA1/hnRNPA2B1) alter their intracellular 
localization and promote aggregation, and thus have been linked to the pathogenic pathway 
(Kim et al., 2013, Liu-Yesucevitz et al., 2010, Vance et al., 2009, Sreedharan et al., 2008, 
Tradewell et al., 2012).
A 4 h incubation with salubrinal induced SG formation, which disappeared during a 4 h
washout period (III/Figure 6A, top panels, with quantitative analysis in 6B).  With the addition 
of DBeQ, an inhibitor that blocks valosin-containing protein-mediated SG clearance,
numerous SGs remained in cells after the 4 h washout (III/Figure 6A, right, 6B). Interestingly, 
when cells were exposed with to conditioned media containing tau-GLuc for 4 h, SGs were
induced but could not be resolved by even a 20 h of washout period using fresh media without 
tau (III/Figure 6A, bottom panels, 6B). In another experiment, cells were exposed to tau 
conditioned media or salubrinal for 4 hours, followed by 4 h washout with fresh media, and 
then cells were treated with rotenone, a mitochondrial complex I inhibitor that induces 
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oxidative stress. A significant reduction in cell viability was observed in the tau media pre-
exposed condition (III/Figure 6E) but not in the salubrinal pre-treatment (III/Figure 6D). Thus, 
SG-association of tau impairs normal clearance dynamics of SGs and sensitizes cells to 
secondary stress. Taken together, these data showed that tau recruitment to SGs after
internalization significantly alters the cells’ normal stress-coping mechanisms and increases 
their sensitivity to other types of stress. This mechanism provides a previously unrecognized 
contributor to tau toxicity that may have particular importance in post-mitotic neurons that are 
exposed to various stresses in the aging or injured brain, as occurs in tauopathies and chronic 
traumatic encephalopathy (CTE)(McKee et al., 2009).
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6 Discussion
Assay development for studying cell-to-cell propagation of α-synuclein and tau6.1
Both aSyn and tau have been identified in healthy human plasma and cerebrospinal fluid,
and their level are altered during the pathogenic processes (Borghi et al., 2000, El-Agnaf et al., 
2003, Blennow et al., 1995, Vigo-Pelfrey et al., 1995). This indicates that aSyn and tau are 
constitutively released, but the mechanisms might be altered during pathogenesis. Braak 
staging proposed by Dr. Heiko Braak and colleagues described the sequential stage of 
development of synucleinopathies and tauopathies that are primarily composed aggregated 
aSyn and tau, respectively, in connected brain regions in a time-dependent manner (Braak and 
Braak, 1991, Bancher et al., 1993, Braak et al., 2003). This may offer a potential clinical 
consequence of aSyn and tau misfolding and transmission in specific brain areas with 
neurological manifestation. Despite the debate between the theories of “the spread of 
pathology”, which suggests that the transmission of disease-associated proteins occurs through 
specific neuronal network and between specific groups of cells, and the theory of “selective 
neuronal vulnerability”, which suggests that the transmission of disease-associated proteins 
are ubiquitous but certain neuronal populations are more affected than others, disease-
associated proteins need first to adapt the conformations that could seed pathology, and then 
spread from the donor cells to the recipient cells (Brettschneider et al., 2015, Walsh and 
Selkoe, 2016).  In the past two decades, the studies of aSyn and tau aggregation pathways 
have been intensively investigated, because these studies can offer potential mechanistic 
explanations for the initial and final events leading to the development of synucleinopathies 
and tauopathies. The missing gaps in between are potentially filled and explained by the cell-
to-cell propagation of aSyn and tau. The seeding of aggregates has been widely demonstrated 
in a series of in vitro and in vivo studies. These recent findings on the cell-to-cell transmission 
of aSyn and tau have received a lot of attention, and may offer hope for better understanding 
of disease mechanisms and identify novel therapeutic targets for many incurable 
neurodegenerative diseases such as AD, PD and ALS.
In this thesis work, a novel system was developed for monitoring cellular oligomerization, 
secretion and uptake of tau and aSyn. The assays were built based on PCA system that is 
widely utilized for studying protein-protein interactions in live cells (Remy and Michnick, 
2006b, Michnick et al., 2007). Although the assay was designed to detect protein-protein 
interactions in their native environment with minimum invasive impact, and thus has many 
benefits, this system also has its own weaknesses. The use of GLuc-reporter fragments fused 
to the protein of interest at N- or C- termini and the requirement of overexpression of reporter 
proteins are the two important caveats. The C-terminal fusion of GLuc reporter fragments to 
tau did not significantly alter cellular tau expression level nor the localization and 
oligomerization/aggregation behaviour in HEK293T cells. N-terminal GLuc fusion of aSyn 
did not interfere with the expression of aSyn nor oligomerization behaviour at the early stage 
of aggregation. A previous immunofluorescence study of aSyn-GLuc showed diffuse cytosolic 
signals, and staining on or near the cell surface and in protrusions, which was similar to 
endogenous aSyn expression (Yan, 2013, Lashuel et al., 2013). In transient transfection-based 
studies (publications I and II), overexpression of aSyn and tau reporter proteins did not cause
significant cytotoxicity or unspecific release of aSyn and tau from N2A and HEK293T cells, 
respectively, as confirmed by the measurement of LDH release.
In the assay system for studying cell-to-cell transmission of tau, the PCA signal from 
intracellular and secreted tau appears to be largely derived from tau dimers, which were 
previously described as the essential building blocks of tau aggregates and PHFs (Friedhoff et 
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al., 1998). Through validation via native gel and Western blotting analysis, tau-GLuc proteins 
were also shown to assemble into dimers, and to some extend into soluble aggregates. These 
observations indicate that tau generated in our system largely represents pathological 
conditions.  
It was previously demonstrated that the association of GLuc-reporter protein fragments 
used in PCA is reversible (Remy and Michnick, 2006b). However, in bimolecular 
fluorescence complementation assay, the complementary fragments of fluorescent reporter 
proteins form irreversible dimers (Kodama, 2012). In our GLuc PCA system, tau-GLuc1/2 in 
conditioned media dissociated with low concentrations of two mild detergents, Triton X-100 
and Saponin, suggesting that our GLuc PCA system replicates the previously described 
reversibility. At 0.1% Triton X-100 that would not be able to dissolve tau aggregates or fibrils, 
PCA signal was lost, suggesting that aggregates were not generating signals. This could be in 
line with a previous observation that tau signal was reduced upon aggregation in the 
bimolecular fluorescence complementation system (Chun et al., 2007a).  
In conditioned media, over 99% tau-GLuc was secreted in vesicle-free form, while a 
minor population represented vesicle-bound tau, in which ectosomes represented the major 
species. Even though this is in line with previous observations, there is still a possibility that 
post-secretion of tau from microvesicles in the media could overemphasize the vesicle-free 
fraction of tau (Dujardin et al., 2014a, Saman et al., 2012b). On the other hand, post-
release/escape of tau from microvesicles may also represent a physiological consequence of 
tau binding to the vesicle membranes in plasma or CSF. Interestingly, the internalization of 
vesicle-associated tau is significantly more efficient than vesicle-free fractions. This 
observation could be explained by vesicle offering a more efficient internalization route into 
cells. However, as tau internalization may take multiple routes that are incompletely 
understood, further studies are needed to address specific mechanisms involved.  
Macropinocytosis represents a subtype of bulk endocytosis, and has been described as a 
major route for cells to uptake macrosolutes such as extracellular tau fibrils (Holmes et al., 
2013). An immunofluorescence study in study III confirmed that macropinocytosis is involved 
in uptake of tau dimers. The mechanisms of how tau escapes macropinosomes and gets 
recruited to other intracellular compartments such as stress granules remain unknown. 
Disruption of vesicle membranes by misfolding and formation of annular protofibrils as 
previously described could be one potential explanation (Jones et al., 2012, Zeineddine et al., 
2015). However, depending on the overall rate of endocytic and exocytic events in cells, 
macropinosomes could undergo rapid recycling through exocytosis (Falcone et al., 2006). This 
offers a potential explanation for the low uptake rate as compared to the higher level of 
secretion. Overall, it could be implicated that most tau is internalized to macropinosomes and 
is recycled back via active secretion, while a smaller pool of vesicle-associated tau gets access 
to the cytosol. It is worth mentioning that ceramide-regulated mechanism may also be 
involved, as GW4869 that is a neutral sphingomyelinase (nSMase) inhibitor increased 
intracellular accumulation of tau following internalization.  
In our system developed to study cell-to-cell transmission of aSyn, aSyn dimers were 
clearly present in the media. The ratio between intracellular and extracellular aSyn dimers is 
similar to tau. The release kinetics of aSyn observed within 18 hours also showed similar 
saturable mechanisms as observed with tau. These preliminary data implicate that the release 
mechanisms of aSyn dimer could be similar to tau. Despite the fact that we have not fully 
characterized the extracellular aSyn oligomer species, intracellular aSyn is predominantly 
soluble with minor SDS-insoluble fraction present possibly indicating a relatively low level of 
aggregation, and suggesting that the assay reports an early event in the aSyn aggregation 
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pathway. The level of internalization of aSyn-GLuc from conditioned media is lower than tau, 
possibly indicating the different routes of aSyn internalization. Further studies are needed to 
address aSyn uptake mechanisms and require more sensitive means to detect internalized aSyn 
dimers/oligomer/aggregates.
The effect of prolyl oligopeptidase on α-synuclein oligomerization6.2
Prolyl oligopeptidase (PREP) has been previously shown to enhance aSyn aggregation 
(Brandt et al., 2008). Immunohistochemical assay also suggests that PREP co-localizes with 
aSyn in Lewy bodies in PD patients’ brain (Hannula et al., 2013). A small-molecule inhibitor 
of PREP, KYP-2047 reduces the amount of aggregated aSyn in cells and transgenic mice 
overexpressing wild-type aSyn and aggregation-prone aSyn mutant as verified by 
immunohistochemical assay and Western blotting, and in addition promotes the clearance of 
aSyn aggregates in transgenic mice models (Myohanen et al., 2012a). Previously, there has 
been interests in KYP-2047 in term of pathology inhibition effect, but the molecular 
mechanisms of PREP-mediated aSyn aggregation and the role of KYP-2047 in this process 
were incompletely understood. It has been suggested that PREP may serve as a nucleation 
point for aSyn aggregation (Brandt et al., 2008, Lambeir, 2011). Many proteins and small 
molecules such as tyrosine hydroxylase, reactive oxygen species, metal ions and lipids, have 
been shown to interact with aSyn, some of which also enhance aSyn aggregation in vitro and 
in vivo (Chavarria and Souza, 2013, Binolfi et al., 2008, Rivers et al., 2008, Lundblad et al., 
2012). It has been proposed that aSyn aggregation exhibits an inducible nucleation-elongation
mechanism, e.g. in the case of aSyn binding to lipids vesicles (Rabe et al., 2013). Hence it is 
possible that some of the interaction partners of aSyn also serve as nucleation points seeding 
aSyn oligomerization and aggregation (Galvagnion et al., 2015, Uversky, 2007).
In our study, PCA system for studying intracellular dimerization of aSyn is 
complemented with microscale thermophoresis (MST), a novel cell-free method to 
demonstrate side-by-side that PREP interacts with aSyn in both live-cell and cell-free
environments, and that this interaction enhances aSyn dimerization. In addition, this effect can
be inhibited by KYP-2047 via modulating PREP conformation but not its enzyme activity. 
Apart from PREP-induced aSyn dimerization, PREP expression also elevated the level of 
intracellular aSyn, which could also contribute to enhanced aSyn dimerization. It was 
previously reported that KYP-2047 inhibition of PREP in aSyn transgenic mice accelerated 
aSyn clearance, and the overexpression of PREP in cell culture reduced autophagy activity 
(Savolainen et al., 2014). Hence the enhanced aSyn level observed in our study may also be 
related to reduced aSyn clearance(Savolainen et al., 2014).
It was previously reported that aSyn colocalizes with PREP in aSyn inclusions that were 
formed under oxidative stress conditions in SH-SY5Y human neuroblastoma cells 
overexpressing aSyn, and this colocalization in inclusions could be reduced by KYP-2047 
treatment (Myohanen et al., 2012a). This led to a hypothesis that KYP-2047 treatment 
interferes with the interaction between aSyn and PREP, which may be responsible for the 
reduced aSyn aggregation.  Based on the data from two independent methods in cell and cell-
free systems, we showed that KYP-2047 inhibition of PREP leads to enhanced PREP-aSyn
interaction. We further explored potential PREP binding sites by generating different C-
terminal truncated aSyn mutants, because the C-terminal of full length aSyn contains proline 
residues that are known to be important for substrate specificity of PREP (Walter et al., 1971).
Our results indicate that the C-terminal proline residues of aSyn are not needed for PREP-
aSyn interaction. This also suggests that PREP-aSyn interaction is likely independent of PREP 
enzyme activity. 
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It has been reported that PREP adopts three different conformations, open and compact 
monomeric forms and an oligomeric form that exist in equilibrium (Szeltner et al., 2013, 
Szeltner et al., 2010, Tarrago et al., 2009). In one of the studies, KYP-2047 induced a large 
portion of PREP shift toward the compact monomeric form (Szeltner et al., 2013). Our data 
from native PAGE confirmed that KYP-2047 induces PREP to adopt the compact monomeric 
form predominantly in our system. Based on previous data, the compact monomers of PREP 
might have a higher binding affinity to aSyn but lower ability in promoting aSyn dimerization. 
These observations are in agreement with previous studies that demonstrated the 
conformations and the higher order oligomer structure of PREP are closely associated with 
PREP-induced aSyn aggregation and fibrillization in cells (Brandt et al., 2008, Szeltner et al., 
2013). Interestingly, PREP(S554A) was also observed to induce aSyn dimerization via a direct 
interaction similarly to wild-type PREP. However, KYP-2047 had no effect on 
PREP(S554A)-induced aSyn dimerization nor on PREP(S554A)-aSyn interaction. We showed 
that PREP(S554A) adopted three oligomeric states similar to wild type PREP, but KYP-2047
treatment did not induce a conformational shift of PREP(S554A) towards the compact 
monomers. This inability for conformational shifting may explain the observation that 
PREP(S554A) is insensitive to KYP-2047 treatment.
The binding sites on PREP for proteins and inhibitors remain incompletely understood, 
but the access loop structures have been suggested to play key roles in mediating ligand 
binding and inhibitor-induced conformational shift (Kaszuba et al., 2012). PREP has three 
loops at 189-209 (loop A), 577-608 (loop B), and 636-646 (loop C), and its two domains are 
held together by a stable network of hydrogen bonds. A molecular dynamics simulation
showed that PREP inhibition breaks hydrogen bonds holding loop B and A, which gates the 
active site of PREP, and this results in an overall conformational shift where the active sites 
are no longer accessible (Kaszuba et al., 2012). Our data suggests that although PREP(S554A) 
is enzymatically inactive, the mutation may have stabilized the monomeric open conformation 
and oligomeric conformation. This may implicate that PREP oligomers and open monomers 
would be responsible for inducing aSyn oligomerization independent of enzymatic activity, 
whereas the compact monomers form strong interaction with aSyn but do no promote aSyn 
nucleation. We tried to isolate these PREP oligomeric and monomeric pools from gels, but 
because PREP activity and structure is very environment-sensitive and does not withstand 
harsh conditions, these attempts failed. In the follow-up studies, we also tried to investigate if 
PREP overexpression alters aSyn dimer secretion, and we observed an elevated level of 
intracellular and extracellular aSyn dimer in the same proportion, possibly indicating that aSyn 
secretion mechanisms were not altered by PREP.
In conclusion, our study for the first time provides solid evidence and mechanistic 
explanation for the direct effect of PREP on aSyn. Together with previous studies showing 
that PREP enhances aSyn aggregation and modulates aSyn autophagy clearance in vivo, the 
study on PREP in this thesis fills an important missing gap in the molecular mechanisms of 
PREP-induced synucleinopathies (Brandt et al., 2008, Savolainen et al., 2014). PREP has long 
been interested as a drug target, and there has been numerous of patents and clinical trials of 
PREP inhibitors (Lopez et al., 2011, Morain et al., 2002). Understanding the molecular 
mechanisms of how KYP-2047 reduces synucleinopathies shed light and confidence in 
developing new therapeutics targeting the PREP-aSyn pathway.
The effect of LOAD genes on cell-to-cell transmission of tau6.3
A siRNA-based screen was conducted to study the functional connection between
cellular secretion and uptake of tau and 10 LOAD susceptibility genes. It has been previously 
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shown that several late-onset Alzheimer’s disease (LOAD) risk genes, such as BIN1, CLU,
and PICALM, might modulate tau propagation or toxicity via direct or indirect interactions 
with tau (Avila et al., 2015).  We hypothesized that two of these selected LOAD susceptibility 
genes, BIN1 and PICALM may regulate tau secretion and uptake, as both genes are 
functionally connected to endocytic pathways (Chapuis et al., 2013a, Xiao et al., 2012).
However, in the tau uptake study, only the knockdown of APOE mildly affected tau uptake, 
which could be related to the previously described interaction between tau and ApoE proteins 
(Fleming et al., 1996, Strittmatter et al., 1994). It was somewhat surprising that the 
knockdown of both BIN1 and PICALM expression had little effect on tau uptake, suggesting 
that tau internalization is not heavily dependent on receptor-mediated endocytosis, such as 
clathrin-mediated endocytosis. On the other hand, a recent study showed that tau uptake can 
occur via a bulk endocytic mechanism, such as macropinocytosis (Holmes et al., 2013). The 
macropinocytotic process involves extensive membrane turnover and is not very active in
mature neurons. Thus cell types and relevant physiological context should be taken into 
consideration in the future studies.
In the tau secretion study, siRNA knockdown of CD2AP, CD33, FRMD4A and TREM2
significantly reduced tau secretion in HEK293T cells. The knockdown efficiency of TREM2
gene was relatively low as compared to other siRNAs, but the effect on tau secretion was 
remarkably high. TREM2 gene cluster was previously reported to contain SNPs associated 
with CSF tau and tau phosphorylation in a genome-wide association study, which used CSF
tau phosphorylation at Thr181 as an endophenotype of LOAD (Cruchaga et al., 2013a).
However, both TREM2 and CD33 are functionally associated with immune responses, and are 
mainly expressed in immune cells. Moreover, their proximal signalling partners such as 
DAP12 are expressed at very low level in HEK293T cells, and thus their function may be 
reduced or altered in the HEK293T cells system, which was used in our siRNA screen (Rohn, 
2013, Crocker et al., 2007, Jandus et al., 2011). Knockdown of TREM2 and CD33 in a 
microglial CHME-5 cell line, which expresses a high endogenous level of both genes, showed 
no effects on tau secretion. It is thus possible that the reduced tau secretion in HEK293T cells 
have been caused by off-target effects of TREM2 and CD33 siRNAs. The false-positive hits 
reflect the fact that although in vitro functional screening of genes is efficient, just like 
genome-wide association studies, functional verification of gene-screen hits in different 
independent population group sample sets should always be included to filter out false-
positive hits. In addition, microglia has been reported to accelerate the cell-to-cell 
transmission of tau by internalizing and packing extracellular free tau into exosomes, and 
delivering them to neighbouring neurons (Asai et al., 2015a). This not only indicates a new 
role of microglia in the propagation of tau pathology but also highlights the importance of 
non-transsynaptic tau propagation mechanisms that need to be studied in the right model 
system. 
Both FRMD4A and CD2AP have been described as scaffolding proteins involved in 
actin cytoskeleton organization and polarity (Dustin et al., 1998, Lehtonen et al., 2002, 
Ikenouchi and Umeda, 2010). In addition, CD2AP was also reported to regulate synapse 
formation and endocytosis (Wolf and Stahl, 2003, Cormont et al., 2003). A recent study in 
CD2AP double-knockout mice revealed a novel function of CD2AP in maintaining blood-
brain barrier (BBB) integrity, which was previously shown to be impaired during the 
pathogenesis of tauopathy in a mouse model  (Cochran et al., 2015, Blair et al., 2015).  In 
addition, CD2AP deficiency also promotes tau-mediated toxicity in a Drosophila model of 
AD (Shulman et al., 2014). Taken together, impairment of CD2AP function(s) might alter the 
physiological cerebrovascular role of CD2AP for maintaining BBB integrity, and lead to AD-
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related vascular changes that may promote tau toxicity and propagation in vivo. The reduction 
of tau secretion induced by knockdown of CD2AP expression level could indicate a potential 
connection between cell-to-cell transmission of tau and CD2AP-mediated BBB dysregulation 
in pathological conditions, which can be a subject of future studies. 
A recent functional screen showed that in vitro knockdown of FRMD4A altered 
phosphorylation of tau (Martiskainen et al., 2015b). Moreover, FRMD4A expression in 
human patients’ brain samples was reported to decrease during progressive development of 
AD pathology. In this thesis work, cellular level of FRMD4A was shown to be closely 
associated with tau secretion. In HEK293T cells, tau secretion level is increased with 
FRMD4A overexpression, and decreased with siRNA knockdown. It is worth mentioning that 
knockdown efficacy of FRMD4A was relatively low as compared to other siRNA (Figure 19), 
suggesting a robust functional effect of partial knockdown. It has been previously suggested 
that reduction in tau secretion might lead to intracellular accumulation of tau with elevated 
toxicity (Gendreau and Hall, 2013, Hall and Saman, 2012). In our study, reduction in tau 
secretion level only increased intracellular tau level in HEK293T cells, and the overexpression 
of FRMD4A only enhanced extracellular tau level without significantly inducing toxicity. As 
there could be an equilibrium between intracellular and secreted tau, overexpression may not 
fully represent physiological conditions. For example, overexpression of tau has been 
previously shown to induce secretion of tau associated with membrane vesicles (Simon et al., 
2012a). However, tau in the condition media was observed to contain hyperphosphorylated tau 
species, a large quantity of dimers and soluble aggregates, suggesting that this is rather a 
model of pathological tau secretion than physiological.
In mature mouse cortical neurons, which represent a more physiological model than 
HEK293T cells, reduced FRMD4A level and inhibition of cytohesin activity remarkably 
enhanced endogenous tau secretion, which is opposite to the response observed in HEK293T 
cells. The different response between neuronal and non-neuronal cell lines may be explained 
by the fact that neurons have more specialized and an intense network of secretion machinery, 
and moreover, tau is mostly expressed endogenously in neurons (Sudhof, 2013, Feng and 
Arnold, 2016). This is also in line with previous observations in AD patients’ brain that 
FRMD4A level is progressively reduced during the development of AD pathology 
(Martiskainen et al., 2015b).
As mentioned above, FRMD4A is associated with altered tau phosphorylation 
(Martiskainen et al., 2015b). Interestingly, in study III, extracellular tau hyperphosphorylation 
at AD-associated epitope AT8 (Ser199, Ser202 and Thr205) was shown to impair stress-
coping mechanisms of cells after tau was internalized. The AT8 epitope of tau is one of the 
most extensively studied tau phosphorylation epitopes, and is suggested to be a central 
mediator of various cascades regulating tau phospho-priming and other related pathways 
(Bertrand et al., 2010). It has been proposed that increased tau level and phosphorylation 
(Thr181, also known as AT270) in CSF are associated with cognitive decline and can be used 
as a biomarker for AD prediction (Kester et al., 2009, Wallin et al., 2010). Phosphorylation of 
tau at Thr231 has also been reported to correlate with memory deficits in AD and mild 
cognitive impairment (MCI) (Hampel et al., 2010). The exact molecular pathway of how these 
abnormal phosphorylation events contribute to AD pathogenesis in human patients are 
incompletely understood, but some of the AD-related tau phosphoepitopes (Figure 6), such as 
Ser202, Thr205 and Thr231 were shown to associate with aggregation and tau-mediated 
toxicity in vitro (Alonso Adel et al., 2004). One potential mechanism was demonstrated by a 
GWAS study using CSF phospho-tau (Thr181) as an endophenotype of AD showing that an 
SNP on PPP3R1 gene that is associated with reduced expression of protein phosphatase B 
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(calcineurin, a known tau phosphatase) in the parietal lobes, could be responsible for elevated 
phospho-tau level in CSF and accelerated AD pathogenesis (Cruchaga et al., 2010). These 
pieces of evidence and examples taken together suggest that FRMD4A is possibly involved in 
modulating both the mechanism of tau phosphorylation and cell-to-cell transmission of tau 
that might contribute to AD- and MCI-related cognitive impairment, memory deficit and 
neuronal death owning to tau-mediated cellular stress and toxicity. In the future studies, it 
would be important to investigate the change in other disease-associated phosphorylation sites 
of tau both in cell and conditioned media that might have been altered by FRMD4A 
knockdown or overexpression. 
It has been reported that by binding to cytohesins, FRMD4A serves as a scaffold protein 
that promotes the interaction between Arf6 and the polarity signalling complex 
Par3/Par6/aPKCζ (Ikenouchi and Umeda, 2010).  This polarity complex has been suggested to 
regulate endocytic trafficking including vesicle recycling and exocytotic secretion (Balklava et 
al., 2007). Cytohesin-1, which is one of the cytohesin family proteins, was reported to 
promote basal synaptic transmission at Xenopus neuromuscular junctions by activating and 
promoting Arf6 translocation to the cell membrane, and moreover, by increasing the amount 
of vesicle priming at the presynaptic terminal (Ashery et al., 1999). In addition, cytohesin-1
was also shown to interact with Munc13-1, which is a key protein for vesicle priming at the 
membrane, thus offering another potential mechanistic explanation for the cytohesin-1-
induced increase in presynaptic vesicle pools (Neeb et al., 1999). As presynaptic vesicle 
release was proposed as one of the routes for tau secretion, both cytohesin-Arf6 and cytohesin-
Munc13 pathway might be involved in modulating tau secretion as described in Figure 21
(Yamada et al., 2014). Arf6 silencing or cytohesin inhibition in hippocampal neuron culture 
was recently reported to increase the amount of synaptic vesicle priming, and also synaptic 
release (Tagliatti et al., 2016). This is in line with our observation that cytohesin inhibition and 
siRNA silencing of FRMD4A significantly boosted tau secretion levels in neurons. This 
implicates that FRMD4A might facilitate synaptic transmission by forming direct interaction 
with cytohesin that further regulates the activity of Arf6 and Munc13-1 to increase the reserve 
of presynaptic vesicles ready to fuse at the synaptic terminals, and thus modulate tau secretion
through presynaptic vesicle release. Interestingly, a recent in vitro study showed that cytohesin 
is also involved in ALS (Zhai et al., 2015). It would be interesting to investigate possible 
connections of this study with our findings in the future studies.
In addition to cytohesins and Arf6, the data indicate that two major components of the 
polarity signalling complex, Par6 and aPKCζ are also involved in the tau secretion pathway. 
The Par polarity signalling complex plays a role in regulating cellular polarization, which is a 
key event involved in many cellular functions such as cell proliferation, development, 
differentiation, and more importantly polarized delivery of proteins and lipids to specific sites 
of the plasma membrane (Suzuki and Ohno, 2006, Goldstein and Macara, 2007). The 
FRMD4A-cytohesin-Arf6 pathway was previously reported to be involved in cell polarization 
events in epithelial cells where the Par complex was shown to activate Arf6 in an FRMD4A-
dependent manner at primordial adherent junctions (Ikenouchi and Umeda, 2010). One 
potential explanation is that the Par polarity signalling complex might indirectly influence tau 
secretion by delivering microtubule-bound tau and vesicles to the presynaptic terminals or 
generally to the polarized plasma membrane in non-neuronal cells, such as HEK293T. 
Nevertheless, addressing this novel molecular pathway of Par6-aPKCζ-FRMD4A-cytohesin-
Arf6 and candidates as illustrated in Figure 21 would benefit the understanding of tauopathy 
propagation, and possibly provide new therapeutic targets. 
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Pathophysiological consequences triggered by tau internalization6.4
6.4.1 Role of TIA-1 in mediating internalized tau-induced stress and toxicity through stress 
granules
In AD pathogenesis, tau pathology appears in connected brain regions in a time-
dependent manner suggesting that pathological tau species might spread from one cell to 
another and induce toxicity and neurodegeneration (Braak et al., 1994a, Lasagna-Reeves et al., 
2012a, Dujardin et al., 2014b).  Little is known about the mechanism of tau uptake and the 
pathophysiological consequences of tau internalization. In this thesis work, extracellular tau 
was for the first time shown to be recruited to stress granules following internalization, which 
resulted in altered stress-coping capability in cells, and increased their sensitivity to other
types of stress. In addition, knockdown of TIA-1 halted the recruitment of tau to stress 
granules, and reduced internalized tau-mediated toxicity. This is in line with a recent study 
that demonstrated the knockdown of TIA-1 reduced tau misfolding and toxicity in neurons 
(Vanderweyde et al., 2016).
Previous literature has described an association of stress granules (SGs) with a number of 
neurodegenerative diseases. As mentioned previously, SGs are transiently formed non-
membrane bound RNA granules, which are nucleated by various RNA-binding proteins 
(RBPs) under stress conditions in order to suppress translation and promote cell survival 
(Anderson and Kedersha, 2008, Gilks et al., 2004). The abnormality of SGs has been 
implicated to be involved in the pathogenesis of neurodegenerative diseases (Maniecka and 
Polymenidou, 2015, Wolozin and Apicco, 2015). Many of the RBPs, particularly TDP-43, 
fused in sarcoma (FUS) proteins and certain heterogeneous nuclear ribonucleoproteins
(hnRNPs), have been shown to be genetically associated with frontotemporal dementia (FTD)
and amyotrophic lateral sclerosis (ALS) (Kim et al., 2013, Liu-Yesucevitz et al., 2010, 
Sreedharan et al., 2008, Vance et al., 2009). SG markers such as TIA-1, which is a key protein 
Figure 21 The proposed role of 
FRMD4A-cytohesin-Arf6 pathway in 
presynaptic tau secretion. FRMD4A 
mediates the activation and 
translocation of Arf6 to the membrane 
by recruiting cytohesin and polarity 
signaling complex Par3/Par6/aPKCζ. 
Other than Arf6, Munc13 that also 
interact with the cytohesins are 
involved in synaptic vesicle pool filling 
and priming. It is yet not fully 
understood how cytohesins modulate 
Munc13 activity in neuronal and non-
neuronal cells. Cellular secretion of tau 
is enhanced by synaptic activity. Hence 
this pathway is closely associated with 
presynaptic tau release. LOAD risk 
variants disrupting physiological 
function of FRMD4A or SecinH3 
inhibition of cytohesin activity increase 
tau release. Image modified from 
Uronen RL and HJ (2016)
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in the assembly of certain types of SGs, were reported to localize to NFTs in AD (Ash et al., 
2014, Vanderweyde et al., 2012).
Together, it was somewhat surprising to see that internalized tau is recruited to SGs in a 
TIA-1 dependent manner. This novel mechanism described a previously unrecognized role of 
TIA-1-containing stress granules in mediating internalized tau-induced cellular stress and 
toxicity that may be an important contributor in tauopathies and chronic traumatic 
encephalopathy, where post-mitotic neurons are exposed to various stresses in post brain 
injury (McKee et al., 2009). In the future studies, it will be interesting to see if knockdown of 
other disease-associated genes/proteins such as TDP-43, FUS and hnRNPs could have an 
effect on cell-to-cell transmission of tau or others and related toxicity. 
Lastly, it is worth mentioning that there could be various SG compositions. For example, 
TTP is another SG marker previously reported to interact with tau in vivo (Vanderweyde et al., 
2012). However TTP did not co-localize with SGs that are tau-positive in N2A and HEK293T 
cells, suggesting that there might be a variety of SGs composed with different components, 
and TTP is not recruited to the SGs induced by tau internalization, or alternatively TTP may 
not interact with tau in in vitro models (Vanderweyde et al., 2012). Thus, the nature of SG 
components should also be taken into account in the future studies. 
6.4.2 The role of tau hyperphosphorylation in cell-to-cell transmission of tau
Tau strains have been previously reported to affect the rate of cell-to-cell transmission 
and the ability to promote seeded aggregation (Sanders et al., 2014a). The internalization of 
the hyperphosphorylated tau species, but not with cytosolic overexpression of tau, was 
observed to induce formation of stress granules. Together with the evidence showing that 
pseudo-hyperphosphorylated tau formed significantly stronger interaction with TIA-1 than 
normal tau and promoted formation of SGs,  it can be concluded that either certain tau species 
are more prone for cell-to-cell transmission or tau composition and structures are modified 
during secretion and uptake, e.g. by phosphorylation and aggregation during these processes. 
This is in line with the observation that secreted, SG-promoting tau is predominantly in 
hyperphosphorylated form, at least at the AT8 epitope. Both Ser202 and Thr205 sites of tau 
protein are phosphorylated by AD-associated kinase CDK5 and GSK3-β, and 
hyperphosphorylation at Ser202 and Thr205 was shown to be linked with a reduction in the 
ability of tau to nucleate microtubule assembly (Wada et al., 1998). As mentioned above, CSF 
tau level and phosphorylation are closely associated with AD pathology, particularly memory 
deficits and cognitive impairment (Hampel et al., 2010, Kester et al., 2009, Wallin et al., 2010, 
Cruchaga et al., 2010). This implicates that the emerging hyperphosphorylation at the AT8 
epitope of extracellular tau may be a result of lost physiological function that impairs 
microtubule functionality and contributes to worsening clinical outcome in memory and 
cognitive functions during AD pathogenesis. Under this hypothesis, it will be highly important 
and interesting to fully characterize the tau phosphorylation state in the conditioned media in 
order to address further hyperphosphorylated epitopes that could be relevant regarding 
pathogenesis.
Increasing evidence support the hypothesis that stress granules (SGs) may provide a 
location for misfolded and normal low complexity proteins to interact, and upon interaction to 
convert normal, misfolding-prone proteins to pathological species, hence seeding aggregation 
(Wolozin, 2012, Wolozin and Apicco, 2015, Maniecka and Polymenidou, 2015).
Hyperphosphorylated tau-induced SGs were shown to be hard to resolve. This may be 
explained by the fact that tau and TIA-1 have low complexity sequences and flexible 
secondary structures, and the initial tau/TIA-1 complexes might lead to the formation of a 
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nucleation core that cannot be degraded or resolved as compared with SGs clearance under 
physiological conditions (Calabretta and Richard, 2015, Wolozin and Apicco, 2015). The role 
of hyperphosphorylation in cell-to-cell transmission and seeding of tau has not been fully 
explored. It was previously demonstrated that certain strains of tau aggregates such as 
preformed fibrils strongly promote tau seeding (Sanders et al., 2014a). On the other hand, 
hyperphosphorylation of tau has been widely recognized as the major factor contributing to 
tau aggregation, dysfunction and related neurofibrillary degeneration in AD (Iqbal et al., 2009, 
Alonso et al., 1994). Taken together, the unresolvable nucleation core appears to consist of 
hyperphosphorylated tau and TIA-1, which may serve as a seeding point for further 
aggregation of normal tau, and thus act as an important mediator of seeded aggregation. This 
proposes a previously unrecognized connection between disease-associated 
hyperphosphorylation and cell-to-cell seeding property of tau.  Further studies are needed to 
confirm this hypothesis, for example by testing the nucleation behavior of TIA-1 and 
hyperphosphorylated tau in a cell-free system such as Microscale Thermophoresis.  
Understanding cell-to-cell transfer of disease-associated protein as a whole6.5
The pathogenic pathways of several neurodegenerative diseases such as Parkinson’s 
disease and Alzheimer’s disease remain incompletely understood. As illustrated in Figure 22,
the development of synucleinopathies and tauopathies start at the sporadic aggregation of 
disease-specific proteins. Despite the fact that previous studies have proposed many factors,
such as genetic risk factors, post-translational modifications, metal ion-related oxidative 
stresses, lipid abnormalities, impaired cellular waste management and altered energy 
homeostasis, could modulate the aggregation pathway(s) of aSyn and tau, we still do not have 
enough knowledge to confidently declare the initial triggers of the pathological protein 
aggregation in human patients. Most likely this process involves a complex interplay of 
genetic and environmental factors, including aging-related deterioration of cellular defence 
mechanisms. One thing that has repeatedly been observed is the progressive development of 
synucleinopathies and tauopathies and related degeneration of neurons in neuroanatomically 
connected brain regions in a time-dependent manner (Braak et al., 2003, Braak and Del
Tredici, 2011). In addition, both aSyn and tau are present in CSF of human patients (Blennow 
et al., 1995, Borghi et al., 2000). Taken together, it seems that aSyn and tau get access to the 
extracellular space and spread from one region to another during the progression of 
neurodegenerative diseases. Thus, for therapeutic purposes, it may be critical to halting the 
pathogenic spreading by interrupting these processes. However, there are many missing gaps 
in our knowledge about the mechanisms of the pathology spreading pathways, as summarized 
in Figure 22, and this hinders us from selecting the right biomarkers for diagnostics and right 
protein candidates for drug targeting. 
In the literature, the term “prion-like” is often used to describe the transmissibility and 
seeded aggregation of aSyn and tau. One recent publication even claimed that aSyn is a prion, 
and aSyn-mediated human multiple system atrophy (MSA) is a prion disease simply because 
inoculation of lysate from human MSA post-mortem brain induced a synucleinopathy in 
transgenic mice and cells (Prusiner et al., 2015). To be “prion-like” would mean pathological 
species of aSyn and tau acting as infectious agents that spread the pathology rapidly by 
interacting and converting normal aSyn and tau proteins into pathological species in a 
template-directed manner, and that this phenomenon could also be transmitted from one 
individual to another (Bolton et al., 1982, Aguzzi and Rajendran, 2009). This is indeed true for 
some species or strains of aSyn and tau as demonstrated in cells and transgenic mice models. 
This thus creates an impression that when aSyn and tau are called "prion-like," the puzzle of 
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how aSyn and tau contribute to the spread of pathology is solved. However, it is not as simple 
as that. First of all, it may be questioned that to what extend mouse models represent human, 
e.g. some NFTs-bearing transgenic mice showed no impairment in neuronal functions 
(Santacruz et al., 2005, Berger et al., 2007). Due to the ethical concerns, a few studies of 
pathological protein propagation have been carried out in human neurons induced from 
pluripotent stem cells (Chai et al., 2012a, Wu et al., 2016). These neurons derived from 
differentiated human stem cells provide a better model for studying tau and aSyn transmission 
in the context of "human," but it is still far away from representing the complex and systemic 
network of the human brain. Apart from the limitation of the model system, the term "prion-
like" only provides an existing model to explain how aSyn and tau might seed the aggregation 
at the molecular level. Except two studies implicated that contaminated surgical grafts of dura 
mater and growth hormones prepared from cadavers of Creutzfeldt–Jakob disease (CJD) 
might be related to Aβ plaques observed in the brain of patients who received the 
transplantation, there has not been any indication that AD and PD are transmissible in man 
(Zane Jaunmuktane and Simon Mead, 2015, Frontzek et al., 2016). Apart from the fact that 
not all the strains and species of aSyn and tau have been fully characterized by their property 
of seeding, the mechanism of cellular release and uptake, potential post-release events in 
extracellular space or human plasma and CSF, and the pathological consequences of 
internalization of these disease-associated proteins are currently poorly understood (Figure 22). 
In addition, many factors such as genetic risk factors, post-translational modifications, 
chemicals and protein modulators can readily modify the propagation pathway(s) of aSyn and 
tau in pathological conditions. Thus, it is important to dissect the entire propagation pathway 
into sub-processes, and to study the mechanisms and modulators involved in each step of the 
pathway in order to understand the propagation of disease-associated proteins as a whole.
In this thesis, the mechanisms of cell-to-cell transmission of disease-associated proteins 
were studied at steps of dimerization/oligomerization, cellular release and uptake, and a post-
internalization event. Both tau and aSyn were used as models, although side-by-side 
comparisons of the two proteins were not directly performed. It may be criticized that the 
study should have just focused on one protein rather than two proteins that are structurally 
different and primarily contribute to distinct disease-specific pathologies. However, the aSyn 
and tau pathologies are not strictly isolated, and a lot of evidence supports significant co-
occurrence and overlap of aSyn and tau pathologies in individual patients in many diseases 
such as Lewy body variant of AD (LBVAD), Parkinson’s disease with dementia (PDD),
dementia with Lewy bodies (DLB), Guam-Parkinson-ALS dementia complex, and even 
Down’s syndrome etc (Lippa et al., 1998, Lippa et al., 1999, Forman et al., 2002, Moussaud et 
al., 2014). In addition, synucleinopathy and tauopathy are not hermetically restricted in PD or 
AD, but often contributes to secondary symptoms. As mentioned previously, there is a lot of 
similarity and overlap in the aggregation pathways and properties of transmissibility between 
aSyn and tau, suggesting convergent pathways of aSyn and tau aggregation and propagation in 
the pathogenesis of clinically divergent neurodegenerative diseases such as AD and PD.
Therefore, further studies of the two remarkably interconnected disease-associated proteins 
could generate complementary knowledge that would benefit our understanding of the poorly 
understood pathogenic pathways as a whole.
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Figure 22 The process of the disease-associated cell-to-cell transmission of aSyn and tau. Seeding of pathology 
starts with sporadic misfolding and aggregation of aSyn and tau, which gain a seeding property which is a 
prerequisite for both toxicities and spreading of pathology. A series of events, including cellular release and 
uptake, occur that transfer these disease-associated proteins from one cell to another. However, there is much 
missing knowledge on many steps. For example, what triggers misfolding and aggregation, and what is the 
physiological and pathological relevance of aSyn and tau species or strains? Are some species released and 
internalized more efficiently than others? What happens in the extracellular space and CSF? Do the proteins 
further aggregate or fibrillize or are they released from secreted vesicles or packed into exosomes by microglial 
cells? How are they internalized into cells? By macropinocytosis or direct membrane penetration via formation of 
annular protofibrils or nanotubes and cell-to-cell contacts? What is the pathological consequence of 
internalization of these disease-associated proteins? How do the internalized species convert healthy proteins into 
pathological ones and where does this occur? How do they impair cellular function that could potentially lead to 
cell death and degeneration? How would various strains/species of the disease-associated proteins, other genetic 
risk factors and proteins/chemical modulators contribute to each step and overall propagation of pathology? Taken 
together, we have just started to explore this complicated cellular machinery and related pathways, and thus it is 
important to begin with addressing the basic mechanisms.
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7 Concluding remarks and future prospects
The aggregation, cellular secretion and uptake of aSyn and tau are fundamental processes 
involved in the propagation of synucleinopathies and tauopathies that contribute to many 
neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease. The studies 
presented in this thesis provide an important novel insight into the mechanisms of aSyn 
aggregation, and cellular secretion and uptake of tau. 
First, we have developed and validated a novel method based on protein-fragment 
complementation assay to study protein-protein interactions of aSyn and tau in live cells and 
conditioned media (I, II, III). Moreover, the protein-fragment complementation assay (PCA)-
based platform was used to study dimerization change of aSyn and tau upon pharmacological 
and genetic modulation in cells (I, II). Additionally, we have further optimized and validated 
these assays to investigate the mechanisms and consequences of cellular secretion and 
internalization of tau in live cell environment (II, III). The main findings of this thesis are:
Study I: Prolyl-oligo peptidase (PREP) interacts with aSyn. The direct protein-protein 
interaction between PREP and aSyn promote aSyn dimerization independent of PREP 
enzymatic activity. KYP-2047, a small molecule inhibitor of PREP, reduces PREP-induced 
aSyn dimerization, possibly by inducing PREP conformational shift to compact monomeric 
form. 
Study II: The expression level of FRMD4A, a late-onset Alzheimer’s disease 
susceptibility gene, modulates cellular secretion of tau, likely through cell polarity signalling 
complex Par6/aPKC?-FRMD4A-cytohesin-Arf6 signalling pathway. 
Study III: Extracellular tau is internalized by cells and recruited to stress granules in a 
TIA-1 dependent manner. Macropinocytosis appears as the main route of entry mediating tau 
internalization. Hyperphosphorylation of tau at the phosphoepitope AT8 likely contributes to 
induction of the abnormal stress granules that are hard to resolve and sensitize cells to
secondary stress.
Due to the increases in demographic aging, age-related diseases such as 
neurodegenerative diseases have emerged as a heavy burden to the society. There is yet no 
effective curable therapeutics or ever ways to delay the disease progression in most of these 
diseases, and most clinical trials for Alzheimer’s disease and Parkinson’s disease have been 
disappointing. There thus is an urgent need for a better understanding of the etiology of these 
diseases in order to forge effective strategies for development of therapeutics. This thesis 
provides novel data in identifying the modulators and risk factors of the diseases and 
identifying novel molecular mechanisms, which give the opportunity for novel drug targets 
and development of disease-modifying treatments and strategies to halt the progression of 
disease-specific pathology in the future.
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